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ABSTRACT 
Doctor of Philosophy 
Cell Penetrating Peptoid Carriers: 
Microwave Assisted Synthesis and Bioactive Molecules Delivery. 
by Mario Antonio Fara 
Effective methods for the selective passage of therapeutic molecules or probes 
through biological barriers are essential for the study of cellular functions. Cell 
penetrating cationic peptoids, based on a lysine like unit, were efficiently synthesised 
using a combination of solid phase synthesis strategies and microwave heating. 
A linear 7rner peptoid was thus prepared by direct solid phase synthesis and 
conjugated to both a peptide hormone ((x- Melanocyte Stimulating Hon-none, a 
I 3rner peptide) and to peptide nucleic acids (9mer, I 2mer and I 5mer prepared using 
Dde/Mmt protected monomers) targeting tyrosinase mRNA. These conjugates were 
able to efficiently penetrate different cell lines (average uptake > 90%), and even 
more, to penetrate human skin, with the heptapeptoid carrier being able to deliver a 
I 2mer PNA deep inside the dermis stratus. 
Antisense DNA oligomers (19mer, targeting tyrosinase mRNA) conjugated to the 
heptapeptoid carrier by a disulfide linkage was able to down-regulate tyrosinase 
expression, showing the potential of the carrier in delivering DNA into cells. 
Delivery of macromolecules such as protein and plasmid DNA were attempted. 
Heptapeptoids functionalised with a tetradentate Ni2 ligand were tested for the 
delivery of hexahistidine (His6) tagged GFP protein into cells, while 3 generations of 
a novel peptoid dendrimer were prepared and tested for the cellular delivery of DNA. 
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Chapter I. Introduction. 
Biological membranes are natural barriers, which isolate the content of cells from the 
extracellular medium, and compartmentalise the cellular environment. Through the 
membranes are distributed various proteins responsible for the controlled efflux-
influx of solutes from cells and cellular organelles, regulating intracellular 
concentrations of ions and small molecules according to cellular demand, but 
otherwise being impermeable to most molecules. This "traffic control" activity of the 
cell membranes is a major problem in studying cells, because without sufficient 
cellular uptake any new promising probe for cellular functions cannot be applied. 
Clearly the development of effective methods for the selective passage of therapeutics 
or probes through biological barriers is a key step for the study of cellular functions 
and advancement of new drug therapies. This "technology" would offer the 
possibility of improving the bioavailability of existing drugs, enabling the delivery of 
new cargoes (e.g., RNAi, siRNA, DNA, proteins, imaging agents, and sensors), and 
allowing access to difficult sites such as through the blood—brain barrier, skin (topical 
administration of drugs avoiding the use of needles) and the eye. The possibility of 
having cell (tissue) selective entry, controlled drug release (and activation), could also 
minimize problems connected with drug toxicity. 
This chapter will discuss the structure of the cellular membrane together with its role 
in cellular uptake, followed by a description of different methods used to deliver 
molecules into cells with focus on cell penetrating peptides (CPPs), the basis of this 
thesis. 
Li. Cellular membranes and uptake. 
Cells possess a physical boundary called the cellular membrane which delirnites the 
intracellular space, isolating it from the extracellular environment. It is composed of a 
thin film (7.5-10 nm) of lipids, the majority of which are phospholipids which are 
amphipatic (or amphiphilic) molecules consisting of a hydrophilic polar head, a 
negatively charged phosphate group, and two hydrophobic fatty acid tails (Figure 
1.1). The phospholipids are held together by non covalent interactions and arranged in 
a continuous double layer called the lipid bilayer. 
Figure I.I. Schematic representation of a phospholipid. 
From Molecular Biology of the Cell, forth edition, by Bruce Alberts et al. Copyright 2004 by Garland 
Publishing, Inc. Permission requested. 
Because of their amphiphilicity, lipids naturally rearrange in such a way that the polar 
heads face the aqueous environment and the fatty acid chains are buried in the middle 
of the hydrophobic interior of the membrane which leads to the spontaneous 
formation of lamellar structures (Figure 1.2). In the case of cells, they organise with 
other lipids also constituting the physical barrier such as cholesterol, sphingolipids 
and glycolipids to form the closed vesicular bilayer structures. Studded throughout, or 
associated with the lipid bilayer, there are various membrane proteins which perform 
-2- 
numerous functions such as cell-cell attachment, communication with other cells or 
the transport of various substances into and out of the cell. 
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Figure 1.2. Schematic representation of a cell membrane (commons.wikirnedia.org, reprinted with 
permission). 
1.1.1. Transport across the cell membrane. 
The lipid bilayer described above is semi-permeable, which means that it is 
impermeable to most molecules with only a few diffusing freely through according to 
their concentration gradient. This is the case for small non polar molecules (such as 
02, CO?) and small uncharged polar molecules (such as urea, glycerol) which can 
diffuse slowly through the cell membrane. However small ions (such as Na', K, 
Ca 2,'  CF) cannot cross the membrane freely and are often transported via ion-
channels across the membrane (Figure 1.3). Ion-channels are transmernbrane proteins 
which response to changes in voltage or ligand binding, leading to conformational 
changes in the protein which results in the movement of the ions through the channel. 
-3- 
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Figure 1.3. Different types of transport across the cell membrane requiring various proteins. 
Transport of larger polar molecules (such as amino acids and sugars) across the 
membrane requires the involvement of membrane proteins called transporters 
(permeases, translocases or carrier proteins) and this family is divided into two 
categories: i) those that facilitate diffusion allowing transport down a concentration 
gradient, and ii) those involved in active transport, which transport substrates uphill 
against the concentration gradient requiring the consumption of ATP. 
1.1.2. Transport of macromolecules across the cell membrane. 
As explained above, the simplest way by which a molecule enters the cell is by 
diffusion, but it has been established' that only small, soluble, preferentially 
uncharged and of low molecular weight molecules can enter the cell in such a way. 
The large size and charge of macromolecules usually prevents them from entering the 
cell through diffusion  and their conventional mode of entry into cells is via an event 
called endocytosis. 
Endocytosis is the process by which cells take up macromolecules, particulates, and 
sometimes other cells where the material to be ingested is progressively enclosed by 
a small portion of cellular membrane which invaginates and eventually pinches off to 
form endosomes, or endocytic vesicles which contain the material of interest. The 
main types of mechanisms are distinguished by the size of endocytic particles 
formed: phagocytosis (cell eating), pinocytosis (cell drinking) and receptor 
mediated endocytosis that are mediated by clathrin proteins, and caveolae 
dependent endocytosis. 
1.2.1. Phagocytosis. 
Phagocytosis is an actin protein dependent process that involves the ingestion of large 
particles and microorganisms, or dead cells (generally > 500 nm) via particles called 
phagosornes. Phagocytosis is carried out only by specialised cells such as 
macrophages, neutrophils and dendritic cells. Once internalised the endosomes fuse 
with lysosymes inside the cells and ingested particles are degraded by numerous 
enzymes found in the lysosomes with degradation aided by an acidic pH, and 
peroxides. 
1.2.2. Pinocytosis. 
Micropinocytosis involves the continuous ingestion of fluids and solute via small 
pinocytic vesicles (usually about 100 nm in diameter) and can be carried out by most 
eukaryotic cells at quite a high rate depending on the cell type. It requires several 
steps, firstly, clathrin assembly at the inner surface of the cell membrane together 
with a complex called adaptin which results in the formation of a bud called a 
clathrin-coated pit. Clathrin proteins assemble to form the clathrin coat at the inner 
surface of the cell membrane which has a very distinctive net-like aspect on SEM 
images (Figure 1.4). After the formation of the clathrin-coated pit, the bud 
invaginates more and more and soluble cytoplasmic proteins such as dynamin 
assemble a ring around the neck of each bud and help to bend the membrane by 
distorting the bilayer structure locally, changing the lipid composition, or both. The 
later brings the two lipid bilayers together which eventually fuse and the vesicle 
pinches off from the membrane into the intracellular space where the clathrin coat is 
lost within seconds before it fuses with early endosomes (Figure 1.5). 
Macropinocytosis process is actin dependent, and occurs under more restrictive 
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conditions in a limited number of cells, such as dendritic cells, and generates vesicles 
with a diameter> I jim. 
1.2.3. Receptor mediated endocytosis. 
Receptor mediated endocytosis (Figure 1.5) is an internalisation process similar to 
pinocytosis with the difference that ligands have to be associated with transmembrane 
receptors, so called cargo receptors, to activate invagination of the cell membrane. It 
provides an efficient pathway for taking up specific macromolecules from the 
extracellular fluid and also acts as a concentrating mechanism as several receptor-
ligand complexes are internalised together. As an example, iron is transferred to the 
cytosol by such a mechanism: in the blood, iron is bound by a protein called 
transferrin and on the external surface of the cell there are transmembrane receptors 
to transferrin which bind the protein when exposed to it. The iron-transferrin-receptor 
complex is then internalised by the mechanism described above and finally iron is 
released inside the cytosol by diffusion through the vesicle membrane. 
Caveolae 	Clathrin coated vesicle 
0.2 pm 
Figure 1.4. Picture of the inner surface of the plasma membrane after rapid freeze-drying. 
Reprinted from Journal of Cell Biology, 84, J.Heuser, 560-583, Copyright 1980, with permission from 
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Figure 1.5. Different steps in the receptor mediated endocytosis process. From Molecular Biology of 
the Cell, forth edition, by Bruce Alberts et al. Copyright 2004 by Garland Publishing, Inc. Reprinted 
with permission 
1.2.4. Caveolae dependent endocytosis. 
Caveolaes are present in the plasma membrane of most cell types and look like deeply 
invaginated flasks as shown in Figure 1.6. 
Lipid raft - 
Sphingolipid 
Phospholipid 
Caveolae 	 Caveolin 
Figure 1.6. Schematic representation of lipid rafts and caveolae. 
Caveolaes are subdomains of lipid rafts, which are patches in the plasma membrane 
that exhibit a high level of cholesterol, sphingolipids and 
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gI ycosylphosphatidyl inositol -anchored membrane proteins. Caveol aes contain 
specific proteins called caveolins whose presence results in the invagination of the 
cell membrane and subsequently in the internalisation of the vesicle (Figure 1.6). 
Once formed the vesicles can fuse with early endosomes, but their overall function is 
believed to be more complex than only intracellular transport. The main difference 
with clathrin coated pits is that the caveolae's invagination is believed to be 
dependent on the lipid composition of the caveolar membrane and not only the result 
of the assembly of the caveolin protein coat as observed in clathrin mediated 
endocytosi s. 
Uptaken macromolecules (by endocytosis) are trapped by a biological membrane in 
endosomes, and not free to diffuse in the cytosol. As described above the endosomes 
reach and fuse with the lysosyrnes, where the compounds are exposed to the action of 
several enzymes and degraded. The delivery of macromolecules into cells without 
being degraded is one of the greatest obstacles in cellular targeting, meaning that 
methods need to be found to address macromolecule delivery into the intracellular 
space. 
1.2. Loading molecules into the cytoplasm. 
Several physical and molecular techniques have been developed over the years to 
enable drug or probe uptake into cells and tissues. 
1.2.1. Physical methods. 
2.].]. Micro injection. 
Microinjection uses a micro-needle with an outer tip diameter in the range of 200-250 
nm, to literally inject the drug or molecule of interest into the cytosol. Relatively high 
volumes of the molecule can be reached (in the range of femtoliter to attoliter), and 
there is virtually no size limit of the material that can be injected as the microinjection 
of organelles, as well as nuclei, has been reported.3 It is a rather universal method as 
most cells can be injected, however, the extent of the cellular damage is unpredictable 
and can be quite high 4'5 as cells have to be able to tolerate the introduction of a large 
glass microinjection pipette (Figure 1.7). Furthermore, the tips are very fragile and 
extremely difficult to see under a light microscope making the positioning and 
injection difficult, which together with its low-speed highly limits the throughput. 
Figure 1.7. Microinjection in a cell embryo. Courtesy of Anne Bower and Manfred Baetscher, Oregon 
Health and Science Universtiy, Porland, 
2.1.2. Gene gun delivery. 
The gene gun delivery belongs to a method called biolistics (also known as the 
bioballistic) method. It uses bursts of helium to fire nanoparticles such as gold or 
tungsten colloids coated with RNA or DNA into cells. This technique has been used 
extensively to transfect cells with DNA, however, it has been used recently to 
introduce polymeric particles into cells  but the applications are limited due to 
shallow penetration of particles and the associated cell damage. However this 
technique has been successfully used to deliver various genes inside cell S.7,8 
2.1.3. Electroporation. 
Also called electro-permeabilisation or electroinjection, electroporation is a well-
proven tool for the introduction into living cells of various membrane-impermeable 
molecules, such as drugs, hormones, proteins, plasmids, and so on. It is based on the 
temporary increase of membrane permeability due to reversible electric breakdown of 
the plasma membrane upon the application of an external high-intensity electrical 
field of very short duration. Brief high-voltage electric pulses result in the formation 
of small (nanometer-sized) pores in the cell membrane which are reversible as the 
membrane heals itself as soon as the electrical field is removed. Cells placed in a 
buffered solution of the purified protein of interest are exposed to a pulsed electrical 
field, with the protein entering the cell via these small pores or during the process of 
membrane reorganisation as the pores close and the cell returns to its normal state. 
The efficiency of delivery is dependent upon the strength of the applied electrical 
field, the length of the pulses, the temperature and the composition of the buffered 
medium, however, the poor loading efficiency of the method has limited its use to the 
delivery of genetic material such as RNA and DNA.4'5  
1.2.2. Molecular carriers. 
2.2.1. Liposoines. 
Liposomes are colloidal, vesicular structures of 20 nm to 10 jim diameter based on 
phospholipid bilayers that can be unilarnellar (meaning only one bilayer surrounds an 
aqueous core) (Figure 1.8) or multilarnellar (several bilayers oriented concentrically 
around an aqueous core) which depends on the processing protocol and choice of 
bilayer components.9 
Aqueous 
Enclosed aqueous compartment 
Lipid bilayer 
Figure 1.8. Schematic representation of a liposome section (commons.wikimedia.org, reprinted with 
permission). 
The liposome drug-carrier concept was proposed and demonstrated in the early 
70.1 when it was proven that soluble molecules could be entrapped within the core 
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of the liposomes which can later be endocytosed by cells. Uptake of liposomes by 
cells can be highly efficient (depending on the particular cell line), however the poor 
release of material from the endosomal vesicles (endosomal escape), especially for 
high molecular weight species, is a serious limitation. Endosomal escape can be 
enhanced by modifications of the liposomes, such as pH sensitive 1-nononiers,'2"3 the 
addition of a lipid helpers (DOPE)14 or complexation of the liposorne with membrane 
disruptive substances. 15  Liposome based delivery is an extensively applied method 
which has been used to deliver many low molecular weight drugs, peptides, 
enzymes, '6 oligonucleotides (as a potential tool to unlock of "gene therapies")'7"8 to 
cells but also ionic sensor-filled microparticles (PEBBLES ).6 
2.2.2. Dendrimers. 
Dendrimers and hyperbranched polymers are a relatively new class of materials with 
unique molecular architectures and dimensions in comparison to traditional linear 
polymers. Highly branched functionalised dendrimers have the potential to act as 
efficient drug carrier systems ' 9 (Figure 1.9). Drug molecules can be associated to the 
dendrimers in two different ways: one is the encapsulation of soluble drugs within the 
dendritic core which acts as a reservoir for drug molecules 20  and the other one is the 
coupling of drug molecules to the free surface functional groups. 21,22  Research to date 
has mainly been focused on the delivery of DNA where its use has enhanced the 
transfection of DNA into cells 23,24  but they have also been used to deliver drugs to 
cancer cells. 25 
Drug bound to the dendrimer 
	
Drug encapsulated inside the dendrimer 
£Th 
Drug 	Solubilising group 	Ligand for targeting 
Figure 1.9. Example of a hyperbranched dendrimer drug delivery device. 
As outlined before an efficient delivery protocol requires more than just high levels of 
cellular uptake, the ability of promoting effective endosomal release of the cargo is 
equally important. Certain materials, known as proton-sponge polymers,2627'28 are 
believed to mediate their own endosornal escape through a unique mechanism. 
Polyamidoamine (PAMAM) dendrirners belong to this class of compounds (Figure 
.10). These proton-sponge polymers, which contain a large number of secondary and 
tertiary amines, exhibit pKa values between the physiological (pH 7.4) and lysosomal 
(pH 4.5) pH's. Endosornes are acidified by the action of an ATPase enzyme that 
actively transports protons from the cytosol into the vesicle. These polymers, 
therefore, undergo large changes in protonation during endocytic trafficking. It has 
been proposed that proton-sponge polymers prevent acidification of endocytic 
vesicles (buffer action), causing the ATPase to transport more protons to reach the 
desired pH. The accumulation of protons in the vesicle has to be balanced by an 
influx of counter ions. The increased ion concentration causes osmotic swelling and 
rupture of the endosome membrane, allowing dispersion of the dendrimer complexes 
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Figure 1.10. Schematic of the proton-sponge mechanism and structure of PAMAM (ethylenediamine 
core) G2. Protonation of the proton-sponge polymer causes increased influx of protons (and counter-
ions) into endocytic vesicles. Increasing osmotic pressure causes the vesicle to swell and rupture. 
2.2.3. Biodegradable microspheres. 
Over the past few decades, there has been considerable interest in developing 
biodegradable microspheres as effective drug delivery devices. The drug is dissolved, 
entrapped, encapsulated or attached to a biodegradable matrix and depending upon 
the method of preparation, nanospheres (also called microspheres, nanoparticles) or 
nanocapsules ranging from 10 to 1000 nm diameter can be obtained. Nanocapsules 
are vesicular systems in which the drug is confined in a cavity surrounded by a 
unique polymer membrane, while nanospheres are made of a matrix in which the drug 
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Figure 1.11. Schematic representation of the two different types of biodegradable microspheres. 
Drugs are then released following different routes: drug release via diffusion through 
the microspheres and drug release via microsphere degradation and this mode of 
delivery has been successfully used to transport oligonucleotides,3° proteins,3 ' 
peptides and various drugs. 32,33  Early research into biodegradable systems focused on 
naturally occurring polymers such as collagen, cellulose, albumin, gelatin, etc, and 
has progressively moved into synthetic polymers such as poly(lactic acid), 
poly(gl ycolic acid), pol yanhydrides, polyesters, p01 yacrylic acids and polyurethanes. 
The most widely used and studied types of biodegradable polymers for the synthesis 
of nanospheres are polyesters, including poly(lactic acid), poly(glycolic acid), and 
35 their copolymers. 34  Macrophages and dendritic cells are often their target, but they 
have also been addressed to tissues, or solid tumours. 
1.3. Cell penetrating peptides (CPPs). 
Delivery of bioactive compounds mediated by peptides is one of the most promising 
technologies in the field of delivery agents. Compared to others agents (or 
techniques), peptides offer high delivery yield and low toxicity. Peptides able to 
penetrate into cells are referred to as cell-penetrating peptides (CPPs), trojan peptides 
or membrane translocating peptides (MTS). For simplicity the Cell Penetrating 
Peptides will be employed here to indicate all these classes of peptides. CPPs have 
been reported to be able to deliver a wide range of bioactive molecules such as 
proteins, 36,37  peptides  '38  oligonucleotides,39'4° and even nano-particles 41  into different 
cells types and to different cellular compartments, both in vivo and in vitro. 
Name Sequence' Origin 
Penetratin42 RQIKIWFQNRRMKWKK D. melanogaster 
transcription 
factor 
HIV 	TAT 43  GRKKRRQRRRPPQ Viral 
peptide 	(48— transcriptional 
60) regulator 
HSV- I VP22 DAATATRGRSAASRPTERPR Viral 	Capsid 
peptide APARSASRPRRVD protein 




Transportan46 GWTLNSAGYLLGKINLKALAALAKKIL- Chimeric 
amide galanin- 
mastoparan 
R847'45  RRRRRRRR Synthetic 
MPG 49 GALFLGWLGAAGSTMGAPKKKRKVC- Chimeric HIV-1 
amide gp4l-SV40 
large T antigen 
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SynB' 	RGGRLSYSRRRFSTSTGR, 	 Antimicrobial 
RRLSYSRRRF 	 peptide 
protegrin I (PG-
1) 
Pep- 152 	 KETWWETWWTEWSQPKKKRKV 	Synthetic 
(Chariot) 
Table 1.1 A selection of commonly used CPPs. 'All peptides are C-terminal free acids unless stated 
otherwise. 
CPP's may vary in size, amino acid sequence and charge, but they all have the ability 
to rapidly translocate across the plasma membrane and enable delivery into the 
cytoplasm or nucleus. 53  The idea of using peptides as delivery vectors originated from 
the observation of the so-called membrane shuttling proteins such as the Drosophila 
homeobox protein Antennapedia, the HIV-1 transcriptional factor TAT, and the 
capsid protein VP22 from HSV- I. The field started when Green -54  and colleagues 
(1988) showed how rapidly the viral protein TAT was able to translocate across the 
cellular membrane into the cytoplasm. After this example, other proteins were shown 
to have the same properties, such as the Drosophila homebox protein. Derossi42 and 
colleagues (1994) demonstrated that a short 16 amino acid peptide from the third 
loop of the Antennapedia protein, was responsible for the translocation of the whole 
protein. Since these first examples many peptides have been reported to have cell-
penetrating properties. These CPPs can be natural peptide sequences derived from 
virus proteins (TAT43 and VP2244) and transcription factors (penetratin42), or 
chimeric peptides (transportan46 and MGP49) or synthetic peptides (polyarginines4748  
and Pep- 152)  (table 1.1). Although there have been a number of studies regarding 
cellular uptake of CPP's, the mechanisms are still not well defined, and so there is not 
yet a clear classification of CPPs based on the internalisation pathways. The 
mechanism of CPP uptake remains ambiguous, with reports diverging even when 
using the same peptide and different cells. What appears evident is that different 
peptides may utilize different uptake pathways. 55 
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L3.1. Mechanisms for cellular uptake. 
Initial studies on CPP uptake mechanisms suggested that peptide internalization was 
not inhibited by reduction of cellular ATP, low temperature (4 °C), or inhibitors of 
endocytosis. Neither was internalization affected by peptide modifications such as 
retro-, enantio-, or retroenantio-analogues.56 These studies suggested that CPP 
translocation consisted of direct transfer through the lipid bilayer of the cellular 
memebrane. Derossi proposed a mechanism which involved the formation of inverted 
micelles, -56  with the cationic residues interacting with the negatively charged plasma 
membrane, consequent invagination of tryptophans into the membrane induced the 
formation of inverted micelles which can open on the inside or outside of the cell (A, 
Figure 1.12). This model seems to explain some aspects of CPP translocation and 
appears to hold for some peptides. A carpet mode157 (C, Figure 1.12), in which 
aggregates of peptides coat the cell surface and disrupt its structure, has also been 
proposed. While pore formation in the membrane is also possible (B, Figure 1.12), 
this mechanism can be ruled out by testing for membrane leakage of lactate 
dehydrogenase or propidium iodide staining. 58  Wender has proposed another non-
endocitotic mechanism of uptake called adaptive translocation 59  (Figure 1.13), which 
involves the recruitment of negatively-charged cell surface constituents by the 
positively-charged guanidine rich CPP as the latter contacts a cell surface, transiently 
forming an ion pair complex with attenuated polarity that is able to adaptively diffuse 
into the membrane and subsequently into the cell. The driving force for the passage of 







Figure 1.12. Uptake mechanism of CPP involving: (A) Inverted micelle formation, association of the 
peptide with the plasma membrane disturbs the lipid bilayer so that the inverted micelle is formed. (B) 
Pore formation, a limited number of peptides first assembles on the plasma membrane and then inserts 
into the lipid hilayer; further peptides are then recruited and a pore is formed. (C) Carpet model, 
peptides accumulate on the plasma membrane to the point where the integrity of the plasma membrane 
is breached and pores are formed. The lipid head groups are always oriented towards the peptide. 
Figure 1.13. CPP uptake by adaptive translocation. 
More recent studies, have shown that CPP tranlocation is mostly an energy-
dependent process 60  and the proposed mechanism models involve extracellular 
heparane sulfate 61  and different types of endocytosis (Figure 1.14) such as 
macropinocytosi s, ci athrin-dependent endocytosis, clathrin-independent endocytosis, 
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Figurel .14. Schematic representation of endocytic uptake of CPPs involving clathrin-dependent 
endocytosis, caveolin-dependentcndocytosis, macropinocytosis, and clathrin (or caveolin) independent 
endocytosis. Endosornal escape is a crucial step for cytosplamic delivery. 
All these different models, derived by experimental observations, suggest that CPP 
translocation could be mediated by multiple different pathways simultaneously, or 
that different peptides use different uptake mechanisms depending on their 
biophysical properties and their cargo (Figure 1.15 ).64 
1.3.2. Factors influencing cellular uptake. 
The main interpretations of CPP indicate the endosomal pathway as the major route 
of uptake, although several reports show an uptake independent of endocytosis.55'65  
There are several factors that can influence the uptake mechanism such as size of the 
cargo, characteristic of the cargo (charge, interaction with the transporter to form 
complexes), temperature, as well as cell type. 66 
The size of the cargo attached to the transporter is one of the factors that affect the 
uptake mechanism. It has been shown that complexes or fusions of Tat with large 
20 nm quantum dots or proteins (>50 amino acids) enter cells primarily through an 
endocytotic, vesicle-associated pathway, whereas a small peptide (<50 amino acids) 
cargo can enter cells through a non-endocytotic pathway. 67  Conjugation of 
negatively-charged amino acid sequences to CPPs has been shown to dramatically 
reduce uptake with the CPP observed only inside endosomal vesicles, indicating the 
presence of an exclusive and limited endocytosis dependent uptake. 68 
A temperature dependence on the mechanism of uptake has also been demonstrated. 
While some studies have shown inhibition of uptake at 4 °C, others have proposed a 
temperature-independent mechanism for some CPPs translocation. A combination of 
two pathways has also been reported in the uptake study of Alexa488-R8 (both L and 
D stereoisomers) into KG I a cells. At temperatures between 4 and 12 °C, fluorescence 
is observed in both the cytoplasm and the nucleus. At 12-30 °C, however, additional 
labeling is observed in endocytotic vesicles. Finally, when the cells are warmed to 
37 °C fluorescence is observed solely in endosomal vesicles. 69 
Plasniid 
Peptid s 	 Protein 
Antisense OJigonucleotides 	\ "siRNA 
Figure 1.15. General representation of proposed uptake mechanisms for CPPs and examples of 
cargoes of interest. 
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L3.3. Cationic CPPs. 
Regarding cationic CPPs, the kind of basic residues composing the peptide (such as 
lysine or arginine), has an important influence on uptake. Arginine rich CPPs have 
been shown to have a higher uptake than lysine and ornithine relatives .4' The 
generally agreed first step of the translocation mechanism involving CPPs is the 
association of the transporter with the membrane (Figure 1.16). The positively-
charged guanidinium headgroup features a specialized, rigid planar array of 
hydrogen bond donors that allows for highly effective bidentate hydrogen bonding 
(Figure 1.16)  formation with negatively-charged carboxylates, phosphates, and 
sulfates which are components of many cell membrane constituents such as 
phospholipids, fatty acids, proteins, and heparan sulfate proteoglycans (HSPGs). 
Relative to the single hydrogen bond that would be possible with the ammonium 
group in lysine, the bidentate hydrogen bond network formed from guanidinium 
groups is stronger and thus has been proposed to provide structural rationalization for 
the differing abilities of oligolysines and oligoarginines to associate with and cross 
cellular membranes. 47  Obviously, the degree of protonation of the systems under 
assay conditions is another factor that could be of consequence, as oligomers of the 
more basic guanidinium group would be more protonated (have more cationic sites) 
relative to lysine analogs. To evaluate the influence of this bidentate hydrogen bond 
Wender 59  and colleagues studied the uptake properties of fluorescein labelled 
oligomers of arginine containing monomethyl- and dimethylguanidinium head groups 
(Figure 1.17). The monomethylated oligomer 1.2, which was able to keep the charge 
but with a reduced ability to form a bidentate hydrogen bond, was 80% less effective 
than the unalkylated oligomer 1.1 (Figure 1.17). Dimethylated oligomer 1.3 (Figure 
1.17), which was not able to form bidentate hydrogen bond, was 95% less effective 
than the unalkylated oligomer. These results indicated that although charge is 
necessary it might not be sufficient, and that hydrogen bond formation plays an 
important role in the uptake process. 
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Figure 1.16. Proposed coordination of CPP to cell surface through hydrogen bonding: guanidinium 
ions form hidentate hydrogen bonding while ammonium ions only single hydrogen bonds. Counter 
ions not specified. 
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Figure 1.17. Cell penetration efficiency of oligorners of arginine containing monomethyl- and 
dimethylguanidinium head groups, compared to the efficiency of the corresponding unmodified 
oligoarginine (100% reference). 
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L3.4. Targeted and enhanced delivery. 
CPPs are able to penetrate a very broad range of cell lines both in vivo and in vitro. 
This indiscriminate cellular uptake unfortunately restricts greatly the use of CPP as a 
pharmaceutical tool. However recent reports in targeted delivery have shown 
promising results. 7M]  Cell features such as extracellular receptors or proteases have 
been used to direct CPP uptake. CPP modification with the addition of cell specific 
ligands such as small molecules, vitamins, carbohydrates, other peptides or proteins 
(growth factors or antibodies) may improve targeted delivery. The intramolecular 
masking of a CPP by a negatively charged stretch of amino acids and proteolytic 
liberation of the active CPP at cancer cells that release a metal loproteinase is one 
elegant example of a combination of strategies. 70 
While most uptake studies have focused on cell entry, the ability of CPPs to enter 
tissue is of critical importance, and is required for the advancement of this class of 
molecular transporters toward therapeutic applications. Research into the tissue 
distribution of cell-penetrating peptides has yielded promising results with examples 
of CPPs penetration in kidney, liver, bone and muscle tissues. 72-74  An octaarginine 
transporter linked to Cyclosporin A has been advanced to phase II clinical trials for 
dermatological applications 75  and a Tat 9-mer linked to a biologically active peptide 
cargo has been advanced clinically for the treatment of ischernia.76 
The stability of the peptide vector is another important aspect when considering in 
vivo delivery. It is important for the vector to stay intact until the target is reached, 
because in this way much less compound is required to achieve a sufficient delivery 
and thereby also minimizing possible side effects. The most common way to increase 
the peptide stability is the use of the D-form77 instead of the L-arnino acids. D-
peptides are much more stables to proteases remaining intact for much longer time 
when injected in vivo. An alternative is the use of non-natural peptide mimics such as 
beta-peptides '78  peptoids79 and oligocarbamates8° which as the D-peptides offer great 
stability to proteases (Figure 1.18). Interestingly peptoids have shown a cellular 
uptake consistently higher than the corresponding peptides. It has been suggested that 
this increased activity is a result of the increased lipophilicity of the peptoid backbone 
as determined by the attachment of the side chains to the amide backbone nitrogen 
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Figure 1.18. Cell penetrating peptide mimetics: Peptoids, D-peptides, -peptides, oligocarbamates. 
Another way to improve the delivery yield is the inclusion of specific functional 
groups in the CPP sequence. It has been reported that the addition of a 20 amino 
acids sequence from the pH-sensitive fusogenic peptide HA2 (derived from the 
influenza virus hemagglutinin protein) to a TAT-peptide fusion protein, gave a 
significant enhancement of protein uptake. 82 Fusogenic peptide HA2 is known to be 
able to destabilize lipid membranes at low pH and thereby to enhance endosomal 
escape which leads to improved delivery. 83 
1.3.5. Delivery of proteins. 
Delivery of proteins using CPPs can offer many advantages compared to the 
traditional approach consisting in the endogenous expression of the desired protein 
from a plasmid, approach that presents complications connected with plasmid 
delivery (particularly in vivo) and possible varied protein expression in different cell 
lines. There are already several example of protein delivery mediated by CPP, 
including proteins involved in apoptosis,84 cell cycle regulation and DNA 
recombination. 82 The protocol most frequently used consists of designing a plasmid 
encoding for the CPP in the coding frame with the desired protein, producing in this 
way a cell permeable fusion protein. 85 However, addition of a highly cationic portion 
to proteins chain may interfere with the protein tertiary structure and cause loss of 
biological activity. This problem can be overcome using CPP able to form a 
noncovalent complex with the protein, facilitating its cellular uptake without 
compromising the native structure and thus biological properties of the protein. 52 
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L3.6. Delivery of siRNA and other oligonucleotides. 
There are many reports regarding the CPP mediated delivery of oligonucleotides 
(ON) into several cell lines both in vitro86 and in vivo87 . These include CPP delivery 
of antisense —PNA,87 DNA decoy-ON,88 siRNA,89 and plasmids.90 Gene silencing 
(Figure 1.19), especially by siRNA, has emerged as a powerful tool in recent years. 
As for many other bioactive compounds, one of the major obstacles for the 
application of siRNA is the delivery across the plasma membrane. Only few peptides 
have been shown to improve siRNA uptake and down regulation of the desired gene. 
CPP and oligonucleotides (antisense ON, siRNA, RNAi) have been covalently linked 
(disulfide bond 39  is widely used) or just incubated together to form a complex through 
electrostatic interactions. 
Oligoniicleoide (ON). 
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Figure 1.19. Gene silencing using CPPs to deliver antisense compounds such as DNA (antisene 
oligonucleotides), PNA and siRNA. 
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L3.7. Commercially available CPPs. 
Over the last few years biotech companies have shown increasing interest in CPPs 
and today some CPPs are commercially available. One of the most famous is the 
Chariot system, known as Pep-], 52  (table 1 .1, page 16), a carrier with the remarkable 
characteristic that efficient import of cargo molecules does not require covalent 
linkage, but instead, it forms noncovalent complexes with its cargoes. Pep-] is a 21 
amino acid peptide, consisting of an II amino acid hydrophobic motif containing five 
tryptophan residues (ETWWETWWTEW) and a second domain corresponding to the 
NLS (PKKKRKV) of the SV-40 large T antigen, linked through a three amino acids 
spacer. The first domain interacts with macromolecular cargoes and is required for 
efficient "targeting" of the complexes to the plasma membrane. The NLS improves 
the intracellular delivery and solubility of the peptide. Pep-] has been applied 
successfully to the delivery of proteins, peptides, and PNAs into mammalian cells. It 
was shown that membrane crossing of Pep-] involves formation of a transient 
transmembrane pore-like structure. 
SynB vectors50'51 (from Syntem) are an other example of commercially available 
CPPs. This family of vectors is derived from the antimicrobial peptide protegrin I 
(PG-I, table 1.1), an 18 amino acid peptide originally isolated from porcine 
leucocytes. These vectors have been applied to the delivery of two famous anti-cancer 
drugs: doxorubicin and camptothecin. 
Express-si (silencing) is a CPP delivery vector for siRNA and oligonucleotides 
which is based on the MPG peptide 49  (table 1.1). MPG, as described for Pep-I, has 
the characteristic that efficient import of cargo molecules does not require covalent 
linkage, forming noncovalent complexes with the cargoes. MPG is composed of 17 
amino acid derived from the fusion sequence of HIV-1 gp41, a 3 amino acid spacer, a 
7 amino acid nuclear localization sequence (NLS) of SV40 large T antigen, and a C-
terminal cysteine amide. It was proposed that translocation proceeds through the 
transient formation of a transmembrane pore-like structure. 
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Chapter II. Peptoid synthesis. 
II.!. Peptidomimetics. 
Libraries of oligomeric biornolecules based predominantly on peptides (or proteins) 
and nucleic acids have been used to investigate and probe a variety of biological 
processes9192, as for example to map epitopes for antibody binding93, to discern 
ribonucleotide sequences with specific binding 94  or catalytic activity 95  (as aptamers), 
and to provide initial leads in receptor-based assays 9697. Key positive features of 
these oligonieric systems are the virtually limitless number of compounds that can be 
generated and the ease with which these oligomers can be made. However such 
compounds suffer metabolic instability and often poor oral absorption, with the result 
that any promising material will require extensive modification before any possible 
application in vivo. 
These limitations of natural oligomers have suggested that alternative systems which 
present the same advantages of modularity and ease of the synthesis but which offer 
metabolic stability could be highly attractive. An important number of systems have 
been developed for the synthesis and study of peptides analogues which offer 
markedly different chemical structures and chemical stabilities. A peptide analogue, 
or peptidomimetic, is generically defined as a substances having a secondary structure 
as well as other structural features analogous to those of the original peptide 
(allowing it to displace the original peptide from its receptor) but no longer has 
classical peptide characteristics, such as enzymatically scissile peptidic bonds. 
A large number of peptidomimetic systems have been developed and adapted to solid 
phase synthesis. This includes, /3-peptides, oligomei of N-substitued glycines (or 
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Figure 2.1. Structure of: a-Peptides, 13-peptides, Oligomres of N-substitued glycines (or Peptoids), 
Sulfonarnidopeptides, Oligourea peptidornirnetics. 
11.1.1. /3-Peptides. 
fl-Peptides100 '04 have particular appeal because ,8-amino acids represent one of the 
smallest step away from classical amino acids in terms of "backbone space". Like a-
peptides, fl-peptides contain amide bonds capable of forming, and stabilizing, 
intramolecular hydrogen bonds. A large body of structural and synthetic work has 
laid a solid groundwork of investigations into fl-peptides. C3-substituted fl-amino 
acid may be prepared by homologation of a-amino acids' 05  and by a number of other 
practical routes, 106,107  providing a convenient and highly diverse source of monomers. 
C2-substitued fl-amino acids are not accessible from a-amino acids and they can be 
prepared using different enantioselective methods, 106  as for example Evan's enolate 
chemistry105 '106 (Scheme 2.1). Early investigations onto polymeric fl-peptides 
indicated that they were able to adopt stable helical structures, although the precise 
helix geometries have been challenging to elucidate.'08"09 Secondary sheet structures 
have also been proposed for fl-amino acid polymers. 110-112 There have been extensive 
studies on the structures of cyclic peptides containing fl-amino acids. 113-115 
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Scheme 2.1. Methods for the preparation of protected 3-amino acids.105 '°6 
11.1.2. Sulfoijainide peptides. 
Among the promising surrogates which can be considered for the replacement of the 
native amide bond of peptides, a particular place should be reserved for sulfonamido 
polymers. Sulfonamides are metabolically stable, can effectively interact through 
hydrogen bond formation (a stronger hydrogen bond donor but a weaker hydrogen 
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bond acceptor) and adopt secondary structures. Several 'J3-sulfonopeptides' inhibitors 
have been prepared and studied (Figure 2.2). 116-118 
oo ' a o COOH 
C-a 
H H COOH 
Figure 2.2. Inhibitor of bacterial peptidoglycan biosynthesis enzyme MurE.118 
Originally 13-peptidosulfonamides were synthesized by the reaction of a 13—amino-
ethanesulfinyl chloride with an amine and subsequent oxidation to the 
sulfonamide. H9I2O  The oxidation step did not always result in high yields and was 
difficult to optimize for use in solid phase synthesis. To circumvent this problem 
different approaches based on Boc'21"22 or Fmoc'22 protected f3—amino-
ethanesulfonyl chlorides have been developed (Scheme 2.2). 
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Scheme 2.2. Synthesis of Fmoc protected f3—amino-ethanesulfonyl chlorides. '22 
11.1.3. Oligourea peptidoini:netics. 
In the field of peptide mirnetics, the urea moiety as a non-peptide linkage has 
attracted much attention. The urea fragment is promising for drug discovery and 
biomedical applications because of its expected resistance to protease degradation and 
interesting hydrogen bonding properties.] 21-121  In the solid state, NN-di substituted 
ureas are often involved in self-complementary bidirectional intermolecular hydrogen 
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bonds because of the trans geometry of the two amide bonds (Z,Z conformer). 26-128 
Self-organization at the molecular level has also been documented. 128" 29 
Burgess and coworkers 130.131 were the first to describe the solid-phase synthesis of 
oligourea peptidomirnetics, employing phthal imido-protected i socyanates as 
monomers. Subsequently, Schultz and co-workers' 32  developed a procedure using 
azido 4-nitrophenyl carbamate monomers. More recently Liskamp and others 
reported protocols for the solid phase synthesis of oligoureas using Boc°3 protected 
and Fmoc°4 protected monomers (Scheme 2.3). 
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Liskamp's Fmoc protected monomers for solid phase synthesis of oligourea peptidomimetics: 
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Scheme 2.3. Monomers for solid phase synthesis of oligourea peptidoniimetics. 
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11.2. Peptoids. 
Oligomers of N-substituted glycines or Peptoids 135 are N-alkylated glycine 
derivatives in which the amino acid side chains are shifted from the a-carbon to 
the a-amino functionality. A variety of applications of this class of compounds in 
medicinal chemistry' 36 has been described in the literature: as protease resistant 
entities,' 37 as antimicrobial agents 138 (2.1, Figure 2.3), as inhibitors of protein - 
protein interactions139 (2.2, Figure 2.3), and artificial protein mimics140. Peptoids are 
non-chiral peptidomirnetics, except for the chirality found in any side chain. 
Moreover, the absence of hydrogen bond donors in the peptoid backbone (except for 
glycine) and the flexibility of the backbone, due to the presence of tertiary amides 
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Figure 2.3. Bioactive peptoids. 
Translation of a peptide sequence may result either in a N-alkylated polyglycine 
(direct translation) or in a retropeptoid (retrosequence) as is shown in Figure 2.4. In 
the retropeptoids, the relative orientation of the carbonyl groups to the side chains is 
maintained and bares better resemblance to the parent peptide, and this may be 
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responsible for the slightly better biological activities of retropeptoids.14 ' In terms of 
nomenclature peptoid monomers corresponding to natural amino acids are indicated 
with an N before the name of the natural amino acid, so for example the 
corresponding monomer for Arg is written NArg. 
N-subsituted glycine oligomer or Peptoid 
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Figure 2.4. Translation of a peptide in an N-alkylated polyglycine (direct translation) or in a 
retropeptoid (retrosequence). 
Peptoids are synthesized following two main synthetic routes: 
Monomer based synthesis (Zuckermann 1992).135 
Sub-Monomer based synthesis (Zuckermann 1992).142 
11.2.1. Monomer based peptoid synthesis. 
The first synthesis of peptoids t35 was described in 1992 by Zuckermann, who defined 
five main desirable attributes for any potential substitute to natural oligomers: 
I. The monomers should be straightforward to synthesize in large amounts. 
2. The monomers should have as broad as possible variety of functional groups 
as side chains "hanging off' the oligomeric backbone. 
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The linking chemistry should be high yielding and amenable to automation. 
The linkage should be resistant to hydrolytic enzymes. 
The monomers should be achiral. 
From the analysis of the peptoid structure (Figure 2.4) it is possible to identify the 
following characteristics: 
I. Peptoid monomers are achiral (unless R is chiral). 
A wide range of possible side chain should be easily accessible. (see later) 
Peptoids are polyamides. 
Non natural arnide bonds are resistant to hydrolytic enzymes.137 
Monomers synthesis readily achievable. (see later) 
Thus offering all the 5 desirable properties highlighted by Zuckermann. 
2.1.1. Monomers Synthesis. 
Fmoc protected N-substituted glycines can be prepared by a number of routes, 
depending mainly on the needs and desirable properties of the side chain (Scheme 
2.4).' 35 
Reductive amination of a "side chain" amine with glyoxylic acid. 
0 	 R. 	 R 	o 
H) 	
0 	Fmoc-OSu 
(OH + RNH2 	
H2  /Pd 	
H NOH 	 Fmoc OH 
0 
Reductive amination of a "side chain" aldehyde with a glycine ester. 
0 	 0 	I) H2/Pd 	R 	
Fmoc-OSu 	
Fmo: OH RH + 	
ii)KOH 
HNOH 
B) 	Alkylation of a "side chain" amine with chioroacetic acid. 
0 	 R 	
Fmoc-OSu 	
0 
CI QH + RNH2 	 H N OH 	 Fmoc OH 
Michael addition of glycine to acrylamide. 




2 	 HNOH Fmoc-OS10 
u FmocNOH 
Scheme 2.4. Three synthetic routes towards Emoc protected N-substituted glycines. All "side chain" R 
functionalities are protected. 
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The three main routes being: 
Reductive amination of a side-chain amine with glyoxylic acid, or of a 
"side- chain" aldehyde with a glycine ester. 
Alkylation of a "side chain" amine with chioroacetic acid. 
Michael addition of glycine to acrylamide. 
In all these strategies the "side-chain" functional groups need to be protected. With 
amino, carboxyl, hydroxyl, indole, guanidine and imidazole moieties protected using 
the standard protecting groups (t-Butyl, Pnic, Trityl) typically employed in Fmoc 
based peptide synthesis. 
Other routes to these monomers have since been developed. Thus for example 
Liskamp synthesised the monomers from ethyl bromoacetate via alkylation with 
different amines (Scheme 2.5). 143  The resulting N-substituted glycine ethyl esters 
were easy to purify by column chromatography (unlike the corresponding free acids). 
The N-alkylted glycine esters could then be treated with NaOH, to give the 
corresponding sodium salts prior to Frnoc protection. 
0 
R 	0 	1) 4 N NaOH 	 R 0 
R—NH, 	0.5 equiv 	H)0-. 	MeOH/dioxane 	Fmoc.._)OH 
2) a. Fmoc-OSu 
THF 	 H20/MeCN 
TEA 
b. H3O 
Scheme 2.5. Liskamp's synthesis of fmoc protected peptoid monomers. 
Liskamp also reported a modification to this protocol for the synthesis of the NArg 
monomer. 141 Thus ethyl bromoacetate was substituted with benzyl bromoacetate 
(Scheme 2.6) used to alkylate N-Boc- 1 ,3-diaminopropane with the amino group of 
the resulting N-alkyl glycine benzyl ester protected with a Cbz group. The side-chain 
amine was deprotected selectively under acidic conditions and the free amine 
subjected to guanylation with N,Nbis(Boc)-1-guanylpyrazole to give Cbz-
NArg(Boc)2-OBn. The benzyl ester and Cbz group were removed by hydrogenolysis 
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Scheme 2.6 Synthesis of Frnoc —Narg(Boc)2-OH by Liskamp. 
2.1.2. Peptoid oligoinerizarion. 
The oligomerization process is based on the same protocols adopted for peptide 
chemistry (Scheme 2.7); the only relevant difference is that the couplings involve 
secondary amines. It is known that N-alkylarnino acids often couple poorly under 
standard conditions, 144  a problem that can affect yield and purity for this particular 
kind of oligomers, and to minimize this problem standard carbodiimide coupling 
reagents have often been substituted with PyBOP and PyBrOP, developed for the 
coupling of hindered or (x-di substituted amino acids.' 41,14'  All the other steps, such as 
Fmoc deprotection and cleavage, were carried out following the usual conditions for 
peptide synthesis. 
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FmocOH 	 i. Coupling 	\[Fmoc_OHI 
A 0 	 H 0 
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Scheme 2.7. Peptoid synthesis vs. Peptide synthesis. 
11.2.2. Sub-mono,ner based peptoid synthesis. 
Immediately after the monomer based synthesis a second synthetic strategy for the 
preparation of peptoids called "sub-monomer" approach was proposed by 
Zukerman.'42 Each N-substituted glycine unit was assembled directly on the solid 
phase using two sub-monomer units: a haloacetic acid and a primary amine. From 
this perspective the oligomer could be considered as an alternating condensation of 
the two sub-monomers (Scheme 2.8). 
-37- 
0 
X OH 	0 	 - R1 NH2 	A1 0 
H2N-0 	 XNQ H)NQ DIC, DMF 	 H 
II 	 DMSO 	 H 
H2N-RINK-Q 
STEP 	 STEP  
Scheme 2.8. Monomer assembly cycle: Acylation (STEP 1), Nucleophilic displacement (STEP 2). 
Each monomer was thus added during a two step cycle consisting of an acylation with 
bromo acetic acid and alkylation of an incoming amine (Scheme 2.8). 
The acylation (first step) was carried out by activation of the haloacetic acid (Br) with 
a carbodiirnide. Although the acylation of a secondary amine can be difficult, in 
particular with bulky amino acids, this problem was "minimised" by the use of 
haloacetic acid which, in the presence of a carbodiimide, are very effective acylating 
agents. 
The nucleophilic displacement (second step) introduced the side chain by 
displacement of the halogen using an excess of a primary amine, with any side-chain 
groups protected to avoid any secondary reactions. The efficiency of the displacement 
was also dependent on the halide used in the first step. When reacted with aniline the 
reported efficiency order of displacement was: I ~! Br >>.Cl. Zuckerman and colleges 
reported that the optimized conditions for displacement of the bromide using a-
butylamine and cyclopropylamine were 16 equiv (1 M) and 40 equiv (2.5 M) 
respectively, but due to the solid phase nature of the synthesis the amine in excess 
was readily washed away. The complete cycle of acylation and nucleophilic 
displacement, took around 3 h for each "monomer" added. 
2.2.1. Microwave heating. 
In an effort to improve the efficiency of the sub-monomer based peptoid synthesis 
approach, Kodadek and colleagues investigated the application of microwave 
irradiation to accelerate the acylation and amination reactions (Scheme 2.9). 147 
Acylation was performed with bromoacetic acid (with I equiv DIC) at a 
concentration of I M. All the amines were used at a concentration of I M. The 
peptoids were prepared at room temperature, at 37 °C (with conventional heating) and 
under microwave irradiation (100 W, 2 X 15 5, Tinax around 35 °C). The efficiency of 
the different protocols was tested with the synthesis of 9-mer peptoids (homo-
oligomers, 2.3-2.6, Scheme 2.9) and a 20-mer homo-oligomer of 2.4 (Scheme 2.9). 
The microwave experiments were performed using a domestic microwave oven under 
so called power control (100 W). Their results showed that reaction times of 30-40 s 
for the acylation, or the amine displacement, were sufficient to prepare the 9-mer 
peptoids with good yields and purities. 
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1 M bromoacetic acid and 1 M DIC in DMF, 100W (2 X 15 s), Tmax 35 °C. 
Step 2: 
1M amine in DMF DMF, 100W (2 x 15 s),Tmax 35 °C. 
Blackwell: 
Stepi: 
2 M bromoacetic acid and 2 M DIC in DMF, 35 °C, 30s. 
Step 2: 
1 M amine in DMF, 95 °C, 90 S. 
Scheme 2.9. MW assisted sub-monomer peptoid synthesis, Kodadek and Blackwell's conditions. 
For comparison conventional heating (37 °C) gave comparable results but with much 
longer reaction times: 45 min for the acylation and I h for the amine displacement. 
Room temperature synthesis provided compounds with much lower purity even with 
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longer reaction times: 60 min for acylation (2 x 30 mm), and 2 h for amine 
displacement. 
The work from Kodadek showed how microwave assisted protocols could be applied 
successfully to peptoids synthesis using a sub-monomer approach. Unfortunately this 
was done using a domestic microwave oven, which is potentially dangerous and no 
longer publishable in most journals due to safety and reproducibility issues. 
Blackwell and co-workers' 48  in 2005 decided to transfer Kodadek's microwave 
assisted synthesis to a commercial microwave reactor (Milestone Ethos Microsynth 
nîultimodal microwave reactor), as the latter systems provide consistently safer and 
more reproducible microwave methodology. The first attempt to reproduce 
Kodedek's synthesis' 47  (100 W, 30 s per step, I M solutions) on identical substrates 
(homononamers of 2.3-2.5, Scheme 2.9) gave peptoid products with irreproducible 
purities and lower yields. More interestingly, their control experiments at room 
temperature with these unhindered primary amines provided horno 9-mer peptoids 
with high and reproducible purities with a reaction time of 30 s (I M solution). The 
unhindered primary amines did not require neither MW heating nor the standard 3 h 
room temperature reaction time, allowing the monomer construction to proceed in 
just 1 mm. Continuing their investigation they decided to test the microwave assisted 
synthesis with electronically deactivated and sterically hindered amines (2.7-2.11, 
Scheme 2.9). The best conditions found were: Acylation, 2 M bromoacetic acid (DIC, 
2 M) in DMF, 30 s, 35 °C; Amination, I M amine in DMF, 90 s, 95 °C. 
The microwave conditions gave some improvement for the amine with some steric 
hindrance (2.7, 2.8), with a 10% purity enhancement relative to the 25 °C control. 
However with a reduced steric hindrance of the amine (2.9, 2.10) the microwave 
conditions gave no significant improvement relative to the 25 °C control. The 
microwave conditions proved to be much more advantageous for deactivated amines, 
as for l-(pentafluorophenyl)ethylamine (2.11) with purities doubled from 22% (room 
temperature) to 56% (microwave conditions). 
The results presented by Blackwell indicate that in the absence of sterically or 
electronically deactivated amines, peptoids can be generated with much reduced 
reaction times: acylation 30 s, amination 90 s, driven by the use of large excesses of 
reagent. 
H.2.3. Monomer approach vs sub-monomer approach. 
Table 2.1 shows the advantages and drawbacks associated with the two strategies: 
Sub- monomer. Monomer. 
Advantages. Advantages. 
No synthesis of protected building block. Application of standard peptide 
synthesis 
Large availability of primary amines (not Synthesis on solid phase 
requiring side protection). monitored by dibenzofulvene 
adduct. 
Haloacetic acids in presence of Automation. 
carbodiimides are effective acylating agents 
for secondary amines. 
Drawbacks Drawbacks 
Large excesses of reagents (amines up to 40 Synthesis of protected building 
equiv) blocks in considerable quantities 
Completion of acylation and substitution Need of expensive coupling 
reactions cannot be determined reagents as PyBrOP or PyBOP 
Fable 2.1. Monomer vs. Sub-monomer strategy. 
The sub-inononier approach is very attractive. It does not require the synthesis of the 
building blocks (except the protection of the side chain when required) and the ready 
availability of primary amines gives it an enormous potential for the creation of 
libraries of compounds. 
It has been shown that with unhindered primary amines the synthesis can be carried 
out very rapidly at room temperature (I residue per minute as reported by some 
authors). In the case of deactivated arnines, microwave assisted protocols can be 
employed to sensibly increase the purities of crude compounds. 
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However this incredible flexibility has some important limitations. Firstly the 
synthesis requires a large excess of material up to 40 equiv, with concentrations of 
primary amine (or haloacetic acid) solutions up to 2 M. Also completion of the 
acylation and substitution reactions cannot be determined, and this is essential for the 
preparation of larger peptoids of reasonable purity. 
The inononier approach has the immediate advantage of the analogy with peptide 
synthesis. The synthesis requires a limited amount of material (4-5 equiv) per residue, 
while the use of Fmoc protected monomers allows monitoring of the synthesis on 
solid phase by quantifying the dibenzofulvene adduct obtained from the cleavage of 
the Fmoc group. The synthesis can be carried out on a automated peptide synthesizer 
applying the same protocols used for peptides giving easy access to longer peptoids. 
But also this approach has important limitations. The most immediate is that the 
monomers are not commercially available and each of them has to be synthesised. As 
a consequence the use of large libraries of different monomers is limited, in particular 
if compared to the direct use of "naked" primary arnines. Another relevant aspect is 
the general lack of reactivity of secondary amines in the amide bond formation, and 
conventional carbodiimide coupling reagents as DIC may not be efficient. 
The "sub-monomer strategy" is potentially the best choice for the synthesis of large 
libraries of small peptoids (3-5 residues) for two main reasons: easy access to 
extremely different primary amines and the acceptable purity of the crudes for testing. 
However "the monomer approach" appears to be a better choice for the synthesis of 
longer peptoids with defined purity. 
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11.3. Cell penetrating peptoid transporter. 
11.3.1. Peptoid monomer synthesis. 
The synthesis of the peptoid monomer N-Fmoc-N-(6-N Boc-aminohexyl )-gl ycine 
(2.12) was reported by Peretto.149 The synthesis (Scheme 2.10) was based on the 
protocol described by Liskamp (see earlier). Mono-Boc protected I ,6-hexanediarnine 
was reacted with ethyl bromoacetate (I equiv) to give the corresponding N-
substituted glycine ethyl ester (55% yield). Saponification of the ester and final Frnoc 
protection in aqueous conditions (pH 9) gave the peptoid monomer N-Fmoc-N-(6-N 






This synthesis was repeated and the yields obtained were consistent with those 
reported. In contrast the yields reported by Liskamp'41  on a similar substrate (1.4 
diaminobutane) were generally much higher (alkylation around 75%, Fmoc protection 
around 95%). 
Br(°  
Boc20 (0.1 eq) 
H2N { NH2 







2.13 	 55% 
NHB0c 
NaOH 	 (Q 6 0 
Fmoc_N QH  
Fmoc-OSu 
40% 	 2.12 
Scheme 2.10. Synthesis of peptoid monomer 2.12 reported by Peretto.'49 
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The lower alkylation yield was not surprising as Liskamp used an excess of primary 
amine (2 equiv) while in the protocol reported by Peretto the primary amine and the 
bromoacetate were equimolar, conditions in which dialkylation reduce the desired 
product. More difficult to explain were the differences in efficiency of the Fmoc 
protection which was carried out under aqueous condition at controlled pH (pH 8-9). 
A new approach was thereby developed to allow the monomer to be prepared on a 
20-30 g scale. 150  The strategy was based on the Fmoc protection of an N-substituted 
glycine ester, not the acid, using organic solvents under more controlled conditions, 
and final conversion of the Fmoc protected ester into the corresponding acid (Scheme 
2.11). To do so required an ester functionality that could be removed compatibly with 
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Scheme 2.11. Synthesis of peptoid monomer 2.12. 
The benzyl ester was chosen because it can be converted into the corresponding acid 
under mild conditions by simple hydrogenolysis, compatibly with Boc and Fmoc 
functionalities. Thus ethyl bromoacetate was replaced with benzyl bromoacetate 
which was alkylated to give the N-substituted glycine benzyl ester 2.15 (54% yield). 
Fmoc protection was carried out in DCM using Fmoc—OSu (1.1 equiv), with a 90% 
isolated yield. Conversion of the benzyl ester 2.16 into the corresponding acid 2.12 
was carried out by hydrogenolysis (Pd/C 10%, 0.1 equiv) giving after filtration the 
peptoid monomer in 94% yield (100% purity by ELS analysis). As reported earlier a 
similar use of the benzyl ester functionality was described by Liskamp (see Scheme 
2.6), however in his protocol the benzyl ester was converted into the corresponding 
acid before the Frnoc protection step, which was still carried out in aqueous 




Figure 2.6 HPLC trace (ELS) of N-Fmoc-N-(6-N '-Boc-arninohexyl)-glycine 2.12, 100% purity. 
11.3.2. Solid phase peptoid synthesis. 
As reported by Peretto'49 the peptoids were assembled on polystyrene aminomethyl 
resin functionalised with the Rink 15 ' amide linker (Scheme 2.12 and Scheme 2.13). In 
each of the coupling steps monomer 2.12 (2 equiv), PyBrOP (2 equiv) in DCM (0.08 
M) and DIPEA (4 equiv) were added to the resin and reacted at room temperature for 
4 h. PyBrOP as reported before was necessary to enable efficient coupling of the 
secondary amine. Deprotection of the Frnoc group (20% piperidine in DMF) and 




Fmocdeprotection 	 = H2NRINK 
0 
Fmoc-Rink amide linker 	 Rink amide resin 
Scheme 2.12. Preparation of Rink amide resin. Reagents and conditions: (i) Fmoc-Rink amide linker 
(3 equiv, 0.2 M), HOBt (3 equiv, 0.2 M), DIC (3 equiv, 0.2 M) in DMF, 12 Ii; (ii) 20% piperidine in 
DMF, 2 x 20 mm. 
- 45 - 
H2N—RINK--0 
NHBoc 
i. 	( 	0 2.12 






ii. Fmoc deprotection 







N NRINK Q 
Scheme 2.13. Synthesis of peptoid oligomers on solid support. Reagents and conditions: (i) monomer 
2.12 (2 equiv, 0.1 M), PyBrOP (2 equiv, 0.1 M), DIPEA (4 equiv, 0.2 M) in DCM, 4 h; (ii) 20% 
piperidine in DMF. 2 x 20 mm. 
As outlined previously this general protocol presented two important limitations: 
- Use of an expensive coupling reagent (necessary for the coupling of 
secondary amines). 
- 	Time consuming synthesis (4 h for each residue added). 
Cost and time of the synthesis had to be minimised as much as possible. To do so we 
decided to investigate the use of microwave heating to reduce the coupling reaction 
time, and the use of the classic and robust DIC/HOBt protocol for acids activation, in 
order to replace the expensive PyBrOP coupling reagent. 
11.3.3. MW assisted solid phase peptide synthesis. 
Microwave heating has been successfully applied to organic synthesis, giving rise to 
so-called M.A.O.S (Microwave  Assisted OrganicSynthesis). The field has developed 
significantly since the first reports of microwave promoted synthesis in 1986. 152,153 
Domestic microwave ovens are increasingly being replaced by scientific microwave 
apparatus for use in synthesis. As well as being safer, these new instruments allow for 
accurate control of key parameters such as initial microwave power, reaction 
temperature and, in the case of sealed vessel reactions, internal pressure. 
Although the outstanding number of microwave assisted synthetic protocols produced 
since 1986 it was quite surprising at the time to learn how little precedent was 
available for microwave-assisted peptide coupling reactions. 
The first example of microwave heating applied to peptide synthesis was reported by 
Wang and co-workers' 54 in 1992 (Figure 2.6). Their microwave heating protocol 
offered a 2-4 fold reduction in amino acid coupling time with two different coupling 
methods, symmetric anhydride and pre-formed N-hydroxybenzotriazole (l-IOBt) 
active ester, especially when using side-chain hindered amino acids. They reported 
that no significant racemization was observed. The reactions were performed using an 
un-modified domestic microwave apparatus (10% of the full power, 6 mm, with an 
"estimated" temperature near to 55 °C), thus accurate temperature measurement was 
not possible and also reproducibility from microwave to microwave proved an issue. 
While the results appeared promising, lack of proper instrumentation and concerns 
regarding acceleration of potential side-reactions delayed further exploration. 
EJ MicrwC)ven 	____ 
/ 
Figure 2.6. Wang's MW reactor for peptide synthesis: Microwave oven and the custom-made solid-
phase reaction vessel. The vessel was left in the middle of the microwave oven, and a Teflon tube from 
the side arm of the reaction vessel was connected to a nitrogen source. During microwave irradiation, a 
stream of nitrogen was blown into the reaction vessel, and the nitrogen gas bubbles served as a stirrer. 
After irradiation was stopped, the reaction solution was filtered off via the side arm by suction.154 
As modern microwave systems that generated a homogeneous microwave field and 
offered temperature control became available, new interest was generated in peptide 
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synthesis applications. Almost a decade after Wang's first report,'54 in 2001 
Santagada and colleagues 155  reported the difficult coupling of a-arninoisobutyric acid 
(Aib) with sterically hindered natural or non coded amino acids, using conventional 
and microwave heating methods, with either PyBOP/HOBt or HBTU/HOBt as 
coupling agents. In the microwave heating experiments, the reaction mixture was 
heated to 55 °C for 15 min followed by a further 15 min at 60 °C. It is interesting to 
note how conventional heating did not present a really significant improvement, for 
example the yield for Z-Aib-Val-OMe changed from 74% (HBTU/HOBt, 25 °C, 16 
h) to 77% (HBTU/HOBt, 55 °C, 16 h), while under microwave irradiation the yield 
was increased up to 94% (HBTU/HOBt, 15 min at 55 °C plus further 15 min at 60 °C, 
in total 30 mi. It was also noticed that under microwave irradiation the coupling 
yields were not influenced by the particular activator employed, the use of PyBOP 
and HBTU, leading to dipeptides in high yields (range 86-96 %) and with 
dramatically reduced reaction time, from 16 h to 30 mm. 
Gogoll and colleagues 156  in 2002 reported the study of common activators TBTU, 
PyBOP, HATU, Mukaiyarna's reagent with microwave heating up to 110 °C and 130 
°C, for the coupling of sterically hindered Fmoc-protected amino acids (tripeptide 
Fmoc-Thr-Val-Ile-NH2, dipeptides Fmoc-Ala-Ile-NH2 and Fmoc-Thr-Ile-NH2). The 
microwave assisted couplings were performed in sealed vessels under temperature 
control conditions at 110 °C uisng PyBOP (20 min), TBTU (10 mm), and HATU (1.5 
mm) then at 130 °C using Mukaiyama's reagent (10 mm). Surprisingly no particular 
levels of racemization were observed under any of the conditions described. 
Microwave heating has been used for the coupling of sterically hindered glycosylated 
amino acid building blocks on solid supports. 157,158 These building blocks (Figure 2.7) 
were used in the synthesis of the 20 amino acid protein MUCL 159  The solid-phase 
synthesis was performed on both Tentagel and PEGA supports functionalised with 
the Rink amide linker. Couplings were performed using HBTU/HOBt, under 
microwave irradiation (monomode microwave apparatus at 50 °C), under 
conventional heating (at 50 °C), and at room temperature. 
NHAc / 





Figure 2.7. Glycosylaled amino acids building blocks.'  7 
When the synthesis was carried out at 50 °C (conventional or microwave heating), 
standard Frnoc amino acids were coupled in 10 min, while the glycosylated amino 
acids required 20 mm. Deprotection was carried out in 3 mm. The whole procedure 
to build manually the 20-mer peptide took only 7h. When the synthesis was 
performed at room temperature couplings were significantly longer, with 2 h for 
Fmoc amino acids and 20 h for the glycosylated amino acids. Fmoc deprotection was 
carried out in 20 mm. As a result, the whole process took approximately 99j1.  The 
synthesis under microwave conditions and the one at room temperature gave 
comparable yields (43% and 41% respectively, 14% with conventional heating) but 
requiring a significantly different amount of time for the synthesis, from 4 days at 
room temperature to 7 h under microwave conditions. 
Microwave heating has also been applied to the preparation of -peptides (2.17 and 
2.18, Figure 2.8).' °  








  J70  p-amino acid 
2.17 
CO2H 
a JO 0 
NH2 	 6N
N6N N N 
CO2H 
H2N 	






Figure 2.8. 3-peptides prepared under microwave assisted conditions. 160 
ZRZ 
Hexamer 3-peptide 2.17 was prepared manually either conventionally at room 
temperature either under microwave irradiation in a monornode microwave apparatus. 
When using conventional methodology (room temperature, 1.5 h per coupling, 15 
rnin deprotection) although the penta -peptide precursor was >95% pure, hexamer 
2.17 was only 55% pure with significant quantities (33%) of the unreacted pentarner 
as well as some of the Fmoc-protected hexamer being present. Under controlled 
microwave heating (coupling 6 rnin at 50 °C, deprotection 4 min at 60 °C) hexamer 
2.17 was obtained in 80% purity with only 5% of the unreacted pentamer and none of 
the Fmoc-protected hexamer being observed. 
Studies were then extended to deca-3-peptide 2.18. However this was obtained in 
only 57% purity, indicating the challenge of coupling extra residues to hexamer 2.17. 
What proved to be a solution for this problem was the use of a solution of LiCI in 
DMF in the coupling protocol. 161  Salt additives are known to alleviate, at least in part, 
the problems of aggregation and/or folding of resin-bound (X-peptides as they increase 
in length. Thus, in this case, the effects of microwave heating alone may not be 
enough to disaggregate the 3-peptide. With the modified reaction conditions, deca--
peptide 2.18 could be prepared in 88% purity and 81% yield. Using the LiCl 
modified conditions for the synthesis of hexamer 2.17 the already high purity was 
increased to 94%. As well as disaggregating the peptide, the salt additive could also 
enhance the ionic conduction mechanism for conversion of microwave energy into 
heat in the reaction mixture. Moving to a multimode microwave apparatus, the same 
group reported the synthesis of a library of 14-helical -peptides. '62 A recent report 
describes the use of microwave heating conditions for the solid phase synthesis of 
pseudopeptides containing an ester bond. 161 
3.3.1. Microwave activation and side reactions. 
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Scheme 2.14. Formation and ring opening reaction of aspartimide. 
Aspartimide formation ](4,165 (Scheme 2.14) can occur during Fmoc removal with 
piperidine. Nucleophilic attack by the amide of the neighbouring group to an aspartic 
acid on the side chain ester (or amide) drives the generation of a 5-membered ring, 
which can then re-open by nucleophilic attack. This potential side reaction 
accumulates during each successive deprotection step and can lead to substantially 
reduced purity. This problem is reduced with bulky protecting groups (R, = t-butyl) 
but not totally eliminated. 
Racemization during the coupling reaction has been extensively documented. 166.167 
The two main mechanisms of racemization are direct enolization and oxazolone 
formation. '68 During the coupling reaction, formation of an activated ester and 
concomitant increased acidity of the a-carbon proton can lead to loss of 
stereochemical integrity. The racemization rate is influenced by the electron-
withdrawing effect of the amino acid side chain, the reaction temperature, the solvent, 
and the activator base. Sterically hindered tertiary amines are used to minimize the 
base—catalyzed removal of the a-proton (Figure 2.9). 
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Figure 2.9 Racemization of activated Fmoc derivatives of cysteine and histidine by direct enolization. 
Formation of an oxazolone (Scheme 2.15) can cause the racemization. 
Enantiomerization by oxazolone formation occurs more frequently during the 
condensation of peptide fragments, however N-urethane protected amino acids can be 
susceptible to this reaction.' 66 
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Scheme 2.15. Oxazolone-mediated racemization occurring during peptide coupling. 
The first reports regarding microwave peptide synthesis had shown no evidence of 
increased epimerisation due to microwave heating.' 54,156  However, this observations 
could be attributed to the fact that none of the troublesome residues (Cys or His) were 
constituent parts of the peptide sequences. 
To investigate if the application of microwave conditions could have a negative 
impact by enhancing side reactions Collins and colleagues 169  prepared a 20-mer 
model peptide (VYWTSPFMKLIHEQCNRADG-NH2) which contained each of the 
natural 20 amino acids, but with a selectively placed C-terminal Asp-Gly segment to 
encourage maximum potential aspartimide formation. At room temperature, although 
the racemization levels were low, the crude product purity was only 68% due to a 
number of deletions. An initial microwave-promoted synthesis of the 20-mer 
indicated that the sequence was susceptible to racemization. Deprotection steps of 30 
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s at 50 W followed by 180 s at 50 W (Tmax = 80 °C) and a coupling step of 300 s at 
40 W (Tmax = 80 °C) led to significant racemization at His, Cys residues and Asp 
residue. A second coupling protocol of 120 s at 0 W followed by 240 s at 40 W 
(Tmax = 50 °C) in which the reaction mixture did not exceed 50 °C proved to be 
effective with high peptide purity (84%) and reduced racemization of His and Cys 
residues. 
Kappe' 7° reported a "cooling before microwave irradiation" approach for the 
preparation of peptides with low racemization and high purity. Compared to other 
microwave protocols the reaction mixture was cooled to 0 °C before and between 
microwave irradiations. In Kappe's synthesis deprotection and coupling reactions 
were performed in standard glass vials and the washing steps in polypropylene 
syringes equipped with a frit and valve. Using a power control protocol, the 
maximum temperature reached in the steps and purity of the final product depended 
on whether the contents of the reaction mixture were cooled to room temperature 
(Tmax 95 °C, 63% purity) or to 0 °C (Tmax 64 °C, 86% purity) prior to microwave 
irradiation. Pre-cooling of reaction mixtures prior to microwave irradiation has shown 
to lead to peptides in high purity with little racemization, but appears to be 
inconvenient and not practical either in an automated reactor or when considering 
performing couplings in parallel or on a large scale. 
11.3.4. Microwave assisted peptoid synthesis. 
Peptoid couplings were carried out in a single-mode microwave reactor (Smith 
synthesiser) in sealed vials; deprotection and washing steps were performed in a SPE 
(Solid Phase Extractor), a polypropylene syringe equipped with a frit and a valve 
(Figure 2.10). 
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Figure 2.10. Schematic representation of the peptoid synthesis. MW assisted coupling in a sealed 
glass vial and Fmoc deprotection at room temperature in a polypropylene syringes equipped with a frit 
and a valve (SPE: Solid Phase Extractor). 
General conditions for the microwave assisted coupling (Table 2.2) were chosen as 
follows: 
MW Assisted DICIHOBt Peptoid Coupling 
Equivalents: 3 (0.1-0.2 M) 
Temperature: 60 °C 
Time: 20 mm. 
Table 2.2 
The temperature was set at 60 °C as: 
- The protocol had to be compatible with peptide synthesis. It was reported that 
higher temperature (over 80 °C) gave high levels of side reactions during 
peptide synthesis. 160J69 
- A temperature of 60 °C was reported to be sufficient to achieve efficient 
coupling with very hindered substrate such as Aib, and glycosylated amino 
acids (Scheme 2.7).155.157 
Therefore, a temperature of 60 °C looked a good compromise between efficiency and 
mildness of the reaction conditions. 
The reaction tune was set at 20. As an approximation, the rate of reactions is doubled 
when the temperature is increased by 10 °C. So, at 60 °C, reactions are approximately 
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16 times faster than at 20 °C. Couplings with DIC/HOBt are usually carried out at 
room temperature in 3 h (180 minutes), therefore, at 60 °C it should require only 10-
11 minutes. In consideration of the hindered nature of the secondary amine used for 
the peptoid synthesis, the time was set at 20 minutes. 
The concentration of the reagents (3 equivalents) was kept in a range between 0.1 
and 0.2 M, and this depending by the loading of the resin used. When using resins 
with a loading around I mmol/g it was possible to keep the concentration of the 
reagents at 0.2 M. When using resin with lower loading, < 0.5 mmol/g, the 
concentration of the reagent was reduced to 0.1 M. The number of equivalents used in 
all the cases was 3; the difference in concentration depended on the need to use 
indentical volumes of solvent to suspend the resin, independently by the loading. 
Peptoid monomer 2.12 (3 equiv) was pre-activated with DIC (3 equiv) and HOBt (3 
equiv) in DMF (0.1-0.2 M solution, see later) for 2 min before being added to the pre-
swollen resin inside a solid phase extractor (SPE). The solution with the resin was 
transferred (using a plastic pipette) into a microwave glass vial then capped. The 
couplings were performed at 60 °C, for 20 min with magnetic stirring of the resin. 
Power and pressure profiles were registered during to ensure maximum 
reproducibility of the conditions. Coupling completion was monitored by the 
Chloranil test, '71 a standard colorimetric test used to detect the presence of free 
secondary amines. The resin was then poured back into a SPE and washed (DMF, 
DCM) without drying to keep the resin swollen. Fmoc deprotection was performed 
using a 20% piperidine solution (in DMF) at room temperature (2 x 10 mi. Fmoc 
deprotection reaction time could be reduced with microwave heating but this does not 
offer a really significant improvement. The synthesis of the 7mer peptoid transporter 
using microwave conditions was reduced to a single day giving material with a high 
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Scheme 2.16. Reagents and conditions: (i) 2.12 (3 equiv.), DIC (3 equiv.) and HOBi (3 equiv.) in 
DMF atO.IM; microwave irradiation at 60 °C for 20 mm. (ii)Fmoc deprotection: 20% piperidine in 
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Figure 2.11. Crude of Fmoc protected hepta-peptoid 2.19: A) HPLC trace, 98 % purity according to 
ELS detection; B) Mass spectrum , m./z (ES+): 667.6 (M+2H) 2+ 445.5  (M+3H)3 , 334.4 ( M+4H)t 
In conclusion the combination of standard DIC/HOBt activation and microwave 
heating proved immediately to be extremely efficient for the preparation of the 
peptoid. Although further optimisation of the synthetic protocol was possible, such 
as a further reduction of the coupling time, it was considered not of relevance. 
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Chapter III. Peptoid conjugation to cargoes and delivery. 
In 2003 Peretto reported the synthesis and cell permeability evaluation of homo-
oligomer peptoids based on monomer 2.12. 149  Analysis by fluorescence microscopy 
and FACS indicated that these materials possessed the ability to successfully 
penetrate the membrane of cells with localisation observed in the cytosol, the nucleus 
and concentration in the nucleoli. Of the peptoid oligomers tested (tn, penta and 
hepta-mer) the heptapeptoid exhibited maximum internalisation with > 99% of cells 
labelled. None of the peptoids assayed were found to be toxic as verified by a MTT'73  
toxicity test and trypan blue 174  assay to ascertain cell viability. To study the 
potentials of these peptoid oligomers as carriers for poor cell permeable molecules, 
the more effective heptapeptoid was conjugated to different cargoes and tested for 
delivery into cell and skin. The test cargoes were: a peptide hormone a-MSH (l3mer 
peptide), peptide nucleic acids (PNA) (91ner, l2mer, l5mer), and a mercapto DNA 
(19rner). In order to visualize cellular internalisation the heptapeptoid conjugated 
compounds were typically labelled with fluorescein. 
111.1. a-Melanocyte stimulating hormone ((x-MSH). 
The hormone a-MSH (Ac-SYSMEHFRWGKPV-NH2) is a ligand of melanocortin I 
receptor (MCIR), a seven pass transmembrane G-protein coupled receptor which is 
expressed on the surface of melanocytes and melanoma cells.' 75"76 Healy and 
colleagues have shown that a-MSH (106  M) stimulates pigmentation of melanocytes 
and melanoma cells in vitro increasing intracellular cyclic-AMP which starts a 
complex signalling cascade resulting in an increased production of black or brown 
eumelanin (Figure 3•)77 Melanocortin 1 receptor (MCIR) gene variants alter 
pigment synthesis in vivo, and are causally associated with red hair and fair skin in 
humans due to an increased production of red or yellow phaeomelanin.178"79 MCIR 
variants may represent a predisposition to melanoma as a result of alterations in skin 
pigmentation, with less eumelanin and more paeomelanin affording less protection 
against incident ultraviolet radiation. 180,181 
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Figure 3.1. Hormone a-MSH. 
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Figure 3.2. Schematic of action of u-MSH at the melanocortin I receptor. -MSH signaling results in 
an increased ratio of eumelanin to phaeomelanin. In contrast, loss of function of MCIR results in 
increased phaeomelanin production. 
111.1.1. a.MSH and peptoid conjugation: synthesis and labelling. 
The peptide a-MSH (3.1) was firstly prepared by standard SPPS using a Rink15 ' 
amide polystyrene resin. Fmoc protected amino acids (3 equiv) were pre-activated 
with DIC (3 equiv) and HOBt (3 equiv) in DMF (0.2 M) for 5 mm, added to the resin 
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standard colorimetric test to detect the presence of unreacted amines (Nynidrin'82 test 
for primary amines, Chloranil' 7 ' test for secondary amines). Fmoc deprotection was 
carried out using 20% piperidine in DMF (2 x 10 mm). 








Scheme 3.1. Synthesis of u-MSH (3.1) and fluorescein (FAM) labelled -MSH (3.2). Peptide 
couplings: amino acids (3 equiv), DIC (3 equiv) and HOBt (3 equiv) in DMF at 0.2 M, room 
temperature 3 It. Fmoc deprotection: 20% piperidine in DMF, 2 xlO min at room temperature. 
Fluorescein labelling: 5(6) carboxyfluorescein (3 equiv), PyBOP (2.8 equiv) and DIPEA (6 equiv) in 
DMF 0.2 M, room temperature 12 h; Cleavage mixture: 81.5% TFA, 5% thioanisole, 5% phenol, 5% 
water, 2.5% EDT (1,2 ethanedithiol), 1% TIS (triisopropylsilane). FAM = 5(6) carboxyfluorescein. 
Side chain protecting groups not indicated. 
In order to visualize cellular internalization the peptide a-MSH was labelled with 
carboxyfluorescein (PAM). Notoriously, 5(6)-carboxyfluorescein 183,184   (Scheme 3.1) 
is an annoying dye to couple to peptides because of the poor reactivity of the acid and 
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possible side reactions of the phenolic oxygen to form fluorescin —fluorescein 
esters.' 85  The coupling was carried out at room temperature using PyBOP as coupling 
reagent (12 h). Before TFA cleavage the resin was treated with 20% piperidine in 
DMF in order to cleave possible fluorescein-fluorescein esters. 185 
Peptide a-MSH (3.1) prepared via standard SPPS was obtained with a 60% purity 
(Figure 3.3), with preliminary data indicating that the low purity was determined by 
difficulties on the coupling of the last 3 aminoacids sequence S-Y-S. Fluorescein 
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Figure 3.3. HPLC trace (X = 220 nm) of crude peptide a-MSH (3.1) prepared at room temperature, 
purity (63%). 
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Figure 3.4. HPLC trace (X 220 nm) of crude peptide 3.2 prepared at room temperature, purity (40%). 
Compounds 3.1 (c-MSH) and 3.2 (FAM-Ahx-(t-MSH) were purified by RP-HPLC 
(purity > 95%) before testing on mammalian cells. 
I.].]. Microwave assisted synthesis and labelling of a-MSH. 
Fluorescein labelled -MSH (3.2) was re-synthesised under the same microwave 
heating conditions that proved to be very efficient in the preparation of heptapeptoid 
2.19 (Scheme 3.2). 
H 
H2N—RINKO 	 Fmoc—SYSMEHFRWGKPV—N--RlNK- 
Microwave peptide 
synthesis. 
TFA cleavage 	 i Micowave assisted 
FAM labelling. 
ii TFA cleavage. 
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3.1 b 
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Scheme 3.2 Microwave assisted synthesis of fluorescein labelled (X-MSH 3•2MW•  Reagents and 
conditions; couplings: acid (3 equiv), DIC (3 equiv) and HOBt (3 equiv) in DMF at 0.2 M; microwave 
irradiation at 60 °C for 10 mm. Fmoc deprotection: 20% piperidine in DMF (2 xl 0 mm) at room 
temperature. Cleavage mixture: 81.5% TFA, 5% thioanisole, 5% phenol, 5% water, 2.5% EDT (1,2 
ethanedithiol), I % TIS (triisopropylsilane). FAM = 5(6) carboxyfluorescein. 
Couplings were performed at 60 °C for 10 min using 3 equivalents of the required 
Fmoc protected amino acid, DIC and HOBt, in DMF at a 0.2 M concentration. Fmoc 
deprotection was performed at room temperature using 20% piperidine in DMF (2 x 
10 mm). The intermediate sequence Fmoc-SYSMEHFRWGKPV-NH2 (3.1b) was 
cleaved to check the peptide purity before labelling. The HPLC trace showed purity 
around 65% (Figure 3.5) comparable with those obtained using longer couplings at 
room temperature. 
The labelling of the peptide with carboxyfluorescein was performed under the same 
microwave conditions (Scheme 3.2). The coupling proved to be straightforward after 
the first cycle with no detection of any un-reacted primary amine. Before TFA 
cleavage the resin was treated with 20% piperidine in DMF in order to cleave 
possible fluorescein-fluorescein esters.' 95  Crude 3.2MW  (prepared under microwave 
heating conditions) was obtained with the same purity (65%) of the intermediate 
Fmoc-SYSMEHFRWGKPV-NH, which indicated a "clean" coupling of the dye. 
More interestingly the purity of crude 3.2MW  appeared to be higher than the purity of 
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Figure 3.5. HPLC trace (? = 220 urn) of crude Frnoc-SYSMEHFRWGKPV-NH, prepared under 
microwave conditions, purity 65%. 
room temperature 
Figure 3.6. HPLC trace (? = 220 urn) of crude FAM -a-MSH 3.2 prepared under microwave 
conditions, purity 65% 
1.1.2. Microwave assisted synthesis and labelling of peptoid conjugated a-MSH. 
Heptapeptoid conjugated o-MSH were prepared by direct synthesis using two 
different spacers between the peptide and the peptoid: 6-aminohexanoic acid (Scheme 
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3.3) and lysine (Scheme 3.4). The synthesis was carried out on Rink amide 
polystyrene resin under microwave heating conditions. 
When the 6-aminohexanoic acid spacer was used, synthesis started with the 
preparation of the heptapeptoid followed by the ct-MSH (Scheme 3.3). 
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Scheme 3.3. Synthesis of fuouorescently labelled hepta-peptoid conjugate c-MSH. Couplings: acids (3 
equiv), DIC (3 equiv) and HOBt (3 equiv) in DMF at 0.2 M, microwave irradiation at 60 °C for 20 
mm. Fmoc deprotection: 20% piperidine in DMF (2 x 1 mm) at room temperature. FAM = 5(6)- 
carhoxyfluorescein. 
The microwave conditions used were the same as described above for the peptoid and 
a-MSH synthesis. The synthesis was also repeated at room temperature using 
PyBrOP for the peptoid synthesis (couplings of 4 h), DICIHOBt for the a-MSH 
(couplings of 3 h), and PyBOP to couple the 5(6)-carboxyfluorescein (12 h). 
With both protocols (microwave heating and room temperature) 3.4 was obtained 
with purities around 60%, (Figure 3.7) confirming that the use of microwave heating 
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offers a faster synthesis compared to standard conditions, but does not improve 
fundamentally the chemistry. 
room temperature 
A 
Figure 3.7. HPLC trace (220 nm) of crude 3.4 prepared under microwave heating, purity 60%. 
When lysine was used as spacer, the synthesis was carried out starting from 
orthogonally protected Fmoc-Lys(Dde)-OH attached to the Rink amide resin. The a-
MSH sequence was synthesised on the a-amine group under microwave conditions 
described for the preparation of the peptide with couplings at 60 °C for 10 mm. 
After completion of the sequence, the heptapeptoid was built on the c-amine group. 
Again couplings were carried out under microwave heating at 60 °C for 20 mm, with 
Frnoc deprotection performed at room temperature (20% piperidine in DMF). 
Labelling was done under microwave conditions, with 5(6)-carboxyfl uorescein 
coupled to the N-terminus of the peptoid using a 6-aminohexanoic spacer (Scheme 
3.4). 
Figure 3.8. HPLC trace (X = 220 nm) of crude 3.6, purity 58 %. 
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Scheme 3.4. Synthesis of fluorescently labelled ct-MSH-Lys(heptapeptoid)-NH2 conjugate ((-MSH = 
SYSMEI-IFRWGKPV). Couplings: acids (3 equiv), DIC (3 equiv) and HOBt (3 equiv) in DMF at 0.2 
M; microwave irradiation at 60 °C for 20 min. Fmoc deprotection: 20% piperidine in DMF (2 x 1 
mm) at room temperature. Dde deprotection: NH20H.H20 in DMF 0.3 M (2 x 30 mm). Cleavage 
mixture: 81.5% TFA, 5% thioanisole. 5% phenol, 5% water, 2.5% EDT (1,2 ethanedithiol), 1% TIS 
(triisopropylsilane). FAM = 5(6)-carboxy.uorescein. 
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111. 1.2. Cell and skin delivery. 
1.2.1. Peptoid modified a-MSHpeptides retained their activity. 
Healy and colleagues reported that (x-MSH (lO M) stimulates pigmentation of 
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Figure 3.9 Pigmentation assay of S91 melanoma cells with a-MSH (3.1) and related compounds (3.2, 
3.3, 3.4, 3.5, 3.6), 5 days exposure at a lO M concentration: (a) cells pelleted in eppendorfs 
(triplicates); (b) cells in culture. 
Pigmentation assays demonstrated that 3.3 (a-MSH-Ahx-heptapeptoid) and 3.5 (a-
MSH-Lys(heptapeptoid)-NH2) as well as 3.2 (FAM-Ahx-a-MSH), 3.4 (FAM-Ahx- 
3.2 
3.3 
Modified ct-MSH derivatives were tested by Pawan Kumar, Prof. Eugene Healy group. at 
Dermatopharmacology, University of Southampton, Southampton. 
(x-MSH-Ahx-heptapeptoi d) and 3.6 (u-M SH-Lys(FAM-Ahx-heptapeptoid)-NH2) 
stimulated eumelanin synthesis by melanoma cells with similar potency to a-MSH at 
10 8  M and l06  M (Figure 3.9). 
1.2.2. Peptoid transports a-MSH into cells. 
To examine whether o-MSH is transported into cells by the peptoid, fluorescently-
tagged compounds 3.2 (scheme 3.1), 3.4 (Scheme 3.3) and 3.6 (Scheme 3.4) were 
employed and intracellular fluorescence documented as a measure of 
penetration. '86'187 FAM-a-MSH 3.2 did not penetrate into any of the cell types used in 
these experiments, however, peptoid conjugated 3.4 and 3.6 at a concentration of 10 
.iM entered in large amounts into all cell types tested (13I6G417, BI6CWT-3, HEK-
293, and B-lymphocytes). Fluorescence microscopy showed bright green fluorescent 
cells following incubation with 10 .tM 3.4 and 3.6 for 3 h, suggesting that these 
compounds had entered into the cell. Confocal microscopy confirmed that the 
heptapeptoid conjugated compounds had penetrated into the cells, and that uptake had 
occurred in 95— 100% of cells in each culture (Figure 3.10-3.12). 
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Figure 3.10. Fluorescence microscopy and confocal microscopy of B I 604F after incubation with 3.4 
and 3.2 (10 l,IM) for 3 Ii. 
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Figure 3.11. Fluorescence microscopy and confocal microscopy of 14EK 293 after incubation with 3.4 
and 3.2 (10 l.IM)  for 3 h. 






Figure 3.12. Confocal microscopy of HaCaT cells after incubation with 3.4 (10 l.tM) for 3 Ii. 
ri 
1.2.3. Peptoid allows a-MSH to penetrate into skin. 
Penetration of heptapeptoid conjugated a-MSH 3.4 and 3.6 into skin was examined 
using an ex-vivo mouse, pig and human skin model.186" 7 Briefly, fresh skin was 
taken separately from the dorsum of euthanized mice, the ear of euthanized pigs, and 
by excision during surgical procedures on dermatology patients. The skin samples 
were inserted, with the outer surface upright, into tightly-sealed diffusion chambers 
(Figure 3.13) and incubated with the compounds under study; these were applied to 
the outer skin surface for three hours, and then washed carefully prior to fixation of 
the skin. As can been seen in Figure 3.14, compound 3.6 applied at a concentration of 
10  -3 	penetrated in large amounts into mouse, pig and human skin; by contrast, in 
multiple experiments 3.2 did not penetrate into skin. Interestingly, 3.4 did not 
penetrate into skin to the same extent as 3.6. 


















Figure 3.14. Fluorescence microscopy. Section of Mouse, Pig and Human skin exposed to 1 mM 3.6 
(Scheme 3.4) (left panel) and I mM 3.2 (Scheme 3.1) (right panel) for 3 Ii. 
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In conclusion peptoid conjugated a-MSH derivatives were efficiently prepared on 
solid phase using a combination of standard DIC/HOBt activation and microwave 
heating. Peptoid conjugated a-MSH compounds showed an activity comparable to 
the unmodified a-MSH, which indicates that the peptoid oligomer did not hinibit the 
activity of the hormone. 
Cellular uptake of fluorescein labelled a-MSH and peptoid conjugated a-MSH 
derivatives was measured. The fluorescein labelled a-MSH did not show any cellular 
uptake when tested on several cell lines. In contrast, fluorescein labelled peptoid 
conjugated -MSH compounds showed a very high cellular uptake when tested on a 
wide range of cell lines (BI6G4F, BI6CWT-3, HEK-293, and B-lymphocytes) with 
an average population of fluorescent cells over 95%. These results clearly show the 
high potential of the heptapeptoid oligomer for the delivery of peptides of medium 
size (10-30 residues). 
Skin penetration was also evaluated. Fluorescein labelled a-MSH was not able to 
penetrate into the skin, in contrast, fluorescein labelled peptoid conjugated a-MSH 
3.6 was able to penetrate into different kinds of skin: human, mouse and pig. These 
first results indicate that the heptapeptoid oligomer can be a potential tool for topical 
delivery of compounds. 
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111.2. Peptide nucleic acid (PNA). 
Peptide nucleic acids (PNAs), first described by Nielsen, in 1991,188 are a DNA 
mimic where the deoxyribose phosphate diester backbone of DNA is replaced by a 
poly(N-(2-aminoethyl)glycine)arnide backbone carrying the nucleobases via a series 
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Figure 3.15. General structure of PNA and DNA. 
Intramolecular distances and configurations of the nucleobases in PNAs are similar to 
those in DNA, and specific hybridisation occurs between PNA and DNA or RNA 
sequences. In addition, due to the uncharged nature of the backbone, PNA/DNA 
duplexes have a higher thermal stability compared to analogous DNA/DNA or 
RNA/DNA duplexes, where the negative charged backbones display electrostatic 
repulsion between the two strands. Moreover PNAs are resistant to biological 
degradation by nucleases and proteases. These properties make PNA an ideal tool in a 
number of different areas of research such as gene therapy, 189,190 as a tag for 
microarray screening,' 91,192 as well as for SNP (single nucleotide polymorphism) 
analysis 193.194 and mRNA profiling. 195 Due to its peptidic structure PNA synthesis 
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can be carried out by straightforward and traditional solid phase peptide synthesis 
methods (SPPS).'96 However PNAs have a number of limitations such as an inability 
to be extended enzymatically, and poor cellular uptake. To overcome this second 
problem several strategies have been reported, involving the use of CPPs,87 '97'198 the 
delivery of PNA-DNA hybrids using Iiposomes,'99 and modifications of the backbone 
structure. 200 
111.2.1. PNA: Monomer synthesis. 
In 2004 Diaz-Mochon reported a strategy for the synthesis of PNA-encoded peptides 
based on the use of Dde-protected PNA monomers (Figure 3.16).201  It was shown that 
the protecting group Dde could be removed without affecting Frnoc functionalities on 
the molecule, while the Dde group is stable to classic Fmoc deprotection conditions. 
Using this Dde/Fmoc orthogonality, amino acids can be coupled using a Fmoc 
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Figure 3.16. DdelMmt protected PNA monomers. 
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Retro-synthetically, the monomers can be disconnected into two synthons (Scheme 
3.5), a backbone and the derivatised nucleobase, and this allows the straightforward 
synthesis of all four desired PNA monomers 
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Scheme 3.5. PNA monomers, retro-synthesis. 
2.1.1. Synthesis of the backbone. 
The synthesis of the backbone followed the protocol described by Bialy.202 The first 
step consisted of reacting ethylene diarnine with chloroacetic acid yielding 3.11 in 
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Scheme 3.6. Synthesis of the backbone. 
The primary amine of 3.12 was then selectively protected with DdeOH in the 
presence of DIPEA to give 3.13 in 60% yield. 
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2.1.2. Synthesis of the thyinine monomer. 202 
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Scheme 3.7. Synthesis of the thymine monomer. 
Thyrnine was alkylated following the procedure described by Buchardt,'96 by 
treatment with methyl bromoacetate using K2CO3  as base, followed by saponification 
of the resulting compound with NaOH yielding thymin- l -yl acetic acid 3.14. 
Thymine nucleobase 3.14 and backbone were coupled using DCC as coupling reagent 
yielding compound 3.15 with a 70% yield. Finally ester 3.15 was treated with 0.1 M 
Cs2CO3 (4 equiv in THF:H20 1:1) overnight to yield thymine monomer 3.7 (85% 
yield). This mild basic condition allowed complete saponification of ester 3.15 
without compromising the Dde functionality. Bialy's protocol 202  reported the use of 
I M Cs2CO3 in MeOHII-120 for I h. This protocol had the inconvenient result of 
substantial Dde instability over long periods, thus requiring a careful and continuous 
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2.1.3. Synthesis of the cytosine monomer. 202 
Cytosine was suspended in pyridine and reacted with Mrnt-Cl in presence of 4-
ethylmorpholine at 40 °C for 48 h under N2 yielding 3.16204  with a 60% yield. The 
low yield was easily explained by the poor solubility of cytosine in pyridine, making 
the reaction extremely slow due to the heterogeneous conditions. Alkylation of 3.16 
with ethylbromoacetate followed by saponification yielded the cytosine nucleobase 
3.18 in 68% yield over the two steps. 204  The building block 3.18 was then coupled to 
the backbone 3.13 using DCC/HOBt (ester 3.19), followed by saponification with 0.1 
M Cs2CO3 to yield cytosine monomer 3.8 in 55% yield. 
.. Mmt
NH Mmt-CI, NEM 
N Pyridine 
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3.18 	 3.13 
i) R = CH3, 3.19 
ll)R=H 3.8 
Scheme 3.8. Synthesis of the cytosine monomer. 
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2.1.4. Synthesis of the adenine monomer. 202 
Adenine was deprotonated with NaH in DMF and reacted with methylbromoacetate 
to give selectively N-9 alkylated adenine 3.20 (68% yield). 196  Exocyclic amino group 
protection 204  with Mint-Cl in the presence of 4-ethylmorpholine was followed by 
saponification with KOH to afford the adenine building block 3.22 in 72% yield over 
two steps. Adenine nucleobase 3.22 and backbone 3.13 were coupled using DCC! 
HOBt to yield ester 323, that treated with Cs2CO3 (0.1 M in TI-IF/H20) afforded 
adenine monomer 3.9 in 62% yield (over two steps). 
NH2 	 NH2 	 HNMmt 
) BrCH2CO2CH3 	
)N 	 i) Mmt-CI, NEM NaH, DMF, 	N 	 Pyridine 
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ii) R=H, 	3.9 
Scheme 3.9. Synthesis of the adenine monomer. 
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2.1.5. Synthesis of the guanine monomer. 202 
2-Amino-6-chloropurine was used as precursor of the guanine nucleobase. This was 
due to the poor solubility of guanine, the lack of reactivity of its exocyclic amino 
group and the difficulty in obtaining selectively the N-9 alkyl derivatives. 
Alkylation204 and Mmt protection 204  were carried out as for adenine, however dry 
THF instead of pyridine was used in the Mmt protection step. In the last step, basic 
hydrolysis of the ester moiety as well as the C-6 chlorine substitution provided the 
guanine nucleobase 3.26. Guanine nucleobase 3.26 and backbone were coupled using 
PyBrOP/DIPEA to yield ester 3.27 which was treated with Cs2CO3 (0.1 M in 
THF/1-120) to give the guanine monomer 3.10 in 45% yield (over two steps). 
CI 	 CI 
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Scheme 3.10. Synthesis of the guanine monomer. 
111.2 .2. Oligomers synthesis. 
To investigate the application of heptapeptoid for the effective delivery of PNA into 
cell and skin, PNA oligomers with a length of 9, 12, and 15 residues targeting mouse 
and human tyrosinase were conjugated and labelled with 5(6)-carboxyfluorescein. 
Human and mouse tyrosinase have different sequences, thus specific sets of PNA 
targeting the two different mRNA sequences were prepared (Scheme 3.11 and 3.12). 
PNA oligomers were prepared on Rink '5' amide PEGA resin (Scheme 3.11). 
Couplings were performed at room temperature following the conditions described 
by Bialy:202 PNA monomers (5 equivalents), PyBOP (4.8 equivalents) and NEM (10 
equivalents) 0.2 M in DMF, at room temperature for 4 h. 
Deprotection of Dde was carried out using a 2% solution of NH20H.H20 in DMF 
(0.3 M) in I h (2 x 30 mm), instead of the NH20H.HCl/irnidazol solution reported by 
Bialy.202 After each coupling the resin was treated with a solution of Ac20 (15%) and 
HOBt (7.5%) in DMF in order to cap any possible unreacted amine and so to avoid 
the labelling and conjugation to the heptapeptoid of incomplete (shorter) PNA 
sequences. Labelling with 5(6)-carboxyfluorescein was carried out under microwave 
conditions, as described previously, using as a spacer 6-aminohexanoic acid. 
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Mouse tyrosinase  
= 	 ITT CTC CTT 3.28 
= 	CAT ITT CTC CTT 3.29 
= GM CAT ITT CTC CTT 3.30 
Human tyrosinase 
= 	 TCT ICC TCT 3.31 
= CAT ICI ICC TCT 3.32 
= GAG CAT TCT ICC TCT 3.33 
Mouse tyrosinase 
= 	 TTT CTC CTT 3.34 
= 	CAT TTI CTC OTT 3.35 
= GM CAT TIT CTC CTT 3.36 
Human tyrosinase 
j= 	TCT TCCTCT 3.37 
j= CAT TCT TCCTCT 3.38 
= GAG CAT TCT TCC TCT 3.39 
Scheme 3.11 Synthesis of PNA oligos using Dde protected PNA monomers: i) Dde-PNA-OH (5.5 
equiv), PyBOP (5 equiv 0.1 M), NEM (11 equiv)in DMF, 3 h; ii) 2% NH20H.H20 in DMF, 2 x 30 
mm; iii) Repeat (i) and (ii) as necessary; iv) Fmoc-Ahx- OH (3 equiv), DIC (3 equiv) and HOBt (3 
equiv) in DMF 0.2 M, 60 °C (MW) 20 mm; v) 20% piperidine in DMF, 2 x 10 mm; vi) 5(6)- 
carboxyfluorescein (3 equiv), DIC (3 equiv) and HOBt (3 equiv) in DMF 0.2 M, 60 °C (MW) 20 mm; 
vii) TFA]TIS/CH2C12 (90/5/5), 1 h. 
Im 
PNA oligorners with 9 residues (3.28 and 3.34, Figure 3.17) and 12 residues (3.29 
and 3.35, Figure 3.18) were obtained with purities >90% confirming the reliability of 
the Dde strategy. 
3.28 
3.34 
Figure 3.17. HPLC trace (ELS) of 3.28 (95% purity) and 3.34 (93% purity). Compound 3.34 showed 
two peaks corresponding to the two fluorescein isomers. 
3.29 	335 
Figure 3.18. HPLC trace (ELS) of 3.29 (90%) and 3.35 (90% purity). Compound 3.35 showed two 
peaks corresponding to the two fluorescein isomers. 
The 1 5mer PNAs were poorly soluble, in particular the fluorescein labelled material, 
giving HPLC traces of very poor quality with different solvent combinations 
(acetonitrile/water, methanol/water) and gradients, that did not allow a proper 
estimation of the crude purity. 
The heptapeptoid was synthesised directly following the PNA sequence separated by 
a spacer (6-aminohexanoic acid). The synthesis was carried out under microwave 
conditions as described previously. 
Mouse tyrosinase 
= 	 TTT CTC CTT 3.40 
= CAT TTT CTC CTT 3.41 
= GAA CAT TTT CTC CTT 3.42 
Human tyrosinase 
= 	 TCT TCC TCT 3.43 
= CAT TCT TCC TCT 3.44 
GAG CAT TCT TCC TCT 3.45 
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Mouse tyrosinase 
= 	 UT CTC CTT 3.46 
= CAT UT CTC CU 3.47 




TCT TCC TCT 3.49 
= 	CAT TCT TCC TCT 3.50 
= GAG CAT TCT TCC TCT 3.51 
Scheme 3.12. Addition of heptapeptoid and fluorescein labelling to PNA oligomers. Reagents and 
conditions; couplings: acid (3 equiv), DIC (3 equiv) and HOBt (3 equiv) in DMF at 0.2 M; microwave 
irradiation at 60 °C for 20 mm. Fmoc deprotection: 20% piperidine in DMF (2 xlO min) at room 
temperature. FAM = 5(6)-carboxyfuorescein. 
Crude heptapeptoid conjugated 9mer (3.40 and 3.46, Figure 3.19) and l2rner (3.41 
and 3.47, Figure 3.20) PNAs were obtained with purities > 90%, confirming the 
reliability of the microwave assisted peptoid synthesis and labelling. 
3.40 	3.46 
Figure 3.19. HPLC trace (ELS) of 3.40 (95% purity) and 3.46(95% purity). 
	
3.41 	3.47 
Figure 3.20. HPLC trace (ELS) of 3.41 (95% purity) and 3.47 (90% purity). 
The heptapeptoid conjugated I 5mer PNAs (3.42 and 3.48) gave HPLC traces with 
slightly broader peaks (Figure 3.21), and an estimated purity around 85% for 3.42, 
and 75% for 3.48. 
3.42 	3.48 
Figure 3.21. HPLC trace (ELS) of 3.42 (85% purity) and 3.48 (75% purity). 
111.2.3. PNA delivery into cell and skin. I 
Fluorescently labelled PNA and fluorescently labelled heptapeptoid conjugated PNA 
(only the one targeting mouse tyrosinase) were tested for cellular uptake and skin 
penetration.205'206 After incubation with BI6FIO cell (3 h) fluorescently labelled PNA 
(3.34, 3.35, 3.36) (10-4M)  did not show cellular uptake. However the heptapeptoid 
proved to be able to deliver efficiently the PNA oligomers independently by the size. 
The l5mer PNA 3.48 was able to penetrate into B 16171 cells with a cellular uptake> 
90% (measured by FACS) after 3 h of incubation (at 10-4 M). Ex vivo skin penetration 
studies using Franz's diffusion chamber showed that the heptapeptoid conjugated 
PNA (3.46, 3.47, 3.48) (at 10- M) were able to enter into skin while the PNA (3.34, 
3.35, 3.36) were not (Figure 3.22). Interestingly the heptapeptoid conjugated 12mer 
PNA 3.47 was able to penetrate deep into the dermis at 3 h, whereas the I 5mer PNA 
3.48 was situated mainly in the epidermis. 
The ability of the heptapeptoid conjugated PNA to inhibit tyrosinase gene function 
was tested in an in vitro 13I6FIO cell based assay. 205  The results have shown that 
heptapeptoid conjugate 15mer PNA 3.42 (10 MM) (Scheme 3.12) was able to 
significantly inhibit c-MSH (10'0 M) induced pigmentation and tyrosinase activity. 
The corresponding 1 5mer PNA 3.30 did not show any antisense activity, as it was 
expected. The PNA oligomer had to bind the mRNA in the cytosol to stop protein 
translation, but the compound was not able to penetrate inside the cell as indicated by 
the fluoscein labelled l5mer PNA 3.33, which did not show any cellular uptake. 







3.48 	 3.36 
Figure 3.22. Fluorescence microscopy. Section of Mouse skin exposed to I mM 3.47(left panel), I 
mM 3.48 (left panel), I mM 3.35 (right panel) and 1 mM 3.36 for 3 h. 
In conclusion PNA oligomers and peptoid conjugated PNA oligomers were 
efficiently prepared on solid phase using Dde protected PNA monomers, obtaining 
crude materials with high purities, from 75% (3.48) up to 95% (3.40, 3.41, 3.46). 
Fluorescein labelled compounds were tested for cellar uptake. PNA oligomers alone 
did not show cellular internalisation. The heptapeptoid oligmer was able to deliver the 
PNA oligomers (12, 15mer) into BI6F1O cells with cellular uptake > 90%. The 
heptapeptoid conjugated PNAs were also able to penetrate into mouse skin, showing 
all the potentials of the peptoid carrier for the topical delivery of even very large 
compounds with molecular weight> 5000. 
111.3. Antisense DNA delivery. 
111.3.1. Conjugation to the heptapeptoid carrier. 
In order to explore further the potential of the heptapeptoid as a "delivery vehicle" we 
decided to test the possibility of delivering DNA oligos, which can be used for 
antisense experiments for the inhibition of specific protein expression, as described in 
Chapter 1. 
A thiol modified 19mer DNA oligo (5'-HS-CCAAGAACATTTTCTCCTT-3') 3.57 
(Scheme 3.15), targeting the translational translational start site of the tyrosinase gene 
(mouse), was conjugated to the heptapeptoid using two different ways: 
- Disulfide bond, cleavable in cellular environment (3.59, Scheme 3.15). 
- Sulfide bond, stable in cellular environment (3.58, Scheme 3.15). 
Heptapeptoid 3.53 with an activated disulfide linker, and heptapeptoid 3.55, with a 
maleimido linker, were prepared on solid phase, as described in Scheme 3.13 and 
Scheme 3.14, with crude purities > 95%. DNA-oligo 3.57 was prepared by reduction 
of disulfide protected oligo 3.56 (purchased from Sigma) with DTT. It was reacted 
with heptapeptoid 3.53 (1 equiv) and heptapeptoid 3.55 (1 equiv) in PBS buffer to 
give the heptapeptoid conjugated oligo 3.58 (sulfide) and the heptapeptoid conjugate 
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Scheme 3.14. Synthesis of compound 3.55. 
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Scheme 3.15. Synthesis of compounds 3.57, 3.58,3.59. 
DNA-heptapeptoid conjugates were characterised by MALDI-TOF, which gave the 
expected ions for 3.58 (C239H380N790128P19S, calcd 7268, found 7266 [M-H]) and 
3.59 (C2 1-1377N780P19S2, calcd 7203, found 7201 [M-H]) as shown in Figure 3.23 
(b and c). MALDI —TOF analysis also gave the peaks of residual thiol protected DNA 
3.56 (intense peaks compared to 3.58 and 3.59) and residual un-conjugated free thiol 
DNA 3.57 (very low intensity peaks compared to 3.58 and 3.59) as shown in Figure 
3.23 (b and c). 
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	 8547 	 9994 
Figure 3.23. MALDI- TOF spectra of: (a) compound 3.57; (h) compound 3.58; (c) compound 3.59. 
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111.3.2 DNA -Peptoid conjugates: antisense activity. 
As described before hormone aMSH stimulates pigmentation and tyrosinase activity 
of melanoma cells by binding the melanocortin I receptor (MCIR). Oligonucleotide 
3.59 (10 IM) was able to inhibit tyrosinase activity stimulated by a-MSH (10'° M) 
on 1316FIO cells. 205  This result did show the ability of the heptapeptoid carrier to 
deliver polyanionic cargoes such as a 19mer oligonucleotide and not just neutral or 
positively charged cargoes. 
In contrast, oligonucleotide 3.58 did not inhibit tyrosinase activity, raising questions 
about the delivery and about possible interferences of the heptapeptoid on the 
oligonucleotide antisense activity, considering that 3.58, differently to 3.59, does not 
split inside the cell separating the heptapeptoid and the oligonucleotide. These 
questions unfortunately could not be answered without experiments with 
fluorescently labelled oligonucleotides that could not be performed. 
Antisense test have been carried out by Pawarn Kumar, Prof. Eugene Healy group, at 
Dermatopharmacology. University of Southampton, Southampton. 
Chapter IV. Macromolecules delivery. 
The possibility of using the peptoid for the preparation of carriers able to deliver 
macromolecules such as proteins and DNA was explored. 
- For the delivery of DNA 3 generations of dendrimers based on the peptoid 
subunit were synthesised. 
- For the delivery of proteins, the possibility of exploiting, what is today, a 
standard approach of tagging proteins for purification, namely the 
polyhistidine tag, was explored 
W.I. Peptoid dendrimers for DNA delivery. 
Dendrimers are fascinating compounds, offering many of the properties of more 
conventional polymers but with a highly defined shape, molecular mass and with a 
structure which displays a large number of functional groups on the periphery, while 
'hiding' much internal functionality. Two dominant synthetic methodologies have 
been used to generate dendrimers (Scheme 4.1): (i) a linear approach as initially 
described by V6gtle,207 where surface functionalities grow at an exponential rate 
while the numbers of synthetic steps increases linearly and (ii) a convergent synthesis 
strategy as introduced by Fr6chet,208 where dendrimeric fragments are synthesised 
before condensation to give the full dendrimeric structure. 
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dendron dendron dendrimer 
= Protective group 	0 = Orthogonal protective group 
Scheme 4.1. Schematic of Dendrinier synthesis. Upper Divergent and lower Convergent strategy. 
Polyamidoamines (PAMAMs) (see Figure 4.1 for PAMAM G2, 1 ,4-diaminobutane 
core) can be regarded as the classical dendrimeric material and are typically 
constructed by the reaction of methyl acrylate with an initiation unit such as 
ammonia, with subsequent treatment with diamines followed by repetitive treatment 
with methyl acrylate and diarnine. Such dendrimers display multiple primary amines 
on their external surface which can vary from 4 (generation 0) to 4096 (generation 
10). 
PAMAM dendrimers have found practical application in the area of gene delivery 209 
211 and a number of other biomedical applications such as magnetic resonance 
imaging (MRI).212214 Another family of dendrimers, which have seen practical 
application, are those based on repeating and amplifying amino acid residues, most 
notably the lysine dendrimers introduced by Tam 215 which offer a chemical route to 
the development of high-density antigenic peptides. A new step forward would be a 
hybrid combination of PAMAM and peptide dendrimers in which peptoids (N-
alkylglycines) are used both as an initiator and a monomer unit. 216 
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Figure 4.1. PAMAM G2. I ,4-diarninobutane core. 
IV.]. 1. Monomer synthesis. 
In order to prepare the peptoid dendrimer by solid phase synthesis a suitable building 
block was required. Bis-Fmoc protected peptoid monomer 4.1216  was prepared by 
treating 2.12 with TFA to remove the Boc group followed by Fmoc protection of the 
side chain amine with Fmoc-OSu (Scheme 4.2, 64% yield). Starting material 2.12 
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Scheme 4.2. Synthesis of monomer 4.1. 
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IV. 1.2. Microwave assisted peptoid dendri:ner synthesis: G1-G2-G3. 
The dendrimers were assembled with high efficiency using monomer 4.1 on Rink 
amide polystyrene resin using HOBtIDIC chemistry and microwave irradiation 
(Scheme 4•3)•2b6  More generally, microwave irradiation offers huge promise in 
dendrimer synthesis, allowing reactions to be readily forced. To ensure coupling 
completion two colorimetric tests were used: (i) The Kaiser' 82  test for primary amines 
and (ii) a chloranil'7' test for detecting secondary amines. The first generation 
dendrimer gave, not unexpectedly, negative tests after a single coupling, but 
subsequent generations required a second coupling to ensure 100% reaction. 
Following final Fmoc removal the polyamidoamines were cleaved from the resin 
using TFA/TIS/DCM (90:5:5) and precipitated with cold diethyl ether to give the 
final compounds displaying 4, 8 and 16 amines (half primary and half secondary) on 
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Figure 4.2. HPLC trace of peptoid dendrimer 4.4 (G3). 
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Figure 4.3. MALDI-TOF spectra of peptoid dendrirner 4.4 (G3). 
MALDI-TOF analisys of 4.4 (G3) (Figure 4.3, HPLC trace in Figure 4.2) showed the 
desired material as the main ion; however it also showed traces of incomplete 
dendrimers with some subunits missing. The presence of incomplete dendrimers was 
expected, since the extension of the branches becomes increasingly difficult with the 
growth of the molecule. More interestingly the spectra presented peaks that appeared 
to be the result of over incorporation of monomer 4.1. This result was unexpected, 
and could be explained by the lost of Fmoc group during the final couplings. MALDI 
spectra of dendrimer 4.4 (G3) showed quite a "clean" and "defined" composition, 
considering that MALDI spectra of dendrimers made in solution which usually show 
a broad distribution of peaks around the theoretical molecular mass of the desired 
materials. 
IV. 1.3. DNA delivery: peptoid dendrimers vs. PAMAM G2. 
To evaluate the properties of these compounds as transfection agents, their complexes 
with pEGFP-NI (a plasmid DNA which carries the gene that encodes green 
fluorescence protein (GFP)) were incubated with human embryonic kidney 
(I-1EK293T) cell S.211  PAMAM G2 (Figure 4.1) was used as a control as it also 
possesses 16 external amino groups. Dendrirner-plasmid complexes were prepared by 
mixing the dendrimers and plasmid DNA in PBS buffer at different molar ratios 
-95- 
(dendrimer-plasmid 5:1, 10:1. 20:1 and 40:1) defined as moles of dendrimer for I 
mole of nucleotide (g (plasmid DNA) / 330 (nucleotide average molecular weight)) 
and incubation for 30 minutes before use. Dendrimer-plasmid complexes were added 
to HEK293T cells in DMEM complete media with 10% FCS (96 well plate, 0.2 jig of 
plasmid per well), and incubated for 48 h at 37 °C. FACS analysis showed that while 
4.2 (G 1) and 4.3 (G2) had no noticeable effect, 4.4 (03) (10:1 molar ratio) was able 
to transfect HEK293T cells 4 times more efficiently than PAMAM 02 (20:1 molar 
ratio) (Figure 4.4). 
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Figure 4.4. Transfection activity of peptoid dendi-imers 4.2 (Cl), 4.3 (G2), 4.4 (G3) and PAMAM G2 
with HEK293T cells. Delivery of plasmid DNA (pEGFP-N I) was tested at different 
dendrimer/plasmid molar ratios (5:1, 10:1, 20:1, 40:1) and determined by FACS analysis of cell 
fluorescence, as a measure of GFP protein expression. 
Transfection activity of 4.4 (03) had its maximum at a 10:1 molar ratio. The lower 
generation dendrimers 4.2 (GI) and 4.3 (02) were probably too small to effectively 
condensate the plasmid even at high molar ratios. Dendrimer 4.4 (G3) complexes at 
20:1 and 40:1 ratio showed a lower activity compared to 5:1 and 10:1 ratios. This 
lower efficiency might have been due to an increased stability of the complexes and 
consequent more difficult "DNA release" even if the dendrirner-plasmid complexes 
entered in large amounts inside the cell. 
Cytotoxycity of 4.4 (133) and PAMAM 2.0 was evaluated by MTT'73 assay (Figure 
4.5). The peptoid dendrimer was found to be non-toxic at all of the ratios tested, 
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Figure 4.5. Cytotoxicity of 4.4 (peptoid dendrimer G3) with HEK293T cells compared to PAMAM 
G2 as measured by MTT assay. 
In conclusion, peptoid dendrimers containing primary and secondary amines on their 
periphery have been successfully synthesised by solid phase synthesis combined with 
microwave mediated methods using a 'lysine-type' peptoid monomer. The higher 
generation peptoid dendrimer 4.4 (133, 16 external amines, 8 primary and 8 
secondary) was able to transfect cells four times more efficiently than PAMAM G2 
(16 external primary amines), and it was found to be non-toxic, making the 
hypothesis of synthesising and evaluating higher generations of this peptoid 
dendrimer appealing. 
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IV.2. Protein delivery. 
The most commonly used tag for purification of recombinant proteins is the 
polyhistidine (His6) tag introduced by Hochuli in 1988.217  Protein purification using 
polyhistidine tags relies on the affinity of histidine residues for an immobilized metal 




















Figure 4.6. Schematic representation of immobilised Ni-Polyhistidine tagged protein interaction. 
NTA.219 HisLinkTM  (Promega), and IDA ligands. 
This affinity interaction is believed to be a result of the coordination of a nitrogen on 
the imidazole moieties of polyhistidine with vacant coordination sites on the metal 
(Figure 4.6) 	The metal is immobilized through complex formation with a chelate 
that is covalently attached to a solid support. Two sites are available and are rapidly 
coordinated with histidine in the presence of a polyhistidine —tagged polypeptide. 
Polyhistidine tags offer several advantages for protein purification. The small size of 
the tag renders it less immunogenic than larger tags. Therefore, the tag usually does 
not need to be removed for downstream applications following purification. A large 
number of commercial expression vectors that contain polyhistidine are available. 
The polyhistidine tag may be placed on either the N- or the C- terminus of the protein 
of interest. Finally the interaction of the polyhistidine tag does not depend on the 
tertiary structure of the tag, making it possible to purify otherwise insoluble proteins 
using denaturating conditions. Although protein purification is the main reason for 
tagging proteins with the polyhistidine residue, there are several reports describing 
many different applications of the tag such as protein labelling with gold (or silver) 
nanoparti des220 used for electron microscopy visualization, protein immobilization 
on Ni2 :NTA coated surfaces22 ' and site specific introduction of fluorescent probes 
using a Ni2 :NTA-fluorochrorne conjugate .222  Kapanidis222 reported the use of 
Ni2 :NTA modified Cy3 and Cy5 fluorescent probes (Figure 4.7) for structural 
studies of the complex between transcriptional activator protein CAP and DNA by 
FRET 223  efficiency measurements between the Ni2 :NTA modified fluorescent probe 
(Ni2 :NTA -Cy3 or -Cy5) coordinated to the hexahistidine tagged protein and the 
fluorescein label attached to the DNA. They measured the affinity of the Ni2 :NTA 
modified fluorochromes Cy3 and Cy5 to the hexahistidine tag of the protein CAP (by 
anisotropic experiments) finding that only 4.7 and 4.8 (Figure 4.7) with 2 Ni2 :NTA 
coordination sites had a sufficiently high affinity for the hexahistidine tag with KD 
values of I M and 0.4 M respectively. Cy3 4.5 and Cy5 4.6 (Figure 4.7) with I 
Ni2 :NTA coordination site had poor affinity for the hexahistidine tag with a KD of 10 
and 40 tM respectively. 
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Figure 4.7. Ni2 :NTA modified Cy3 and Cy5 for site specific fluorescent labelling of hexahistidine 
tagged proteins. 141,222 
IV.2. 1. Synthesis of Ni2'-ligandfunctionalised peptoids. 
Considering the great availability of vectors expressing hexahistidine tagged proteins 
the idea of using this tag to conjugate the heptapeptoid carrier to proteins with the 
intention of allowing their cellular uptake appeared appealing. 
For this first attempt a Ni ligand similar to the one employed by Promega (Figure 4.6 
and Scheme 4.4) was easily prepared from glycine methyl ester which was 
dialkylated using 2-bromo 'butylacetate, followed by saponification to yield the 
'butyl protected ligand required to be coupled to the heptapeptoid on solid phase. As 
described in chapter 11 the heptapeptoid was built using a Rink '5 ' amide polystyrene 
resin under microwave conditions. The heptapeptoid was functionalised with one 
Ni2 -ligand (4.11, Scheme 4.5) and with two Ni2tligands (4.14, Scheme 4.7) using 
4.13224 (Scheme 4.6) to introduce two symmetric branches. 
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Scheme 4.5. Synthesis of 4.11. Reagents and Conditions: 1)4.10(3 equiv), DIC (3 equiv) and HOBt (3 
equiv) in DMF at 0.2 M; microwave irradiation at 60 °C for 20 mm; ii) 95% TFA, 2.5% water, 2.5% 
TIS (triisopropylsilane), 3 h. 
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Scheme 4.6. Synthesis of compound 4.13. 
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Scheme 4.7. Synthesis of 4.14. Reagents and Conditions: i) 4.13(3 equiv), DIC (3 equiv) and HOBt (3 
equiv) in DMF at 0.2 M, microwave irradiation at 60 °C for 20 mm; ii) NH20H.H20 in DMF 0.3 M (2 
x 30 mm); iii) Fmoc-Ahx-OH or 4.10 (4 equiv), DIC (4 equiv) and HOBt (4 equiv) in DMF at 0.25 M, 
microwave irradiation at 60 °C for 20 mm; iv) 20% piperidine in DMF, 2 xl 0 mm; v) 95% TFA, 2.5% 
water, 2.5% TIS (triisopropylsilane), 3 h. 
2.1.1. Ni 2 + -ligands do not inhibit the heptapeptoid cellular uptake. 
In order to verify if the Ni2 -ligand did not inhibit the cellular uptake of the 
heptapeptoid, fluorecein labelled compounds 4.15 and 4.16 (Scheme 4.8 and Scheme 
4.9) were prepared and cellular uptake determined. 
The labelling of the compounds was carried out using a Fmoc-Lys(Dde)- residue 
introduced after the heptapeptoid (Scheme 4.8 and Scheme 4.9). For the synthesis of 
4.15 the coupling of 5(6)-carboxyfluorescein was done as last step after Dde 
deprotection of the c amine of the lysine residue. The synthesis of 4.16 required 
another approach, due to the use of the Dde protected building block 4.13. Using the 
labelling approach described by Brock, 185  the dye was coupled to the a amine of the 
- 102- 
lysine followed by tritylation of the phenolic hydroxy groups of the fluorescein 
moiety, that otherwise could react during the following coupling steps. The rest of the 
synthesis was carried out on the c amine of the lysine as described in Scheme 4.9. 
Both the compounds at a 5 jiM concentration were able to efficiently penetrate 
BI6FIO cells after 4 h of incubation at 37 °C, however the percentage of 
fluorescently labelled cells was reduced to around 80% (Figure 4.8), against the 95% 
of the heptapeptoid alone, with heptapeptoid 4.16 showing a lower cellular uptake 
compared to 4.15 (Figure 4.8, panel B) as shown by the lower mean fluorescence 
intensity of the cells (Figure 4.8, panel Q. The result was not completely unexpected 
since at pH 7.4 the anionic carboxylates (2 in 4.15 and 4 in 4.16) might reduce the 
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Scheme 4.8. Synthesis of fluorescently labelled 4.15. Reagents and conditions: i) 20% piperidine in 
DMF, 2 x 10 mm; ii) Fmoc-Ahx-OH (or 4.10, or 5(6)-carboxyfluorescein) (3 equiv), DIC (3 equiv) 
and HOBt (3 equiv) in DMF at 0.2 M, microwave irradiation at 60 °C for 20 mm; iii) NH20H.H20 in 
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Scheme 4.9. Synthesis of fluorescently labelled 4.16. Reagents and conditions: i) 20% piperidine in 
DMF, 2 x 10 mm; ii) 5(6)-carboxylluorescein (or 4.13) (3 equiv), DIC (3 equiv) and HOBt (3 equiv) 
in DMF at 0.2 M, microwave irradiation at 60 °C for 20 mm; iii) Trityl-CI (0.1 M) and DIPEA (0.1 M) 
in DMF, 16 h; iv) NH20fl.HO in DMF 0.3 M, 2 x 30 mm; v) Fmoc-Ahx-OH (or 4.10) (4 equiv), 
DIC (4 equiv) and HOBt (4 equiv) in DMF at 0.25 M, microwave irradiation at 60 °C for 20 mm; v) 
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Figure 4.8. FACS analysis of: A) B I 6F1 0 untreated cells; B) B I 6F10 cells treated with 4.15 (5 pM, 4 
h); C) BI6FIO cells treated with 4.16(5 pM, 4 h). P2 is the population of cells with a fluorescence 
intensity> 1000. 
- 105- 
IV.2.2. Delivery of GFP protein. 
The ability of the Ni2 mofied heptapeptoids 4.11 and 4.14 to induce protein 
internalisation was tested on hexahistidine tagged green fluorescent protein (His6-
GFP). The GFP protein was chosen because cellular internalisation can be easily 
















Figure 4.9. Hexahistidine tagged GFPNi21 -Heptapeptoid (4.11 and 4.14) complexes. 
Heptapeptoids 4.11 and 4.14 were dissolved in PBS buffer (pH 7.4) at a concentration 
of 1 mM, to this solution was added NiCl2. The Ni2theptapeptoids were mixed with 
the His6-GFP protein (purified His6-GFP protein was kindly donated by Dr. David 
Nagel, Aston University. Birmingham) at a 1:1 molar ratio and incubated for 1 h at 
room temperature. The heptapeptoidsNi2tGFP complexes were tested on B I 6F10 
cells at different concentrations (1, 2, 5. and 10 tM) under serum and serum free 
conditions. Both the heptapeptoids 4.11 and 4.14 did not give any significant positive 
result at any of the conditions tested. However, heptapeptoid 4.14-Ni2 -(His6-GFP) 
complex (10 jiM) did show a slight increment in fluorescent labelling compared to 
the controls (Figure 4.10), although it was not very significant. Confocal microscopy 
showed that the protein was mostly on the cellular membrane and very little was 
visible inside the cell, mainly localised in endosomal vesicles (Figure 4.11). 
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Figure 4.10. FACS analisys of: A) Bi6FIO untreated celist,; B) BI6FIO treated with His5-GFP (10 
I.LM, 24 h); C) BI6FIO treated with (4.14)-Ni2 -(His( -GFP) complex (10 jiM, 24 h). P2 is the 
population of cells with a fluorescence intensity >400. 
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Figure 4.11. Confocal microscopy image of B IÔFI() treated with (4.14)-Ni2 - (His-GFP) complex (10 
1iM, 24 h). 
In conclusion heptapeptoids functionalised with Ni2 ligands for conjugation to 
hexahistidine tagged proteins were prepared by solid phase synthesis. The presence of 
I or 2 Ni2tligands did not inhibit significantly the cellular uptake of the 
heptapeptoid. The first attempts to deliver His6-GFP unfortunately gave negative 
results, however the work is still at an embryonic stage and many modifications can 
be attempted in order to achieve the delivery of hexahistidine tagged proteins, as for 
example the use of different metal ions such as Co2 or Cu 2+,  and experimentation of 
other ligands such as the NTA and IDA. 
Sam 
IV.3. Peptoid carriers Summary: peptide, protein and plasmid 
delivery. 
This thesis describes the preparation of peptoid oligomers and their application as 
carriers for cellular delivery of compounds such as peptides, PNAs, DNAs and 
proteins. The synthesis of the oligomer unit (2.12, page 43) has been optirnised to 
allow a straightforward preparation on large scale (up to 30 g). The application of 
microwave heating to the synthesis of the peptoid oligomer led to a significant 
reduction in preparation time (DICIHOBt, 60 °C, 20 min for each coupling) and to 
obtain the compound with high purity (crude purity > 95%, see page 53-56). The 
heptapeptoid carrier has proved to be extremely efficient in delivering peptides 
(l3mer peptide (x-MSH) and PNAs (12 and 15mer) into different cell lines (BI6G4F, 
BI6CWT-3, l-1EK293, B-lymphocytes) and even more into skin (pig, mouse and 
human), one of the most challenging targets for the delivery of molecules with high 
molecular weight. Also the delivery of a polyanionic cargo such as an antisense DNA 
oligo (19mer oligonucleotide) gave positive preliminary results, providing a platform 
for further investigation. To achieve the delivery of macromolecules such as proteins 
the heptapeptoid carrier was modified with a Ni2 ligand (see pages 100-104), in 
order to allow the conjugation of His6 tagged proteins that can coordinate the Ni2 
using two histidine residues of the hexa-histidine tag (see page 98). Preliminary 
results are not positive, but several modifications are still possible, such as the use of 
different metals (CO2 , Cu2 ) and ligands (NTA, IDA). To achieve the delivery of 
macromolecules such as plasmids, the peptoid unit was used to prepare 3 generations 
of a peptoid dendrimer (see page 94). The peptoid dendrimer G3 (4.4, page 94) was 
able to deliver a GFP plasmid into HEK293T cells 4 times more efficiently than 
PAMAM G2. The work described in this thesis shows how the peptoid carrier 
strategy can be effectively applied to a wide range of cargoes with different sizes and 
charges. Regarding the efficiency of the delivery (usually > 90% of cell population), 
it was observed that it is not dependent on the particular cell line used. High cellular 
uptake is obviously a strongly positive aspect of the peptoid carrier, however, the 
actual absence of selectivity is a serious limitation for its application in vivo. At this 
stage I would consider a clear step forward for this research to develop the aspect of 
the carrier selectivity towards different cell lines and tissues. 
Chapter V. Experimental. 
V.!. General information. 
Reagents commercially available were used without further purification. Solvents 
were not dried or distilled except where specified. 
All solution-phase reactions were stirred magnetically, unless otherwise stated, and 
followed by HPLC or thin-layer chromatography (TLC) where appropriate, using 
aluminium-coated Silica Gel 60 (Macheray Nagel: 0.20 mm layer). TLC visualisation 
was performed using short wavelength UV light (254 urn) and/or potassium 
permanganate oxidation. 
NMR spectra were recorded on Bruker DPX 300 or ARX 250 spectrometers in the 
solvents indicated at 298 K. Chemical shifts are reported on the 8 scale in ppm and 
are referenced to residual non-deuterated solvent resonances. All '3C NMR 
experiments were supported with DEPT assignment. 
IR spectra were obtained on a Thermo Mattson Satellite FTIR spectrometer or a 
Bruker Tensor 27 Spectrometer, with 16 scans, at a resolution of ± 4 cm* The FTIR 
spectrometers were fitted with a Specac single reflection diamond ATR Golden Gate, 
and neat compounds were used for analysis. Frequencies are reported in cm-1 and 
only frequencies corresponding to significant functional groups are reported. 
Mass spectra were recorded either on a water ZMD single quadrupole MS, with a 
2700 Autosampler and a 600 Pump, or an Agilent Technologies LC/MSD Series 1100 
Quadrupole Mass Spectrometer (QMS), both with an electrospray ion source. 
MALDI-TOF spectra were recorded on a Applied Biosystems Voyager DESTR 
MALDI-TOF mass spectrometer. 
HPLC were recorded using an Agilent 1100 with a U.V. absorption detector coupled 
to a Polymer Lab 100 ES Evaporative Light Scattering Detector (ELSD). 
The following HPLC conditions were used: 
Column 1: Sulpelco Discovery 50 mm x 2.1 mm, 5 gm C18 column. 
Column 2: Phenomenex Prodigy 150 x 4.6 mm, 5 pm (ODS3) C 1 column. 
Column 3: Phenomenex Gemini Cl8, 5 [tm, 10 cm column 
HPLC grade solvents: water (0.1% TFA), MeOH (0.1% TFA), MeCN (0.042% 
TFA). The following methods were used: 
,J1sI 
Method 1 (column 1, H20/MeCN, I rnL/min): 0 min (90/10), 3 mm (10/90), 4 mm 
(10/90). 
Method 2 (column 2, H20/MeCN, 1 mL/min): 0 nun (90/10), 10 mm (10/90), 15 mm 
(10/90). 
Method 3 (column 2, H20/MeOH, I rnL/rnin): 0 mm (95/5), 4 mm (5/95), 12 mm 
(5/95). 
Method 4 (column 2, H20/MeOH, I mL/nuin): 0 mm (95/5), 3 mm (95/5), 8 mm 
(5/95), 12 (5/95). 
Method 5 (column 3, H20/MeCN, I mL/rnin): 0 mm (95/5), 6 mm (5/95), 9 mm 
(5/95). 
Method 6 (column 2, H20/MeOH, I mL/rnin): 0 mm (95/5), 12 (5/95), 13 mm 
(5/95). 
Semi-preparative HPLC separations were performed on an Agilent Technologies 
1100 HPLC equipped with automated fraction collection triggered by absorbance at 
220 nm, using water (0.1 % TFA), MeCN (0.042% TFA) and a Phenomenex Prodigy 
C18 250 x 10.0 mm, 5 pm (ODS3) C18 column. Method (H20/MeCN, 2.5 mL/min): 
0 mm (100/0), 40 mm (0/100), 45 mm (0/100). 
Melting points (Pyrex capillaries) are uncorrected. 
HRMS analyses were performed by the Mass Spectrometry Service of Edinburgh 
University, UK. 
Flow cytometry analyses and sorting were carried out on a Becton Dickinson 
FACSAriaTm using FACSDivaTM. 
For cell viability, 96-well plates were read on a Benchmark® Bio-Rad microplate 
reader at 570 nm using Microplate manger®  4.0. 
Confocal images were taken on a Delta Vision RT Microscope fitted with a water 
contact lens 63x. 
Microwave reactions were carried using a Smith Synthesizer, monomodal 
microwave reactor (Biotage). 
V.2. Experimental: Chapters II and III. 
V.2.1. Peptoid monomer synthesis. 




A solution of (130020 (10.0 g, 45.8 mrnoles) in DCM (100 mL) was added dropwise 
over a period of 2 h to a solution of I ,6-hexanediamine (42.5 g, 366 rnmoles) in DCM 
(150 mL). The reaction mixture was stirred for 24 h. The solution was filtered and the 
filtrate was concentrated in vacuo. The oily residue was suspended in water (200 mL) 
and extracted with DCM (3 x 150 mL). The organic phase was washed with brine (2 
x 100 mL) and dried over MgSO4. The solvent was removed in vacuo to give 
compound 2.13 (7.5 g, 34 mmol) as a yellowish oil, in 78% yield. 
m/z (ES+): 217.0 IIM+HI  (100%). 
'H NMR (CDC13, 300 MHz) 8 = 4.58 (br s, IH, B0cNHCH2), 3.12 (m, 2H, 
B0cNHCH2), 2.65 (m, 2H, CH2NH2), 1.60-1.33 (m, 19H, CH2NH2, 
BocNHCH2(CH2)4C1-12 and C(CH03). 
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2.1.2. Ethyl ((ó-[(tert-buroxycarbonyl)ainin 	nn o]hexlJano)acetate 2.14.149  
H 
0 	 0 
A solution of ethyl brornoacetate (3.8 mL, 34 mmoles) in THF (20 mL) was added 
dropwise to a solution of 1,6-Di am i no-N-tert-B utyl ox yc arbonyl hex ane  (2.13, 7.34 g, 
34 mmoles) and TEA (14 niL, 102 mmoles) in THF (50 rnL). The reaction mixture 
was stirred for 24 h. The solvent was evaporated in vacuo and the residue was re-
suspended in diethyl ether. The reaction mixture was filtered to remove triethylamine 
hydrobromide, the residue was washed with ether and the filtrate was concentrated in 
vacuo. Column chromatography (silica, eluent: DCM/MeOH, 9/I) gave 2.14 (5.64 g, 
18.7 rnmol), as an oil in 50 % yield. 
R1 (DCM/ MeOH, 9/1) = 0.45. 
nilz (ES+): 303.2 IM + HJ (100 %); 325.1 FM + NaI (48 %). 
'H NMR (CDC],, 300 MHz) 8 = 4.62 (hr s, I H, BocNHCH2), 4.13 (q, J = 7.0 Hz, 
2H, OCH2CH 3), 3.33 (s, 2H, NHCH2CO), 3.05 (in, 2H, BocNHCH2), 2.55 (m, 2H, 
CH2CH2NHCH2), 1.70 (br s, IH, CH2NHCH2), 1.59-1.28 (m, 17H, 





NaOH (0.4 g, 10 mmoles) was added to a solution of 2.14 (3 g, 10 nimoles) in MeOH 
(15 rnL), H20 (4 rnL) and dioxane (35 rnL). After stirring for 60 mill at room 
temperature the reaction mixture was concentrated in vacuo to give sodium ({6-[(tert-
butoxycarbonyl)ami no] hex yl } amino)acetate, which was used without purification. 
The sodium salt was dissolved in water (25 mL) and the pH was adjusted to 9.0-9.5 
with concentrated hydrochloric acid. To this mixture a solution of Frnoc-OSu (3.37 g, 
10 mmoles) in acetonitrile (25 niL) was added in one portion. Stirring was continued 
for 45 minutes, and the pH was maintained at 8.5-9.0 by the addition of TEA. The 
reaction mixture was concentrated in vacuo to remove the acetonitrile, and the 
residual solution was poured into 20% citric acid (30 mL). The aqueous layer was 
extracted with DCM (3 x 40 mL), the combined organic layers were washed with 
brine, dried (MgSO4) and concentrated in vacuo. Column chromatography (silica, 
eluent: gradient EtOAc to EtOAc/MeOH = 90/10), gave 2.12 (1.8 g, 4 nimoles) as a 
white solid in 40% yield. 
R1 ( EtOAc/MeOI-I, Ill) = 0.32. 
HPLC (method 1): purity 100% (220 nm), RT 4.22 mm. 
m/z (ES+): 519.4 [M + Naf (100 %), 1015.8 [2M+ Naf'  (35 %). 
'H NMR (CDCI3, 300 MHz) two rotamers 8 = 7.72 (d, J = 7.2 Hz, 2H, ArH-Fmoc), 
7.53 (d, J = 6.8 Hz, 2H, ArH-Fmoc), 7.35 (m, 2H, ArH-Fmoc), 7.26 (m, 2H, ArH-
Frnoc), 4.58 (br s, IH, BocNHCH2), 4.51 and 4.45 (two m, 2H, CH2-Fmoc), 4.10 (m, 
111, CH-Fmoc), 3.81 and 3.89 (two s, 2H, NCH2CO), 3.23 and 3.07 (two m, 4H, 
BocNCH2 and FmocNCH2CH2), 1.61-1.32 (m, 17H, BocNHCH2(CH2)4CH2 and 
C(CH3)3). 
-114- 
2.1.4. Benzyl (16-[(tert-biitox)7carbonyl)ainino]hexylJamino)acetate  2.15. 
H 
Oy N NOO 
10 	 0 
A solution of benzyl 2-bromacetate (5.8 g, 25 mmol) in THF (20 mL) was added 
drop-wise to a stirred solution of I ,6-Diamino-N-tert-Butyloxycarbonylhexane (2.13) 
(5.5 g, 25 mmol) and triethylaniine (5.4 g, 0.075 mol) in THF (50 ml) over 2h, and 
stirred for a further 24 h. After filtration of the white solid, the solution was 
concentrated in vacuo. Column chromatography (silica, eluent: ethyl acetate) gave 
compound 2.15 (5.0 g, 13 mrnol) as a pale yellow oil in 54 % yield. 
Rf ( EtOAc) = 0.42. 
HPLC (method 1): purity 100% (220 nm), RT 3.20 mm. 
IR (neat oil): 3339 (N-H, w), 1737 (C=Oester, s), 1697 (COurethane s) cm'. 
m/z (ES+): 365.0 [M+Hj (100%). 
'H NMR (300 MHz, CDCI3) 8 = 7.35 (m, 5H, ArH), 5.14 (s, 2H, COOCH2), 4.61 (hr 
s, IH, BocNHCH2), 3.42 (s, 21-I, NCH2CO), 3.10 (rn, 2H, BocNHCH2), 2.56 (t, J = 
7.3 Hz, 2H, CH2CH2NHCH2), 1.58 (br s, IH, CH2NHCH2), 1.50-1.23 (m, 17H, 
BocNHCI-12(CH2)4CH2 and C(CH3)3). 
'3C NMR (62.9 MHz, CDCIa) ö = 172.5 (NCH2CO), 156.0 (Boc C=O), 135.7 (Ar-
C), 128.6, 128.4, 128.3 (Ar-CH), 79.0 (C(CH 3)3), 66.5 (NCH2COOCH2), 51.0 
(NCH2CO), 49.5 (CH2CH2NHCH2), 40.5 (BocNHCH2), 30.0, 29.9 
(BocNHCH2CH2(CH2)2CH2), 	28.5 	(C(C113)3), 	26.8, 	26.6 
(BocNH(CH2)2CH2CH2CH2). 
HRMS (FAB) for C20H33N204 [M+H1 calcd 365.2440, found 365.2439. 
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2.1.5. 	Benzyl 	f{6-[(tert-butoxycarhonyl)amino]hexyi)[(9H-fluoren-  9-ylinethox),) 
carbonyiJaininojacetare 2.16. 
0 
Fmoc-OSu (4.6 g, 13.7 mmol) was added to a solution of 2.15 (5.0 g, 13.7 mmol) in 
DCM (50 ml). The reaction was monitored by TLC until completion (4h). The 
solvent was removed in vacuo and the crude product was purified by column 
chromatography (silica, eluent: EtOAc/Hexane, 1:1) to give 2.16 (7.2 g, 12.3 mmol) 
as a light yellow oil in 90 % yield. 
R ( EtOAc/Hexane 1:1) = 0.35. 
HPLC (method 1): purity 100% (220 nm), RT 4.82 mm. 
IR (neat oil): 1753 (C=Oesiei., s), 1701 (C=Ourei i ane, s) cm'. 
m/z (ES+): 587.3 [M+H]F  (60%), 609.2 [M+Na] (100%). 
'H NMR (300 MHz, CDCI3) two rotamers 6 = 7.79 (ni, 2H, ArH-Fmoc), 7.57 (m, 
2H, ArH-Fmoc), 7.44-7.27 (m, 9H, ArH-Fmoc and Ph), 5.13 and 5.18 (two s, 2H, 
COOCH2), 4.55 (br s, Ill, BocNHCH2), 4.53 and 4.40 (two d, J = 6.2 Hz, 2H, CL!2-
Fmoc), 4.13 and 4.26 (two t, J = 6.2 Hz, lH, CH-Fmoc), 3.96 and 4.03 (two s, 2H, 
NCI-12C0), 3.13 and 3.49 (two m, 4H, BocNHCH2 and FmocNCH2CH2), 1.47-1.13 
(m, 17H, B0cNHCH2(CH2)4CH2 and C(CH3)3). 
'3C NMR (75 MHz, CDCI3) two rotamers 6 = 169.7 and 169.6 (NCH2CO), 156.5, 
156.0 and 155.9 (Boc C=O and Fmoc C=O), 144.1 (ArC-Fmoc), 141.5 and 141.4 
(ArC-Fmoc), 135.5 and 135.4 (ArC-Ph), 128.6 and 128.5, 128.3, 127.7, 127.1, 124.9 
and 124.8, 120.0 (ArCH-Fmoc and ArCH-Ph), 79.1 (C(CH3)3), 67.6 and 67.4 (CH2-
Fmoc), 67.0 (NCH2COOCH2), 49.2 (NCH2CO), 48.8 and 48.7 (CH2CH2NCH2), 47.4 
(CH-Fmoc), 40.5 (BocNHCH2), 30.0 and 29.9 (B0cNHCH2CI-12), 28.4 (C(CH3)3), 
28.2 and 27.9 (CH2CH2NCH2), 26.4, 26.3 (BocNH(CH2)2CH2CH2CH2). 
HRMS (FAB) for C35H43N206  [M+H]F  calc. 587.3121, found: 587.3113. 
,ff 
2. 1.6. 	1(6-1(terr-butoxycarbonyl)ainino]hexyl)f(9H-fluoren-9-ylmethox)7)carbonyl] 
amino)acetic acid 2.12"-'(b), hydrogenolysis of benzyi ester 2.16). 
y N OH 
QIOo 
Compound 2.16 (4.0 g, 6.8 mmol) and Pd/C 10% (0.24 g) were dispersed in MeOH 
(100 nil). The reaction mixture was stirred under hydrogen atmosphere (1 atm) for 4h 
at room temperature. The reaction mixture was filtered through celite to remove Pd/C 
and the filtrate was concentrated in vacuo. The product was filtrated on silica gel 
(DCM/MeOH, 10/1) to give 2.12 (2.7 g, 5.4 mmol) as a white solid in 80 %. 
(m/z and 1 1-1 identical to the one reported for 2.12 in section V.2.1.3). 
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V.2.2. Detection of pri/nary and secondary anzines on solid supports. 
2.2.1. Qualitative Ninhydrin test for primary a/nines. 182 
To a small sample of washed resin in a test tube were added I drop of reagent A and 
3 drops of reagent B. The mixture was heated at 100°C for 5 minutes and the 
resulting blue or yellow color of the soluton indicated a positive or negative test 
respectively. 
Reacent A: Solution 1) Reagent grade phenol (40 g) was dissolved in absolute ethanol 
(10 mL) with warming and then stirred over Amberlite mixed-bed resin MB-3 (4 g) 
for 45 min The mixture was then filtered. Solution 2) Potassium cyanide (65 mg) was 
dissolved in water (100 rnL). A 2 mL aliquot of this solution was diluted with 
pyridine (freshly distilled from ninhydrin) and stirred over Amberlite mixed-bed resin 
MB-3 (4 g). The solution was filtered and mixed with solution I to form reagent A. 
Reagent B: Ninhydrin (2.5 g) was dissolved in absolute ethanol (50 mL). 
2.2.2. Chioranil test ftr secondary amines.171  
To a small sample of washed resin in a test tube were added few drops of 
acetaldehyde (2% in DMF) followed by one drop of a saturated solution of chloranil 
in toluene. A resulting dark-blue resin or a colourless resin indicated a positive or 
negative test respectively. 
'El 
V.2.3. General protocols for peptide and PNA synthesis, labelling and cleavage. 
General rule for the ratio of solvent- resin used for couplings: 10 mL of solvent for I 
g of resin. 
All the conditions described are for 200 mg of resin. All peptides were prepared on 
polystyrene resin (1% DVB, loading = I rnmol/g) using a Rink 151  amide linker. All 
PNAs were prepared on PEGA resin (loading = 0.4 mmol/g) using a Rink 151  amide 
linker. For Rink amide resin preparation see section V.2.3.10. 
2.3.1. Amino acids coupling at room temperature. 
The Frnoc-protected amino acids (3 equiv, 0.2 M) and HOBt (3 equiv, 0.2 M) were 
dissolved in DMF, DIC ( 3 equiv, 0.2 M) was then added and the solution stirred for 
10 minutes. The solution was added to the resin (pre-swollen in DMF for 20 nun) and 
the mixture stirred for 3 h at room temperature. The resin was then washed with 
DMF (3 x 5 mL) and DCM (3 x 5 mL). Couplings were monitored using qualitative 
colorirnetric tests and repeated if unsatisfactory. 
2.3.2. Amino acids coupling under microwave irradiation. 
The Fmoc-protected amino acids (3 equiv. 0.2 M) and HOBt (3 equiv, 0.2 M) were 
dissolved in DMF, DIC (3 equiv, 0.2 M) was then added and the solution stirred for 5 
minutes. The solution was added to the resin (pre-swollen in DMF for 20 mm) and 
the mixture transferred into a 5 mL microwave vessel. The vessel was capped and 
subjected to microwave irradiation to keep the temperature at 60 °C for 10 mm 
(peptide synthesis) or 20 mm (peptoid synthesis) under magnetic stirring using a 
single-mode microwave. The resin was then transferred to a solid phase extractor 
(SPE), a polypropylene syringe equipped with a fit and a valve, and washed with 
DMF (3 x 5 mL) and DCM (3 x 5 mL). Couplings were monitored using qualitative 
colorimetric test and repeated if unsatisfactory. 
2.3.3. PNA monomers coupling. 
Dde PNA monomers (5 equiv, 0.2 M) and PyBOP (4.8 equiv) were dissolved in DMF 
followed by the addition of NEM (10 equiv). The resulting solution was mixed for 10 
sec. before adding to the resin (pre-swollen in DMF) and the mixture was then shaken 
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for 4 h. Resins were washed with DMF (3 x 5 mL) and DCM (3 x 5 mL). Couplings 
were monitored using qualitative colorimetric tests and repeated if unsatisfactory. 
2.3.4. Capping protocol. 
The peptide resin was treated for 20 minutes with a capping solution of 15% acetic 
anhydride, 7.5% HOBt in DMF. 
2.3.5. Finoc deprotection. 
Fmoc deprotection was carried out by suspending the resin in 20% piperidine in DMF 
(5 mL) and shaking for 10 min The resin was then filtered, washed with DMF (3 x 5 
mL), DCM (3 x 5 mL) and re-suspended in 20% piperidine in DMF (5 mL) and 
shaken for a further 10 min after which time the resin was washed with DMF ((3 x 5 
rnL), DCM (3 x 5 mL). 
2.3.6. Dde deprotection. 
Dde deprotection was carried out by suspending the resin in 2% Nl-120H-H20 in 
DMF (3 x 5 mL) and shaking for 30 min The resin was then filtered, washed with 
DMF (3 x 5 mL), DCM (3 x 5 mL) and re-suspended in 2% NH20H-H20 in DMF (3 
x 5 rnL) and shaken for a further 30 min after which time the resin was washed with 
DMF (3 x 5 mL) and DCM (3 x 5 mL). 
2.3.7. Fluorescein labelling at room temperature. 185 
5(6)-Carboxyfluorescein (3 equiv, 0.2 M) and PyBop (2.8 equiv, 0.2 M) were 
dissolved in DMF. Then DIPEA (6 equiv) was added and the solution added to the 
pre-swollen resin. The mixture was stirred for 12 h. The resin was then washed with 
DMF (until obtaining a colourless solution) and treated with 20% piperidine in DMF 
for I h (under stirring). 185  The resin was then washed with DMF and treated again 
with 20% piperidine in DMF for 10 minutes, if a fluorescent solution was generated, 
the resin was left to stir for I h. The treatment was repeated until a colourless solution 
was obtained. The resin was then washed with DMF and DCM. 
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2.3.8. Fluorescein labelling tinder microwave irradiation. 
5(6)-Carboxyfluorescein (3 equiv, 0.2 M) and HOBt (3 equiv, 0.2 M) were dissolved 
in DMF. DIC (3 equiv, 0.2 M) was then added and the solution stirred for 5 minutes. 
The solution was added to the resin (pre-swollen in DMF for 20 mm) and the mixture 
transferred into a microwave vessel (5 or 2.5 mL). The vessel was capped and 
subjected to microwave irradiation to keep the temperature constant at 60 °C for 10 
min under magnetic stirring using a single-mode microwave. The resin was then 
transferred to a solid phase extractor (SPE), washed with DMF and treated with 20% 
piperidine in DMF (see above). The resin was then washed again with DMF and 
DCM. 
2.3.9. TFA cleavage and cold ether precipitation. 
The resin was washed with DMF (3 x 5 mL), DCM (3 x 5 mL), MeOH (3 x 5 mL), 
Et20 (3 x 5 mL) and dried in vacuo. Washed dry resin was suspended in TFA (5 mL 
of solution I or 2,) and stirred for 4 h. The solution was then separated by filtration 
from the resin which was washed with 5 rnL of TFA solution. The TFA solutions 
were collected and concentrated in vacuo (I mL Ca.) and transferred in a centrifuge 
tube containing cold diethyl ether (12 ml). The precipitated peptide was separated by 
centrifugation, washed with ether (3 x 12 mL) and then dried in vacuo. 
Solution 1: 95% TFA, 2.5% TIS, 2.5% H20. 
Solution 2: 81.5% TFA, 5% thioanisole, 5% phenol, 5 % water, 2.5% EDT (1,2 
ethanedithiol), I% TIS (triisopropylsilane). 
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2.3. 10. Preparation of Rtnk'5' amide resin. 
H2N 
oY —o 
Fmoc-Rink amide linker was coupled to the polystrene resin as described in section 
V.2.3.1. The linker was coupled to the PEGA resin as described in section V.2.3.1, 
but the number of reagent equivalents was increased to 5. Fmoc deprotection was 
carried out using 20% piperidine in DMF (V.2.3.5). 
V.2.4. aMSH Peptides and Peptide-Peptoid conjugates. 




(06 0  
-	ONNH,  
OL 
Fmoc-heptapeptoid 2.19 was prepared on Rink amide polystyrene resin (1% DVB, 1 
mmol/g) under microwave conditions (section V.2.3.2). Compound 2.19 was cleaved 
with TFA (solution I) and precipitated in cold ether. 
HPLC (method 2) purity 100% (220 nm), RT 3.41 minutes. 
m/z (ES+) 667.6 [M+2H]2  (15%),445.4 [M+3H]3(32%),  334.4 {M+4H14 (25%). 
2.4.2 a-MSH (Ac-S YSMEHFR WGKP V-NH2 ) 3.1. 
Peptide ct-MSH 3.1 was prepared using Rink amide polystyrene resin (100 mg, I 
mmol/g, 0.1 mmol). Peptide couplings (Side chain protected amino acids: Fmoc-
Lys(Boc)-OH, Fmoc-Trp(Boc)-OH, Fmoc- Arg(Pbf)-OH, Fmoc-His( I -Trt)-OH, 
Fmoc-Glu(O'B u)-OH, Fmoc-Ser('Bu)-OH, Fmoc-Tyr('Bu)—OH) were performed at 
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room temperature (see V.2.3.1). After Fmoc deprotection of the last residue the resin 
was capped (see section V.2.3.4, two cycles). TFA cleavage (see section V.2.3.9, 
solution 2), cold ether precipitation and semipreparative HPLC (RT 31.3 mm) gave 
peptide 3.1 (40 mg, 0.025 rnmol) in 25% overall isolated yield. 
HPLC (method 2) purity 95% (crude 63 %) (220 nm), RT 5.73 minutes. 
m/z (ES+) 833.2 [M+2H]2 (32%), 556.0 [M+3H]3 (100%). 
2.4.3. FAM- a-MSH (FAM-Ahx-SYSMEHFR WGKP V-NH2) 3.2. 
I: 
NH2 
Peptide FAM- a-MSH 3.2 was prepared using Rink amide polystyrene resin (100 mg, 
I mmol/g, 0.1 rnniol). Peptide couplings and fluorescein labelling were performed at 
room temperature (see V.2.3.1 and V.2.3.7). TFA cleavage (see V.2.3.9, solution 2), 
cold ether precipitation and semipreparative HPLC (RT 36.8 mm) gave peptide 3.2 
(41 mg, 0.02 mrnol) in 20% overall isolated yield. 
HPLC (method 2) purity > 95% (crude 40 %) (220 nm), RT 6.21 minutes. 
m/z (MALDI-TOF) for C102H128N22025S calcd 2094.3, found 2095.8 [M+H]t 
2.4.4. Frnoc-S YSMEHFR WGKP V-NH2 3.1b. 
Peptide 3.1b was prepared using Rink amide polystyrene resin (1 mmol/g). Peptide 
couplings were performed under microwave conditions (see V.2.3.2). The Fmoc 
group on the last residue (Ser) was not removed. Peptide IN was cleaved using TFA 
(see V.2.3.9, solution 2) and precipitated in cold ether. 
HPLC (method 1) purity 65% (220 nm), RT 6.81 minutes. 
nilz (ES+) 924.1 [M+2H]2 (35%), 616.3 1M+3H13 (100%). 
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2.4.5. FAM- a-MSH (FAM-Ahx-SYSMEHFRWGKPV-NH2) 3.2pw. 
H 
SYSMEH FR WG KP V-N H2 
.)II 
0 
Peptide FAM- a-MSH 3.2 was prepared using Rink amide polystyrene resin (200 mg, 
I mmol/g, 0.2 mmol). Peptide couplings and fluorescein labelling were performed 
under microwave conditions (see V.2.3.2 and V.2.3.8). TFA cleavage (see V.2.3.9, 
solution 2), cold ether precipitation and semipreparative HPLC (RT 36.8 mm) gave 
peptide 3.2 (120 mg, 0.058 mmol) in 30% overall isolated yield. 
HPLC (method 2) purity > 95% (crude 65 %) (220 nm), RT 6.21 minutes. 
m/z (MALDI-TOF) for C102H128N22025S calcd 2094.3, found 2095.9 [M+H]t 
2.4.6. a-MSH-Ahx-heptapeptoid 3.3. 
r21 
Ac-SYSMEHFRWGKPV-N -3N _jNH 
a-MSH-Ahx-heptapeptoid 3.3 was prepared using Rink amide polystyrene resin (100 
mg, I mmol/g, 0.2 mmol). Peptide couplings and peptoid couplings were performed 
under microwave conditions (see V.2.3.2). After Fmoc deprotection of the last 
residue (Ser) the resin was capped (see V.2.3.4, two cycles). TFA cleavage (solution 
2), cold ether precipitation and semipreparative HPLC (RT 15.7 mm) gave peptide 
3.3 (80 mg, 0.028 mmol) in 28% overall isolated yield. 
HPLC (method 2) purity > 95% (crude 63 %) (220 nm), RT 5.12 minutes. 
m/z (MALDI-TOF) for C139H232N36027S calcd 2871.6, found 2872.8 [M+H]t 
H 
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2.4.7. FAM-Ahx- a-MSH-Ahx-heptapeptoid 3.4. 
rNH, 1 
0 
FAM—N 	SYSMEHFRWGKPV—N '\ 15Olr H —NH 
o 	 °L 	i 
FAM-Ahx-a-MSH-Ahx-heptapeptoid 3.4. was prepared using Rink amide 
polystyrene resin (100 mg, I mmol/g) at room temperature and under microwave 
conditions. 
Peptide couplings, peptoid couplings and fluorescein labelling were performed under 
microwave conditions (see V.2.3.2 and V.2.3.8). TFA cleavage (see V.2.3.9, solution 
2), cold ether precipitation and semipreparative HPLC (RT 15.7 mm) gave peptide 
3.4 (105 mg, 0.032 mmol) in 32% overall isolated yield. 
HPLC (method 2) purity> 95% (crude 58 %) (220 nm), RT 5.46 minutes. 
rn/i (MALDI-TOF) C164H251N37033S:  calcd 3301.04, found 3302.2 M+HI. 
Peptide couplings, peptoid couplings and fluorescein labelling were performed at 
room temperature (see V.2.3.1 and V.2.3.7). Compound 3.4 was cleaved using TFA 
(solution 2) and precipitated in cold ether. 
HPLC (method 2): crude purity 60 % (220 nm), 
2.4.8. a-MSH-Lys(heptapeptoid)-NH2 3.5. 
AcSYSMEHFRWGKPV_ NH  
H 	NH 
L NH2 
a-MSH-Lys(heptapeptoid)-NH2 3.5 was prepared using Rink amide polystyrene resin 
(100 mg, I mmol/g, 0.1 mmol). Peptide couplings and peptoid couplings were 
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performed under microwave conditions (see V.2.3.2). Fmoc-Lys(Dde)-OH was 
coupled to the Rink amide resin and used as core for the synthesis of 3.5. a-MSH was 
prepared on the a-amine group after selective Fmoc deprotection of the Fmoc-
Lys(Dde)-Rink-resin. a-MSH-Lys(Dde)-Rink-resin was Dde deprotected (see 
V.2.3.6) and the peptoid was built on the c-amine group of the lysine core. TFA 
cleavage (solution 2), cold ether precipitation and senhipreparative HPLC (RT 16.54 
mm) gave peptide 3.5 (100 mg, 0.035 mrnol) in 35% overall isolarted yield. 
HPLC (method 2) purity> 95% (crude 65 %) (220 nm), RT 4.94 minutes. 
m/z (MALDI-TOF) for C102H128N22025S calcd 2885.65, found 2886.9 [M+H]. 
2.4.9. a-MSH-Lys(FAM-Ahx-heptapeptoid)-NH2 3.6. 
H 0  
AcSYSMEHFRWGKPV_N.) NH  
FAM 
cc-MS H- Lys (FAM-Ahx-heptapeptoid)-Nl-12 3.6 was prepared using Rink amide 
polystyrene resin (250 mg, I mmol/g). Peptide couplings, peptoid couplings and 
fluorescein labelling were performed under microwave conditions (see V.2.3.2 and 
V.2.3.8). Fmoc-Lys(Dde)-OH was couple to the resin and used as core for the 
synthesis of 3.6. a-MSH was prepared on the a-amine group after selective Fmoc 
deprotecti on of the Fmoc-Lys(Dde)-Rink-resin. a-MSH-Lys(Dde)-Rink-resin was 
Dde deprotected (see V.2.3.6) and the FAM-Ahx-heptapeptoid was built on the c-
amine group of the lysine core. TFA cleavage (see V.2.3.9, solution 2), cold ether 
precipitation and semipreparative HPLC (RT 18.8 mm) gave peptide 3.6 (104 mg, 
0.031 mmol) in 31 % overall isolasted yield. 
HPLC (method 2) purity > 95% (crude 58 %) (220 nm), RT 5.31 minutes. 
iutz (MALDI-TOF) for C166H254N38034S calcd 3358.09, found 3359.5 [M+H]. 
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V.2.5. Dde-Mint protected PNA monomers. 
2.5.1. N-(2-amino ethyl) glycine. HG! 311203 
H2N 
Ethylendiamine (140 mL, 213 mmol) was stirred at 40  C while 2—chloroacetic acid 
(20 g, 213 mmol) was added portion—wise. The reaction was stirred at room 
temperature overnight. The excess diarnine was evaporated in vacuo at 50 °C to give 
an oil that was triturated with DMSO (500 mL). The resulting solid was collected by 
filtration, washed with DMSO (3 x 100 mL) and diethyl ether (3 x 100 mL) and dried 
in a vacuum oven at 50 °C for 24 h to give the title compound as a white solid (24.5 
g, 95%). 
'H NMR (250 MHz, D20) 8 =3.l8 (s, 2H, NHCH2COOH), 2.96-2.87 (rn, 4H, 
CH2CH2) 
2.5.2. Methyl N-(2-ainino e hyl)glycinate . 2HC1 3.12.203 
To a stirred solution of acid 3.11 (5 g, 42.3 mmol) in MeOH (60 mL) at 0 °C was 
added SOd 2 (30 mL, 423 mmol). Then the reaction was refluxed for 12 h before 
cooling to 0 °C to give compound 3.12 (7 g, 81 %) as a white solid which was 
collected by filtration, washed with MeOH:DCM (1:1), diethyl ether and dried in a 
vacuum oven at 50 °C for 24 h. 
m/z (ES+): 133 [M+H] (100%) 
'H NMR (250 MHz, D20) 8 = 4.12 (s, 3H, COOCH3), 3.83 (s, 2H, 
CH2NHCH2COOH), 3.30-3.20 (ni, 4H, CH2CH2). 
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2.5.3. Methyl N- [2-[] -(4,4-Di,nethvl-2,6-dioxo-cyclohex),liden)-ethyiamino]-ethyl}- 
glycinate 3.13.202 
To a stirred solution of diamine salt 3.12 (25 g, 122 rnmol) and DIPEA (42 mL, 244) 
in DCM/MeOH (1:1, 250 mL) was added Dde-OH (22.2 g, 122 mmol). The solution 
was stirred at room temperature for 16 h before evaporating the solvent in vacua. The 
crude was taken up in EtOAc (200 mL) and the insoluble DIPEA salt removed by 
filtration. The compound was extracted into I M KHSO4 (4 x 50 mL). The pH was 
then brought to 9 with NaHCO3 and the compound re-extracted with EtOAc (3 x 100 
mL). The organic phase was washed with brine (1 x 100 mL), dried over MgSO4 and 
concentrated in vacua to give the title compound as a brown solid (21.6 g, 60%). 
HPLC (method I) purity 98% (254nm), RT 2.36 mm 
m/z (ES+): 297 [M+HI (100%). 
'H NMR (250 MHz, CDC13) S = 13.48 (br s, IH, NH-Dde), 3.71 (s, 3H, 0013), 
3.43-3.47 (m, 4H, NH(CH2)2), 2.92 (t, J = 6.0 Hz, 2 H, NHCH2CO), 2.54 (s, 3H. 
CCH3), 2.33 (s, 4H, CH2-Dde), 1.87 (br s, IH. NH), 0.99 (s, 6H, C(CH3)2). 
OWN 
2.5.4. Thymin-] -ylacetic Acid 3.14.196 
To a suspension of Thymine (25 g, 198.5 rnmol) and K2CO3  (27.4 g, 198.5) in dry 
DMF (600 mL) was added methyl bromoacetate (18.75 rnL, 198.5 mmol), and the 
mixture was stirred vigorously overnight under N2. The mixture was filtered and 
evaporated to dryness, in vacuo. The solid residue was cooled to 0 C, treated with 
water (188 mL) and 4 M HCI (aqueous, 8 mL), and stirred for 30 rnin The precipitate 
was collected by filtration and washed with water (3 x 100 mL). The precipitate was 
treated with water (200 mL) and 2 M NaOH (aqueous, 100 mL) and boiled for 10 
mm. The mixture was cooled to 0 °C, treated with 4 M HCI (aqueous, 67.5 mL), and 
stirred for 30 min The title compound was collected by filtration, washed with water 
(3 x 100 mL) and dried over P205 (21 g , 58%). 
HPLC (method 3) purity 100% (ELSD), RT 3.44 mm 
mlz (ES+): 185 [M+H] (100%), 207 [M+NafF  (90%), 
'H NMR (250 MHz, CD3SOCD3) ö= 11.32 (s, lH, NH), 7.46 (s, IH, CH), 4.36 (s, 
2H, CH2), 1.74 (s, 3H, CH3). 
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2.5.5. 	Methyl 	N12-(Thyinin-] -yl)-aceiyl]-N-(2-[] -(4,4-diinerhyl-2, 6-dioxo 
cyclohexyliden) ethylamino]-ethyl)-glycinate 3.15202  
Acid 3.14 (5 g, 27.5 mmol) was dissolved in DMF (55 mL), DCC (5.7 g, 27.5 mmol) 
and HOBt (4.2 g, 27.5 mmol) were added to the solution which was left to stir at 40 
°C for 20 mm. Compound 3.13 (8.2 g, 27.5 mmol) was then added and the solution 
stirred at 40 °C overnight. DCU was removed by filtration and washed with DMF, the 
combined solutions were concentrated in vacuo. The oil residue was taken up in 
DCM (250 mL) and washed with 1 M KHSO4 (3 x 75 mL), I M NaHCO3 (3 x75 
mL), and brine (3 x 75 mL). After drying over MgSO4 the solvent was removed in 
vacuo. Column chromatography (silica, eluent: DCMIMeOH, 95:5) gave 3.15 (8.8 g, 
19.25 mmol) as a white solid in 70% yield. 
R (DCM/MeOH, 95:5) = 0.35. 
HPLC (method 3) purity 100% (ELSD), RT 4.99 mm 
m/z (ES+): 463 [M+H] (100%), 485 [M+Na] (60%),947 t2M+NaJ (60%). 
1H NMR (250 MHz, CDCI3) (two rotamers) 5 = 13.54 and 13.34 (two s, I H, Dde-
NH), 10.20 (br s, 1H, NHm), 7.17 and 7.04 (two s, 1H, CHTI1Y), 4.62 and 4.44 (two s. 
2H, CH2CO2CH3), 4.24 and 4.06 (two s, 2H, CH2CON), 3.72 and 3.64 (two s, 3H, 
CH2CO2CH3 ), 3.68-3.58 (m, 4H, CH2CH2), 2.53 and 2.48 (two s, 3H, CCH3), 2.31 
and 2.28 (two s, 4H, CH2-Dde), 1.81 and 1.82 (two s, 3H, CH3TI1 ), 0.94 (s, 6H, 
C(CH3)2). 
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2.5.6. N-[2-(Th)7min-] -yl)-aceiyiJ-N-(2-[] -(4,4-dimeth),l-2, 6-dioxo-cyclohexyliden)- 
ethylainino]-ethvl)-glycine 3.7. 
202 
Compound 3.15(5 g, 10.8 mmol) was suspended in a 1:1 (v/v) mixture of THF and 
0.2 M Cs2CO3 (400 mL) and stirred at room temperature overnight. The THF was 
removed in vacua and the aqueous phase was acidified with 4 N HCI (pH = I), the 
water was then removed in vacua and the residue was treated with hot 2-propanol. 
The hot suspension was filtered to remove the salt and the 2-propanol solution 
collected. After removing the solvent in vacua the residue was sonicated in water (20 
mL), filtrated and dried over P205 in vacua to give 3.7 (4.2 g, 9.18 mmol) as a white 
solid in 85 % yield. 
HPLC (method 3) purity 100% (ELSD), RT 5.73 mm. 
m/z (ES+): 449 [M+H] (100%), 471 [M+Na]' (60%). 
'H NMR (250 MHz, CDCI 3) two rotamers 8 = 13.19 and 13.13 (two s, I H, Dde-NH), 
11.29 and 11.27 (two s, 111, NHTI1 ), 7.32 and 7.31 (twos, IH, CHThY),  4.66 and 4.51 
(two s, 2H, CH2CO2CH3 ), 4.27 and 4.02 (two s, 2H, CH2CON ), 3.68-3.58 (rn, 4H, 
CH2CH2)), 2.53 and 2.47 (two s, 3H, CCH3), 2.29 and 2.26 (two s, 411, CH2-Dde), 
1.75 (s, 3H, CH3m ), 0.94 and 0.93 (two s, 611, C(CH3)2). 
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2.5.7. N4-(4-methox),trityl)-cytosine 3.16. 
Cytosine (4.5 g, 40 mmol) was dissolved in dry pyridine (200 mL). Mmt-Cl (18.6 g, 
60 mniol) and NEM (6.45 mL, 40 mmol) were added and the solution stirred at 40 
C for 48 h under N2. The solvent was removed in vacuo, water (150 mL) and DCM 
(150 mL) were added. Diethyl ether was added until formation of a precipitate which 
was collected by filtration and dried over P205 affording 3.16 as a white solid (9.2 g, 
60%). 
HPLC (method 3) purity 100% (ELSD), RT 5.12 mm 
m/z (ES+): 273 [Mrnt] (100%), 767 [2M+H] (20%) 
(The title compound was insoluble in common deuterated solvents and therefore 
could not be analysed by NMR as reported in the literature for a Z-protected 
cytosine' 96) 
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2.5.8. Met/I)'! fN4-(4-inerhoxyrriiy!)-cyrosin-1 -)'l]-acetate 3.17.204 
H 	/ 
O\ 
Compound 3.16 (10.0 g, 26 mmol) was dissolved in dry DMF (100 mL). NaH (1.04 
g, 60% in mineral oil, 26 mmol) was added protion —wise to the stirred solution. 
After stirring for lh at room temperature methyl 2-brornoacetate (3.4 mL, 31 mmol) 
was added dropwise and the solution was left to stir for other 16 h at room 
temperature. The reaction was then quenched by adding MeOH (1 mL) and the 
solvent evaporated in vacuo. To the resulting oil was added water (50 mL), the white 
precipitate was collected by filtration and washed with water (2 x 25 mL) to give a 
white solid which was dried over P205 in vacuo (10 g, 85 %). 
HPLC (method 1) purity 98% (254 rim), RT 3.51 mm. 
m/z (ES+): 273 IIMmtI  (90%), 912 112M+HfF  (100%). 
'H NMR (250 MHz, CD3SOCD3) 8 = 8.44 (br s, IH, NH), 7.47 (d, J = 7.0 Hz, IH, 
CHc ), 728 - 7.16 (m, 12H, CHM II1t), 6.84 (d, J = 8.2 Hz, 2H, CHMflM ), 6.21 (d, J = 
7.0 Hz, IH, CHc ), 4.32 (s, 2H, CH2), 3.72 (s, 3H, CH3OAr), 3.61 (s, 3H, COOCH3). 
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4 	 202,204 2.5.9. IA' -(4-merhox),trityl)-cyrosm-] -yl]-acetic  acid 3.18. 
Compound 3.17 (10 g, 22 mrnol) was suspended in 2N aqueous NaOH (100 mL) and 
the mixture was stirred for 2 h at reflux. The reaction was cooled to room temperature 
and washed with DCM (3 x 20 niL). The solution was then acidified with 2 N 
aqueous HCI until pH 2. The precipitate was collected by filtration and washed with 
small portion of water until the filtrate was neutral (pH = 7), and dried in vacuo over 
P205 overnight to give 3.18(8 g, 17.6 rnmol) as a white solid in 80% yield. 
HPLC (method I) purity 95% (254 nni), RT 3.51 mm. 
m/z (ES+): 273 [Mmt]' (100%), 884 I2M+Hf (30%). 
'H NMR (250 MHz, CD3SOCD3) ö = 8.37 (br s, IH, NH), 7.44 (d, J = 7.2 Hz, I H, 
7.26-7.16 (m, 12H, CHM111 ), 6.83 (d, J = 6.9 Hz, 2H, CHMmt ), 6.19 (d, J = 
7.2 Hz, IH, CHc 1 ), 4.24 (s, 2H, CH2), 3.72 (s, 3H, CH3). 
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2.5.10. 	Methyl 	N-12-[N"4-(4-methoxytrityl)-cytosin-1-yl1aceiy1)-N-(2-[J -(4,4- 
diniethyl-2, 6-dioxo-c),clohexy 	m liden) ethylaino]ethyl)-glycinate 3. 19.202 
Acid 3.18 (10 g, 22 mmol) was dissolved in DMF (44 mL). DCC (4.56 g, 22 mmol) 
and HOBt (3.36 g, 22 mmol) were added to the solution and left to stir at 40 °C for 
20 min. Compound 3.13 (6.6 g, 27.5 mmol) was then added and the solution stirred at 
40 °C overnight. DCU was removed by filtration and washed with DMF (2 x 10 mL). 
The solvent was removed in vacuo and the residue was taken up in DCM (250 mL) 
and washed with I M KI4SO4 (3 x 75 mL), I M NaHCO3 (3 x 75 mL), and brine (3 x 
75 mL). After drying over MgSO4 the solvent was removed in vacuo. Column 
chromatography (silica, eluent: EtAcO/MeOH, 4:1) gave 3.19 (10.4 g, 14.52 mmol) 
as a white solid in 66% yield. 
Rf (EtOAc/MeOH, 4:1) = 0.4. 
HPLC (method 3) purity 97% (ELSD), RT 6.25 mm. 
in/z (ES+): 273 [Mmtj (92%), 720 IIM+Hf'  (100%) 
1H NMR (250 MHz, CD30D) two rotamers 8 =7.30-7.l6 (m, 12H, CHMIt, 11-I, 
CHc ), 6.83 (d, J = 8.5 Hz, 2H, CHMIt), 5.19 (d, J = 6.9 Hz, I H, CHc1), 4.67 and 
4.51 (two s, 2H, CH2CO2Me ), 4.38 and 4.13 (two s, 2H, CH2CON), 3.74-3.63 (m, 
3H, 0CH3M1111, 4H, CH2CH2, 3H, COOCH3), 2.57 and 2.52 (two s, 3H, CCH3), 2.31 
and 2.28 (two s, 4H, CH2-Dde), 0.96 and 0.95 (two s, 6H, C(CH3)2). 
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2.5.11. N-(2-JP/4-(4-inethoxyrrit),i)-cytosin-] -yi]-acelyi)-N-(2-1 I -(4,4-dimethyi-2, 6- 
dioxo-cyclohexyliden) ethvlanino]ethyi]-glycine 3.8 
.202 
HN4/ 
Ir  00 
NN OH 
4 	0 H 
Compound 3.19 (7.76 g, 10.8 rnmol) was suspended in a 1:1 (v/v) mixture of THF 
and 0.2 M Cs2CO3 (400 mL) and stirred at room temperature overnight. The THF 
was removed in vactio, the aqueous phase was acidified with IM KHSO4 (pH = 2), 
and extracted with DCM (3 x 200 rnL). The organic phase was washed with brine (2 
x 100 mL), dried over MgSO4. The solvent was removed in vacuo to give 3.8 (6.24 g, 
8.8 mmol) as a white solid in 82% yield. 
HPLC (method 3) purity 100% (ELSD), RT 9.51 mm. 
m/z (ES+): 273 [Mmtj (100%), 706 [M+HI (20%). 
'H NMR (250 MHz, CD30D) two rotamers S = 7.28-7.16 (m, 12H, CHM II(, I H, 
CHc 1), 6.84 (d, J = 8.7 Hz, 2H, CHM II1t), 5.25 and 5.21 (two d, J = 7.5 Hz, IH, 
CHc 1), 4.68 and 4.50 (two s, 2H, CH2CO2H), 4.22 and 4.09 (two s, 2H, CH2CON), 
3.73-3.61 (m, 3H, OCH3M11(, 4H, CH2CH2), 2.53 and 2.50 (two s, 3H, CC113 ), 2.30 
and 2.26 (two s, 4H, CH2-Dde), 0.92 and 0.96 (two s, 6H, C(CH3)2). 
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Adenine (32.8 g, 230 mmol) was suspended in dry DMF (500 mL). NaH (10.58 g, 
60% in mineral oil, 260 mmol) was added portion-wise with mechanical stirring. The 
reaction mixture was stirred at room temperature for 2 h. Methyl 2-bromoacetate (33 
rnL, 345 mmol) was added dropwise during 3 h, and stirred for a further 2 h. The 
solvent was removed by evaporation in vacuo, the remaining oil was stirred with 
water (450 mL) resulting in the precipitation of a white solid. The solid was collected 
by filtration and washed with water (2 x 50 mL), followed by recrystallization from 
EtOH (34.2 g, 68 %). 
HPLC (method I) purity 100% (254 nm), RT 1.35 mm 
m/z (ES+) 208 [M+H] (100%). 
'H NMR (250 MHz, CD3SOCD3) S= 8.14 (s, IH, CH), 8.12 (s, IH, CH), 7.32 (s, 
2H, NH2), 5.09 (s, 2H, CH2), 3.69 (s, 3H, OCH3 ). 
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N N' 0 
0- 
Compound 3.20 (25 g, 120 mrnol), NEM (15 mL, 120 mmol) and Mmt-Cl (55 g, 
1180 rnmol) in dry pyridine (350 mL) were stirred at 45 °C for 48 h under N2. The 
solvent was removed in vacuo and the remaining oil was dissolved in DCM (250 
mL), washed with I N aqueous KHSO4 (3 x 50 mL), 10% aqueous NaHCO3 (3 x 50 
mL), brine (3 x 50 mL) and dried over MgSO4. Column chromatography (silica, 
eluent: AcOEt) gave 3.21 (39 g, 92.4 mmol) as a white solid in 77% yield. 
Rf (AcOEt)= 0.45. 
HPLC (method I) purity 100% (254 nrn), RT 3.88 mm. 
m/z (ES+): 273 [MmtI (100%), 480 [M+H] (35%) 
'H NMR (250 MHz, CD3SOCD3) 8 = 8.22 (s, lH, CHpur), 7.94 (s, IH, CHpur), 7.30-
7.20 (m, 1211, CHMn1I), 6.85 (d, J = 8.9 Hz, 2H, CHM 1I ), 5.11 (s, 2H, CH2), 3.70 (s, 
3H, COCH3), 3.69 (s, 311, COOCH3). 







Compound 3.21 (38 g , 79 mrnol) was suspended in a 1: 1 (v/v) mixture of THF and 2 
N NaOH (150 mL) and stirred at room temperature overnight. The THF was 
removed in vacuo, the aqueous phase was acidified with IM KHSO4 (200 mL) and 
extracted with EtOAc (3 x 100 mL). The organic phase was washed with brine (3 x 
50 mL) and dried over MgSO4. The solvent was removed in vacua to give 3.22 (32.7 
g, 62.41mrnoI) as a white solid in 89 % yield. 
HPLC (method I) purity 100% (254 nm), RT 3.61 mm. 
m/z (ES+): 273 [Mmtf (100%), 466 [M+H] (35%). 
'H NMR (250 MHz, CD3SOCD3) 8 = 8.20 (s, IH, CHpur), 7.91 (s, IH, CHpur), 7.30-
7.20 (m, 12H, CHMmI), 6.85 (d, J = 8.7 HZ, 2H, CHMmt), 4.96 (s, 2H, CH2), 3.71 (s, 
3H, COCH3). 
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2.5.15. 	Methyl 	N-(2-[!'/6-(4-inethoxytrii),l)-adenin-9-yl]-acetyl)-N-{2-/ 1-(4,4- 
dimeth),1-2, 6-dioxo-cyclohexyliden) ethylamino]ethyl)giycinate 3.23.202 
Acid 3.22 (10.23 g, 22 mmol), DCC (4.56 g, 22 mrnol) and HOBt (3.36 g, 22 mmol) 
in DMF (44 mL) were stirred at 40 °C for 20 min. Compound 3.13 (6.6 g, 27.5 mmol) 
was then added and the solution stirred at 40 °C overnight. DCU was removed by 
filtration and washed with DMF (2 x 10 niL). The solution was concentrated in 
vacuo. The residual oil was taken up in DCM (250 mL) and washed with I M KI-1SO4  
(3 x 75 mL), I M NaFIC03 (3 x 75 mL), and brine (3 x 75 mL). The organic phase 
was dried on MgSO4 and concentrated in vacuo. Column chromatography (silica, 
eluent: EtOAc/MeOH, 10:1) gave 3.23 (10.4 g, 15.18 rnmol) as a white solid in 69 % 
yield. 
Rf (EtAcO: MeOH, 10:1) = 0.4. 
HPLC (method 3) purity 100% (ELSD), RT 6.40 mm. 
lutz (ES+): 273 [Mmt] (100%), 744 [M+H] (75%). 
1H NMR (250 MHz, CDCI 3) two rotamers 8 = 13.46 (s, lH, Dde-NH), 7.99 and 7.96 
(two s, IH, CHPur), 7.88 (s, IH, CHpur), 7.30-7.20 (m, 12H, CHM flI), 6.73 (d, J = 8.9 
Hz, 2H, CHMmI), 5.11 and 4.94 (two s, 2H, CH2CO2Me), 4.30 and 4.07 (two s, 2H, 
CH2CON), 3.72-3.59 (m, 3H, 0CH3M1111, 4H, CH2CH2, 3H, COOCH3), 2.52 and 2.49 
(two s, 3H, CCH3), 2.34 and 2.32 (two s, 4H, CH2-Dde), 0.98 (s, 6H, C(CH3)2). 
2.5. 16. 	N-{2-fI'/6-(4-methox),trityl)-adenin-9-yl]-acetylJ-N-(2-/] -(4,4-dimethyl-2,6- 
dioxo-cyclohexyliden) ethylainino]ethyl]giycine 3.9.202 
Compound 3.23 (8 g, 10.8 mmol) was suspended in a 1:1 (v/v) mixture of THF and 
0.2 M Cs2CO3 (400 mL) and stirred at room temperature overnight. The THF was 
removed in vacuo, the aqueous phase was acidified with IM KHSO4 (pH = 2), and 
extracted with DCM (3 x 200 mL). The organic phase was washed with brine (2 X 
100 mL), dried over MgSO4. The solvent was removed in vacuo to give 3.9 (7.1 g, 
9.72) as a white solid in 90% yield. 
HPLC (method 1) purity 100% (254 nm), RT 3.69 mm. 
m/z (ES+): 273 [Mmt]1  (100%), 730 [M+Hf (55%). 
'H NMR (250 MHz, CD3SOCD3) two rotamers 6 = 13.16 ( s, IH, Dde-NH), 8.13 (s, 
IH, CHpur), 7.92 (s, IH, CHPUI ), 7.34-7.21 (m, 12H, CHMt), 6.90 (d, J = 8.5 Hz, 2H, 
CHM1 ), 5.22 and 5.12 (s, 2H, CH2CO2H), 3.95 (s, 2H, CH2CON ), 3.77-3.53 (m, 3H, 
OCH3M111 , 4H, CH2CH2), 2.56 and 2.50 (s, 3H, CCH3), 2.30 (s, 4H, CH2-Dde), 0.96 
(s, 6H, C(CH3)2). 
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2-Aniino-6-chloropurine (15 g, 88 mmol) was suspended in dry DMF (250 mL). NaH 
(3.6 g, 60% in mineral oil, 88 mmol) was added protionwise to the stirred suspension. 
The reaction mixture was stirred at room temperature for 2 h, and methyl 2-
bromoacetate (12.6 mL, 132 mmol) was added dropwise over I h. The mixture was 
then stirred for a further 2 h. The solvent was removed in vacuo, the remaining oil 
was stirred with water (200 mL) resulting in the precipitation of a white solid. The 
solid was collected by filtration, washed with water (2 x 50 mL) and dried in vacuo 
over P205. Column chromatography (silica, eluent: DCM/MeOH, 9:1) gave 3.24 
(16.1 g, 68 mmol) as a white solid in 76% yield. 
R (DCM/MeOH, 9:1) = 0.44. 
HPLC (method 5) purity 100% (ELSD), RT 4.69 mm. 
mlz (ES+): 242 (35C1) and 244 (37C1) [M+Hf (100%), 264 (35C1) and 266 (37C1) 
[M+Naj (75%). 
'H NMR (250 MHz, CD3SOCD3) ö = 8.12 (s, JH, CH), 7.01 (s, 2H, NH2), 5.01 (s, 
2H, CH2), 3.68 (s, 3H, CH3). 
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2.5. 18. Methyl N2  -(4-inetho,yrrir)7l)-ainino-6-chloropurin- 9-yl acetate 3.25.202  
CI 
QHN N N a 
Compound 3.24 (5 g, 20 mmol), 4-methoxytrityl chloride (9.58 g, 30 mmol) arnd 
DIPEA (3.6 mL, 20 mmol) in dry THF (135 mL) were stirred at 40 °C under N2 
atmosphere for 12 h. The solvent was removed by evaporation in vacuo and the 
remaining oil was taken up in Et20 (150 mL). The solution was washed with I M 
KHSO4 (3 x 25 mL), 10% aqueous NaI-1CO3 (3 x 25 mL), brine (I x 25 mL) and 
dried over MgSO4. The solvent was removed in vacuo and the remaining oil was 
triturated with petroleum ether 40-60 °C to give 3.25 (5.3 g, 10.2 mmol) as a 
yellowish solid in 51% yield. 
HPLC (method 5) purity 100% (ELSD), RT 10.03 mm. 
mlz (ES+) 514.2 ("Cl) and 516.2 ("Cl) IIM+Hf F (100%). 
'H NMR (250 MHz, CDC13) ö=7.67 (s, IH, CHpur), 7.35-7.24 (m, 12H, CHMmt), 
6.81 (d, J = 8.6 Hz, 2H, CHMI ), 6.65 (s, JH, NH-Mmt), 4.37 (s, 2H, CH2), 3.81 (s, 
311, OCH3Mflt), 3.67 (s, 3H, COOCH3). 
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Ester 3.25 (5.0 g, 9.6 mrnol), was suspendeed in 2 N aqueous NaOH (150 niL) and 
the mixture was stirred for 4 h at reflux. The reaction was cooled to room temperature 
and acidified with 2 N aqueous HCI (pH2). The precipitate was collected by 
filtration, washed with water and dried in vacuo overnight giving a solid which was 
washed with diisopropyl ether to give 3.26 (3.5 g, 7.2 mmol) as a yellowish solid in 
75% yield. 
HPLC (method 5) purity 100% (ELSD), RT 7.50 mm. 
mlz (ES+) 482.2 [M+H] (100%). 
'H NMR (250 MHz, CD3SOCD1) ö= 11.15 (s, lH, NHPUr), 8.12 (s, IH, NH-Mmt), 
8.06 (s, IH, CHPUE), 7.29-7.16 (m, 12H, CHMIflI), 6.81 (d, J = 8.4 Hz, 211, CHMII1I), 
4.28 (s, 2H, CH2), 3.72 (s, 3H, OCH3Mt) 
2.5.20. 	Methyl 	N-(2-[N'2-(4-metho),triiyi)-guanin-9-yl]-aceiyl)-N-[2-[1-(4,4- 









PyBrOP (5.07 g, 10.9 mmol) and DIPEA (3.7 mL, 21.8 rnmol) were added to a 
solution of acid 3.26 (5.24 g, 10.9 mmol) and amine 3.13 (3.38 g, 10.9 rnmol) in 
DMF (25 mL) at 0 °C. The reaction solution was removed from the ice bath and 
stirred under N2 at 25 °C for 2 h. The solvent was removed in vacuo and the residue 
was taken up in DCM (300 mL). The solution was washed with I M KHSO4 (100 
mL), 10% aqueous NaHCO3 (100 mL) and brine (100 mL). The organic phase was 
dried over MgSO4 and concentrated in vacuo to afford 3.27 as a brown solid (3.9 g, 
50%) which was used for the next step without any further purification. 
Analytical sample purified by chromatography (DCMIMeOH, 5: 1). 
Rf (DCM/MeOH, 5:1): 0.31. 
HPLC (method 5) purity 96% (ELSD), RT 8.42 mm. 
m/z (ES+) 760.4 IM+Hf (100%). 
'H NMR (250 MHz, CD3SOCD3) two rotamers ö= 13.23 and 13.17 (s, IH, Dde-
NH), 10.58 and 10.55 (two br S, IH, NHpur), 7.44 and 7.42 (two s, IH, CHPUF), 7.30-
7.13 (m, 12H, CHM ITt), 6.81 (d, J = 8.7 Hz, 2H, CHMmt), 4.41 and 4.22 (two s, 2H, 
CH2COOMe), 4.10 and 4.05 (two s, 2H, CH2CO), 3.72-3.43 (m, 3H, OCH3Mmt, 4H, 
CH2CH2, 3H, COOCH3), 2.51 and 2.48 (two s, 3H, CH3C), 2.30 and 2.26 (two s, 4H, 
CH2-Dde), 0.95 and 0.94 (two s, 6H, C(CH3)2) 
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2.5.21. 	N-/2-[N'2-(4-methox),triryl)-giianin-9-vl]-aceiyl]-N-[2-I1  -(4,4-dinieth),l-2, 6- 





Compound 3.27 (3 g , 4 mmol) was suspended in a 1: 1 (vlv) mixture of THF and 0.2 
M Cs2CO3 (160 mL) and stirred at room temperature overnight. The THF was 
removed in vacuo, and the aqueous phase was washed with DCM (3 x 20 mL). The 
basic water solution was acidified with IM KHSO4 (pH = 2). The precipitate was 
collected by filtration and washed with water. The solid was dissolved in a minimum 
volume of MeOH and re-precipitated with the addiction of water. The solid was 
collected by filtration and dried in vacuo to give 3.10 (5 g, 3.2 rnmol) as a brown 
solid in 80% yield. 
HPLC (method 5) purity 94% (ELSD), RT 7.07 mm. 
m/z (ES+) 746.3IM+H1  (100%). 
1H NMR (250 MHz, CD3SOCD3) two rotamers = 13.16 and 13.15 (two br s, IH, 
Dde-NH), 10.51 (br 5, IH, NHpur), 7.45 and 7.43 (two s, IH, CHPUr), 7.277.15 (iii, 
12H, CHMmt), 6.81 (d, J = 8.7 Hz, 2H, CHMII), 4.45 and 4.23 (two s, 2H, CH2COO), 
3.98 and 3.93 (two s, 2H, CH2CO), 3.73-3.41 (in, 3H, OCH3M1t, 41-I, CH2CH2), 2.50 
and 2.47 (two s, 3H, CH3C), 2.31 and 2.28 (two s, 4H, CH2-Dde), 0.95 and 0.94 (two 
s, 6H, C(CH3)2). 
V.2.6. PNAs and PNA-peptoid conjugates. 
PNAs and PNA-peptoid hybrids were prepared using Rink '5' amide PEGA resin (25 
mg, loading 0.4 mmol/g, 10 tmol). 
- Peptoid couplings and fluorescein labelling were carried out under microwave 
conditions (see V.2.3.2 and V.2.3.8). 
- PNA couplings were followed by a capping step (see V.2.3.4). 
- Dde deprotection and Fmoc deprotection were carried out as described in 
sections V.2.3.5 and V.2.3.6. 
- TFA cleavage (solution I) and ether precipitation were accomplished as 
described in V.2.3.9. 
2.6.]. PNA oligorners 3.28-3.33. 
H4N~ANH,   
H 
TTT CTC CTT (3.28). 
Yield: 7.2 mg, 2.6 pmol. 
HPLC (method 4) crude purity 95% (ELSD), RT 6.06 minutes. 
m/z (MALDI-TOF) for C96H126N40033 calcd 2368.27, found 2368.56 tIM+HJ. 
CAT TTT CTC Crc (3.29). 
Yield: 9.3 mg, 2.5 ltmol. 
HPLC (method 4) crude purity> 95% (ELSD), RT 6.35 minutes. 
m/z (MALDI-TOF) for C128H,66N56042 calcd 3161.03, found 3158.38 [M+H]t 
GAA CAT TTT CTC Crc (3.30). 
Yield: 15.4 mg, 3.1 limol. 
HPLC (method 4) poor solubility, broad peak RT 6.68 minutes. 
m/z (MALDI-TOF) for C,61 H205N77049 calcd 4002.83, found 3998.34 [M+H]. 
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TCT TCC TCT (3.31). 
Yield: 7.5 mg, 2.6 jimol. 
HPLC (method 4) crude purity > 95% (ELSD), RT 5.94 minutes. 
m/z (MALDI-TOF) for C95H125N41032 calcd 2353.26, found 2353.96 FM+HIt 
CAT TCT TCC TCT (3.32). 
Yield: 11.6 mg, 3 prnol. 
HPLC (method 4) crude purity 90% (ELSD), RT 6.25 minutes. 
m/z (MALDI-TOF) for C127H165N57041 calcd 3146.02, found 3143.77 [M+H]t 
GAG CAT TCT TCC TCT (3.33). 
Yield: 12.8 mg, 2.6 jimol. 
HPLC (method 4) poor solubility, broad peak RT 6.27 minutes. 
m/z (MALDI-TOF) for C160H204N78049 calcd 4003.82, found 4002.07 [M+H]t 
2.6.2. FAM-A hx-PNA oligomers 3.34-3.39. 
B 1 
H 
FAM_NN 	Ntf NH 
5 LH 
FAM-Ahx-TTT CTC CTT (3.34). 
Yield: 9.5 mg, 2.9 irnoi. 
HPLC (method 4) crude purity > 95% (ELSD), two isomers RT 7.36 and 7.54 
minutes. 
m/z (MALDI-TOF) for C123H147N41040 calcd 2839.73, found 2836.21 [M+H]. 
FAM-Ahx-CAT TTT CTC Cli' (3.35). 
Yield: 10.8 mg, 2.5 jimol. 
HPLC (method 4) crude purity 92% (ELSD), two isomers RT 7.16 and 7.17 minutes. 
mlz (MALDI-TOF) for C35514187N57049 calcd 3632.49, found 3633.10 ljM+HIt 
FAM-Ahx-GAA CAT TTT CTC CTT (3.36). 
Yield: 16.2 mg, 3 j.tmol. 
HPLC (method 4) very poor solubility, broad peak. 
m/z (MALDI-TOF) for C188H226N780 6 calcd 4474.29, found 4477.06 [M+H]t 
FAM-Ahx-TCT TCC TCT (3.37). 
Yield: 8.7 mg, 2.6 imo1. 
HPLC (method 4) crude purity> 95% (ELSD), two isomers RT 7.05-7.24 minutes. 
m/z (MALDI-TOF) for C122H146N42039 calcd 2824.72, found 2825.84 [M+H]. 
FAM-Ahx-CAT TCT TCC TCT (3.38). 
Yield: 13.5 mg, 3.1 jimol. 
HPLC (method 4) crude purity 85% (ELSD), two isomers RT 7.03 and 7.16 minutes. 
rn/z (MALDI-TOF) for C154H186N 8048 calcd 3617.48, found 3618.84 [M+H]'. 
FAM-Ahx-GAG CAT TCT TCC TCT (3.39). 
Yield: 13 mg, 2.4 irno1. 
HPLC (method 4) very poor solubility, broad peak. 
m/z (MALDI-TOF) for C187H22 N79056 calcd 4475.28, found 4477.37 [M+H]. 
2.6.3. Heptapeptoid-Ahx-PNA oligomers 3.40-3.45. 
B 1 
H 
Oy 0  




Heptapeptoid-Ahx-TTT CTC CTT (3.40). 
Yield: 12.5 rng, 2.6 j.tmol. 
HPLC (method 4) crude purity 95% (ELSD), RT 6.06 minutes. 
m/z (MALDI-TOF) for C158H249N55041 calcd 3575.01, found 3578.30 IjM+HIt 
Heptapeptoid -Ahx-CAT TTI' CTC CTT (3.41). 
Yield: 13.7 mg, 3.1 pmo1. 
HPLC (method 4) crude purity 95% (ELSD), RT 6.30 minutes. 
m/z (MALDI-TOF) for C190H289N71050 calcd 4367.77, found 4367.26 [M+H]t 
Heptapeptoid -Ahx-GAA CAT TFT CTC CTT (3.42). 
Yield: 15.5 mg, 2.2 jimol. 
HPLC (method 4) crude purity 85% (ELSD), RT 6.62 minutes. 
m/z (MALDI-TOF) for C223H328N92057 calcd 5209.57, found 5209.06 [M+H]t 
Heptapeptoid -Ahx-TCT TCC TCT (3.43). 
Yield: 13.5 mg, 2.8 imo1. 
HPLC (method 4) crude purity 93% (ELSD), RT 5.92 minutes. 
m/z (MALDI-TOF) for C17H248N56040 calcd 3560.00, found 3560.34 [M+H]t 
Heptapeptoid -Ahx-CAT TCT TCC TCT (3.44). 
Yield: 12.8 mg, 2.2 pmol. 
HPLC (method 4) crude purity 86 % (ELSD), RT 6.27 minutes. 
m/z (MALDI-TOF) FOR C1891-1288N72049 calcd 4352.76, found 4353.55 [M+H]. 
Heptapeptoid -Ahx-GAG CAT TCT TCC TCT (3.45). 
Yield: 18.4 mg, 2.6 jimol. 
HPLC (method 4) crude purity 55% (ELSD), RT 6.60 minutes. 
m/z (MALDI-TOF) for C222H327N93057 calcd 5210.56, found 5212.81 [M+H]t 
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2.6.4. FAM-AIix-heptapeptoid-AIu-PNA oligorners 3.46-3.51. 
B 1 
H 	 H 
FAM_N N N
ii  
N N 4NH2 
[NH2 j 
FAM-Ahx-heptapeptoi d-Ahx-TTT CTC CTT (3.46). 
Yield: 14.4 mg, 2.7 pmoI. 
HPLC (method 4) crude purity> 95% (ELSD), RT 6.33 minutes. 
m/z (MALDI-TOF) for C185H270N 6048 calcd 4046.46, found 4047.83 [M+H]t 
FAM-Ahx-heptapeptoid -Ahx-CAT iTT CTC CTT (3.47). 
Yield: 14.3 mg, 2.3 jimol. 
HPLC (method 4) crude purity 90% (ELSD), RT 6.34 minutes. 
m/z (MALDI-TOF) for C217H310N72057 calcd 4839.23, found 4839.79 [M+H]. 
FAM-Ahx-heptapeptoid -Ahx-GAA CAT TTF CTC CTT (3.48). 
Yield: 15.5 mg, 2.0 tmo1. 
HPLC (method 4) crude purity 75% (ELSD), RT 6.48 minutes. 
m/z (MALDI-TOF) for C250H349N93064  calcd 5681.03, found 5683.37 [M+H]. 
FAM-Ahx-heptapeptoid -Ahx-TCT TCC TCT (3.49). 
Yield: 15.6 mg, 2.9 jimol. 
HPLC (method 4) crude purity> 95% (ELSD), RT 6.29 minutes. 
m/z (MALDI-TOF) for C18414269N57043 calcd 4031.45, found 4032.40 [M+H]. 
FAM-Ahx-heptapeptoid -Ahx-CAT TCT TCC TCT (3.50). 
Yield: 15 mg, 2.4 imo1. 
HPLC (method 4) crude purity 84% (ELSD), RT 6.28 minutes. 
m/z (MALDI-TOF) for C216H309N730 6 calcd 4824.22, found 4826.12 [M+H]t 
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FAM-Ahx-heptapeptoid -Ahx-GAG CAT TCT TCC TCT (3.51). 
Yield: 18 mg, 2.4 imo1. 
HPLC (method 4) crude purity 65% (ELSD), RT 6.33 minutes. 
m/z (MALDI-TOF) for C249H348N94064calcd  5682.0 1, found 5686.36 [M+H]. 
V.2.7. DNA oligo-peptoid conjugates. 




Mal eimido-heptapeptoid 3.53 was prepared on Rink '5 ' amide polystyrene resin (25 
mg, I mmol/g, 25 j.imol). H2N-Ahx-heptapeptoid-Rink—resin (polystyrene) was 
prepared under microwave conditions (see V.2.3.2). 3-(Maleimido)propionic acid N-
hydroxysuccinimide ester 3.52 (3 equiv, 0.2 M) in DMF was added to the resin and 
the mixture stirred overnight. Compound 3.53 was cleaved using TFA (see V.2.3.9, 
solution I) and precipitated in cold ether. 
Yield: 21 mg, 16 imol. 
HPLC (method 5) crude purity > 95% (ELSD), RT 3.68 minutes. 
m/z (ES+) C69H132N17011  [M+H]calcd 1375.9, found: 688.4 [M+2H]2 (35%), 459.3 
[M+3H]3 (100%), 344.8 IIM+4flJ4  (55%). 
2.7.2. Pyridildithio-heptapeptoid 3.55. 
[NH2 1 ° 
NI 11 a_N 	H 
5T N NH, 
DL 
3-(2-Pyridyldithio)propionic acid N-hydroxysuccinimide ester 3.54 (3 equiv, 0.2 M) 
in DMF was added to the H2N-Ahx-heptapeptoid-Rink—resin (see above) and the 
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mixture stirred overnight. Compound 3.55 was cleaved using TFA (see V.2.3.9, 
solution 1) and precipitated in cold ether. 
Yield: 24 mg, 15 irnol. 
HPLC (method 5) crude purity > 95% (ELSD), RT 4.36 minutes. 
mlz (ES+) C70H134N1709S2 [M+H] calcd 1422.0, found: 711.4 [M+2H]2 (30%), 
474.6 [M+3H13 (100%), 356.3 IM+4HI4 (70%). 
2.7.3. Preparation of HS-CCAA GAAc'A T17TCTCC1T 3.57. 
Disulfide protected 5'-thiol modified DNA oligonucleotide 3.56 (52.5 nmol, from 
Sigma) was dissolved in I mL of DTT solution (0.004 M in 0.17 M phosphate buffer, 
pH = 8) and incubated for 16 h to cleave the disulfide linkage. Thiol oligonucleotide 
3.57 was purified using a size exclusion NAP-10 column following the manufacturer 
instructions (eluent DNAse free water, low molecular weight compounds such as 
DTT and thiol by-products eluted after the oligo). The fractions containing 
oligonucleotide 3.57 (verified by absorbance reading at 260 nm) were dried and the 
DNA oligo re-suspended in DNAse free water, 0.525 mL. 
m/z (MALDI-TOF) C190H249N620117P19S calcd 5893.93, found 5892.16 IM-H]. 
2.7.4. Oligonucleotide-S-heptapeptoid 3.58. 
rNH2 1 
TTCCTCTTTTACMGAACC-S o 	OL 
3' 	 5' 
Thiol oligonucleotide 3.57 (0.2 mL, 100 [tM) and Mal eimi do-heptapeptoid 3.53 (0.2 
mL, 100 tM in PBS) were mixed and incubated overnight. m/z (MALDI-TOF) for 
C259H380N790128P19S calcd 7268.71, found 7266.09 [M-H]. 
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2.7.5. Oiigonucleotide-S-S-heptapeptoid 3.59. 
[NH2 1 
° 	I(() 91 
N -M NH2 3 	 5' 	
H O[ 
Thiol oligonucleotide 3.57 (0.2 mL, 100 1iM) and Pyridildithio-heptapeptoid 3.54 
(0.2 mL, 100 tM in PBS) were mixed and incubated overnight. m/z (MALDI.-TOF) 
for C25H377N780126P19S2 calcd 7203.81, found 7201.62 [M-I-I]-. 
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V.3. Experimental to chapter IV. 
V.3.1. Peptoid dendrimer: synthesis and gene delivery. 
3.1.1. N-Fmoc—N-(6-N '-Fmoc-aniinohexyl)-glycine 4.1.2/6 
PH 
(OyN N OH 
çoo 
Compound 2.12 (1 g, 2 mmol) was dissolved in TFAIDCM (1:1, 20 niL), and stirred 
for 2 h to remove the Boc protecting group. The solution was concentrated in vacuo 
and the crude compound precipitated with diethyl ether to give a sticky oil. The 
compound was dissolved in THF/H20 (9:1, 20 mL) before adding Frnoc-OSu (0.8 g, 
2.4 mmol) and DIPEA (0.64 mL, 4 mmol). The reaction mixture was stirred at room 
temperature for 16 h. I N HCI (20 mL) was added to the solution before removing the 
TI-IF in vacuo. The compound was extracted with DCM (3 x 30 mL), the organic 
phase was washed with brine (3 x 20 mL), dried over magnesium sulfate and 
concentrated in vacuo. Column chromatography (silica, eluent: from DCM to 
DCM/MeOH 9:1) to give acid 4.1 (800 mg, 1.3 mmol) as a white powder in 64% 
yield. 
Rf (DCM/MeOH 9:1) = 0.34. 
mp = 95-100 °C. 
HPLC (method 2) purity 100% (ELSD), RT 9.39 mm. 
IR (solid): 3100-2600 (COO-H), 1703 (C=O, s) cm-1. 
m/z (ES+) 619 [M+H] (100%), 641 M+Na] (25%). 
'H NMR (CDC13, 250 MHz) two rotamers ö = 7.76-7.70 (m, 4H, ArH-Fmoc), 7.60-
7.52 (m, 4H, ArH-Fmoc), 7.34-7.23 (m, 8H, ArH-Fmoc), 4.89 and 4.78 (two br s, 
1H, FmocNH), 4.50 and 4.39 (two m, 4H, 2 x CH2-Fmoc), 4.17 (m, 2H, 2 x CH-
Fmoc), 3.95 and 3.86 (two hr s, 2H, NCH2CO), 3.35 and 3.12 (two hr m, 4H, 2 x 
Fm0cNCH2CH2), 1.46-1.09 (m, 8H, CH2(CH2)4CH2). 
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13C NMR (CDCI3, 62.9 MHz): 8 = 174.2 (COOH), 156.8, 156.1 (NCOO), 143.9 
(ArC-Fnioc), 141.4 (ArC-Frnoc), 127.7, 127.1, 125.0 and 124.8, 120.0 (ArCH-Fmoc), 
68.1 and 67.8 (CH,-Fnioc), 48.5 (CH2CH2NCH2), 47.3 (CH-Fmoc). 40.9 
(FmocNHCFI2), 29.7 (Frn0cNHCH2 CI-12), 28.1 (CH7CH2NCH7), 27.7 
(CH2CH2CI-I2NCH2), 26.1 and 26.2 (FmocNHCH2CH2CH1). 
HRMS (ES+): for C38H47N06 [M+NH4] calcd 636.3068, found, 636.3067. 
3.1.2. Synthesis ofpeptoid dendri,ners 4.3, 4.4, 4.5. 
Core (GO). To a solution of compound 4.1 (0.1 M, 3 equiv) in DMF were added 
HOBt (3 equiv) and DIC (3 equiv) and the solution was stirred for 2 mill and then 
added to pre-swollen PS-Rink '5 ' amide resin in a SPE (Solid Phase Extractor) 
syringe. The mixture was transferred into a 5 mL microwave vessel (Biotage). The 
vessel was capped and subjected to microwave irradiation (60 °C for 20 inin with 
magnetic stirring). Resin was transferred into a SPE and washed with DMF and 
DCM. Chloranil'7 ' and Kaiser' 82  test were carried out before Frnoc deprotection (20% 
piperidine in DMF (2 x 10 mm). In case of a positive colorimetric test the couplings 
were repeated. 
Growing peptoid dendrimer generations. The number (mmols) of amines (primary 
and secondary) on the solid support was theoretically doubled after each generation, 
and so as consequence quantity of reagents and solvent had to be doubled to keep 
consistent coupling conditions: 3 equivalents and a 0.1 M solution. However in order 
to save reagents and solvent, coupling solutions were prepared following the relation: 
Equivalents of monomer 4.1 = 2 + 2 with n = I (GI), 2 (G2), 3 (G3) 
The equivalents were calculated on the initial loading of the resin, and the amount of 
solvent used was the volume required to give 0.1 M solutions with 3 equivalents of 
reagent. 
In this way for each coupling there were 2 extra equivalents of reagents to push to 
completion the coupling of the residual amines on the resin. The relatively low 
generation of the dendrimers prepared allowed the use of this strategy without having 
any problem of reagent solubility or coupling failure. 
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Following final Fmoc removal the polyamidoamines were cleaved from the resin 
using TFAITIS/DCM (90:5:5) and precipitated with cold diethyl ether. 
Peptoid dendrimer 4.3 (G 1). 
m/z (ES+): 486.3 IM+H1 (70%), 243.7 [M+2H]2  (100%). 
HPLC (method 2) purity 94% (ELSD), RT 6.42 mm. 
Peptoid dendrimer 4.4 (G2). 
m/z (MALDI-TOF) for C56H1 15N1507 calcd 1109.91 (average mass), found rnlz: 
1110.64 [M+H]. 
HPLC (method 2) purity 85% (ELSD), RT 4.51 mm. 
Peptoid dendrimer 4.5 (G3). 
m/z (MALDI-TOF) for C12OH243N31015  calcd 2358.92 (average mass), found 2359.94 
IM+HF. 
HPLC (method 6) broad peak, RT 4.63 mm. 
3.1.3. General protocols for cell based assay. 
PAMAM dendrimer, I ,4-diaminobutane core, generation 2.0 was purchased from 
Sigma —Aldrich. 
Cell culture. 
BI6FIO murine melanoma cells and HEK293T (human embryonic kidney) cells were 
grown in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% 
foetal calf serum (FCS), 4 mM L-glutamine and 100 units/mL penicillin / streptavidin 
(complete Dulbecco's medium) in T75 cell culture flask until 80% confluence. Cells 
were suspended using trypsin / EDTA and counted on a hemacytometer (an etched 
glass chamber that holds a quartz coverslip in a total surface area of 9 mm2) after 
resuspension in trypan blue (10 1iL cell suspension, 40 j.iL trypan blue, repeated 3 
times). Cells were seeded in 96-well plates (2 x 10 cells/well) or 24-well plates (4 x 
10 cells/well). Cell cultures were then incubated at 37°C in a 5% CO2 atmosphere for 
the required periods. 
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Flow cytolnerry analysis (FA CS). 
Cells were washed twice with PBS, harvested with trypsinlEDTA, washed again with 
PBS and re-suspended in 2% FCS in PBS buffer. Cell fluorescence (determined by 
GFP synthesis) was analyzed by flow cytornetry analysis using a FACSAria flow 
cytometer (Becton Dickinson). A total of 10,000 events per sample were analyzed. 
Cell samples were excited with a 488-nm (Coherent® Sapphire TM  solid state) laser 
and a 530/30 nm (Fluorescein) band pass filters was used for fluorescence analysis. 
3.1.4. Preparation of dendriiner-DNA complexes. 
Dendrimer-DNA complexes were prepared at different molar ratios (5:1, 10:1, 20:1, 
40: 1). The molar ratio is equal to: (moles of transfection agent) / (number of plasmid 
equivalents). Plasmid equivalents are equal to: (mass of plasmid used) / 330, where 
330 is the average mass of a single nucleotide, and is approximately equal to the 
number of moles of phosphate within the plasmid. Appropriate volumes of dendrimer 
solution (5 mM in PBS) were added to 2.5 tL of DNA solution (4.7 Kb plasmid 
pEGFP-N I) containing 0.20 g of DNA (0.5 x 10-9 equiv in TE buffer). PBS buffer 
was then added to correct the volume to 10 jtL. The solutions were incubated at room 
temperature for 30 minutes. 
3.1.5. Tran.sfection protocol. 
HEK-293T (human embryonic kidney) cells were seeded in a 96 well plate and 
incubated overnight (37 °C, 5% CO2) until 50-70% confluence (see above). The 
growth medium was replaced with 100 jsL of fresh medium (10% FCS). DNA-
Dendrimer complex solution, 10 .iL containing 0.2 tg of plasmid, was then added to 
the cells. Transfection activities were measured by FACS analysis (see above) 
following 48 h of incubation. 
PAMAM G2 4.3 (G 1) 4.4 (G2) 4.5 G3 
Untreated Cells 176 - - - 
5:1 382 156 182 2778 
10:1 821 150 165 3605 
20:1 904 161 382 1728 
40:1 537 	j 154 165 943 
Table 5.1 Fluorescence intensity of HEK cells iransfected with plasmid pEGFP-N1 using PAMAM 
G2, 4.3 (G 1), 4.4 (G2), 4.5 (G3) at different dendrimer/plasmid molar ratios. 
3.1.6. Cytotoxiciry. Cell viability assay (MTT assay). 173 
Cells were seeded in a 96-well plate and allowed to attach for 15 hours. The growth 
medium was replaced with 100 tL of fresh Dulbecco's complete medium. To each 
well were added 10 jiL of dendrimer-plasmid complex solution (0.2 jig of DNA). 
After 48 h of incubation cells were washed with PBS buffer pH 7.4 and the medium 
replaced with a phenol red-free medium (90 jiL). 10 iL of MTT solution (1 mg/mL, 
in PBS buffer) were added and cells were incubated at 37°C for 3 hours. Formazan 
formed during this period was dissolved by adding 100 jiL of a 10% TRITON X- 100 
in acidic isopropanol (0.1 N HCI) solution and thoroughly mixed. The 96-well plate 
was read on a microplate reader at 570 nm and cellular viability was calculated 
according to the following equation: 
Cellular viability = A570 sample / A570 ref 
Where: 
A570 sample= absorbance at 570 nm of the sample (treated cells), 
A570 ref= absorbance at 570 nm of the reference sample (untreated cells). 
PAMAM G2 4.3 (GI) 4.4 (G2) 4.5 (G3) 
Untreated Cells 100 - - - 
Only DNA 98.7 - - - 
5:1 97 102 100 96 
10:1 93 97 99 95 
20:1 82 101 92 95 
40:1 83 97 90 98 
Table 5.2 Percentage of cell vailability (1-1EK293) after 48 h of incubation with the DNA-dendrimer 
complexes different dendrimer/plasmid molar ratios. 
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V.3.2. Ni2 complex mediated delivery of His6-GFP. 




Gly-OMe.HCI (1.25 g, 10 mmol), TEA (3.78 mL, 30 rnmol), and bromo-
tertbutyl acetate (3 mL, 20 mmol) in DMF (50 mL) were stirred at room temperature 
for 3 days. The solution was filtrated and the filtrate was concentrated in vacuo. The 
resulting oil was then dissolved in DCM (100 mL) and washed with a saturated 
NaHCO3 solution (2 x 30 mL). The organic phase was dried over MgSO4 and then 
concentrated in vacuo. Column chromatography (silica, eluent: Hexane/AcOEt, 2:1) 
gave compound 4.9 (2.38 g, 7.5 mmol) as a colorless oil in 75% yield. 
R1 (Hexane/AcOEt, 2: 1) = 0.45 
IR (neat oil): 1741 (C=O, s), 1142 (C-O, s) cm1. 
m/z (ES+) 318 lIM+Hi (55%), 340 [M+Naf (100%). 
'H NMR (250 MHz, CDC],) S 3.63 (s, 3H, OCH3 ), 3.56 (s, 2H, NCH2CO2Me), 
3.45 (s, 4H, 2 x NCH2CO21But), 1.37 (s, 1811, 2 x C(CH3)3). 
'3C NMR (62.9 MHz, CDCI3) 5 171.2 (CH2CO2Me), 170.3 (CH2CO21But), 81.4 
(C(CH3)3), 56.2 (NCH2CO21But), 55.1 (NCH2CO2Me), 51.9 (OCH3), 28.4 C(CH3)3). 
HRMS (FAB) for C1 H28NO6 [M+H] calcd 318.1916, found 318.1906. 
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3.2.2. 2-(bis((tert-butoxycarbonyl)meth)71)amino)-acetic acid 4.10. 
HO 
4 
 0 0 ,,)~~N,A,O,k 
Compound 4.9 (2.10 g, 6 mmol) was dissolved in THF (10 mL) and NaOH I N (12 
mL) was added. The solution was stirred at room temperature until complete loss of 
starting material (I h) (reaction was followed by TLC). The THF was removed in 
vacuo, and HCI I N was added until pH 3. The compound was extracted with DCM 
(3 x 20 mL), the organic phase was then washed with brine (I x 20 mL) and dried 
over MgSO4. The solution was concentrated in vacuo to give compound 4.10 (1.55 g, 
5.1 mmol) as a white solid in 85% yield. 
Mp: 82-85 °C (DCM). 
IR (solid): 3100-2600 (COO-H), 1731 (C=O, s) cm 1 . 
m/z (ES+) 304 (80%), 326 (100%) 
'H NMR (250 MHz, CD30D) ö 3.55 (s, 2H, NCH2CO2H), 3.52 (s, 4H, 
NCH2CO21 But), 1.47 (s, 18H, C(CH3)3). 
'3C NMR (62.9 MHz, CD30D) 6 174.5 (CH2CO2H), 171.8 (CH2CO21But), 82.6 
(C(CH3)3), 57.0 (NCH2CO21But), 56.5 (NCH2CO2H), 28.3 (C(CH3)3). 
HRMS (FAB) for C14H2 NO6 [M+H] calcd 304.1760, found 304.1766. 
3.2.3. (Ni2+  )Ligand-heptapeptoid 4.11. 
0 
HO 	 rNH2 
1 





Compound 4.11 was prepared on a Rink 151 arnide resin (polystyrene) (100 mg, I 
mmol/g, 0.1 rnmol). The synthesis followed the peptide synthesis protocols described 
in section V.2.3 (2.3.2. 2.3.5, 2.3.9). TFA cleavage (solution I), and ether 
precipitation gave 4.11 (133 mg, 62 tmo1). 
HPLC (method 5) crude purity 95% (ELSD), RT 3.45 mm. 
mlz (ES+) 699.4 [M+2H]2  (30%), 466.7 [M+3H]3  (70%), 350.3 [M+4H]4  (100%). 








Compound 4.15 was prepared on Rink '51 amide resin (PEGA) (25 mg, 0.4 rnmol/g, 
10 imol). Synthesis followed those described in section (V.2.3). Dde protected side 
chain of the lysine was deprotected using NH20H and 5(6) carboxyfluorescein was 
coupled to the c lysine amine (carried out as last step). TFA cleavage (solution 1) and 
ether precipitation gave 4.15 (15 mg, 5.9 tmol). 
HPLC (method 5) purity 93% (ELSD), RT 4.38 mm. 




3.2.5. 	N',N9-bis- I -(4,4-dimerhyl-2, 6-dioxocyclohexylidene)ethyi-norsperinidine 
4.12 .224 
0 0 
H 	H 	H 
Norspermidine (2.5 g, 19 mmol) and 2-acetyldiniedone (10.4 g, 57 mmol) in DCM 
(50 mL) were stirred overnight. The solvent was removed in vaciio. Column 
chromatography (DCMIMeOH, 9/I) gave compound 4.12 (6 g, 13 mmol) as a brown 
solid in 68% yield. 
R f (CH2Cl2/MeOH, 9:1) = 0.30. 
'H NMR (250 MHz, CDCI3) 5 = 13.44 (br s, 2H, NH-Dde), 3.43 (m, 4H, 2 x 
CH2NHDde), 2.67 (t, J = 7.0 Hz, 4H, CH2NHCH2), 2.48 (s, 6H; 2 x C=CCH3), 2.27 
(s, 8H, COCH2), 1.76 (tt, J = 7.1, 7.0 Hz, 4H, 2 x CH2CH2CH2), 0.94 (s, 12H, 2 x 
(C(CH3)2). 
m/z (ES+) 460.1 IIM+H1  (100%). 
3.2.6. 	 N',N9-bis-I, 1-(4,4 -diinethyl-2 , 6-dioxocyclohexylid(,ne)erhyl-N5-(3- 





Succinic anhydride (0.5 g, 4.74 mmol) was added to a solution of 4.12 (2.0 g, 4.31 
mmol) in DCM (5 mL) and the mixture was stirred for 1 h. The reaction mixture was 
poured into water (200 mL) and extracted with EtOAc (2 x 100 mL). The combined 
organic layers were dried over anhydrous Na2SO4 and evaporated under reduced 
pressure to afford the title compound as a brown amorphous solid (2.22 g, 95%). 
R f (CH2CL2/MeOH, 9:1) = 0.45. 
HPLC (method 5): 7.67 mill. 
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'H NMR (250 MHz, CDC13) 8 = 13.51 and 13.34 (two hr s, 2H, NH-Dde), 3.31-3.49 
(rn, 8H, 2 x NHCH2CH2CH)N), 2.60 (m, 2H, CH2CO2H), 2.52 (m, 2H, 
CH2CH7CO2H), 2.50 and 2.46 (two s, 6H, 2 x C=C-CH3-Dde), 2.29 and 2.28 (two s, 
8H, CH2CO-Dde), 1.97 and 1.85 (two m, 4H, 2 x NCH2CH2CI-I2NB), 0.95 and 0.94 
(two s, 12H, 2 x C(CH3)2). 
m/z (ES+) 560.5 [M+H] (100%), 582.5 1M+NaI(90%). 
3.2.7. [(Ni 2+  )Ligand] 2-heptapeptoid 4.14. 










OH Y 0 
OH 
Compound 4.14 was prepared on Rink amide resin (PEGA) (100 mg, 0.4 mmol/g, 40 
j.imol). The synthesis followed the protocols described in section (V.2.3) (couplings 
under microwave conditions, Fmoc deprotection, Dde deprotection). TFA cleavage 
(solution 1), and ether precipitation gave 4.14 (61 mg, 23 .tmol). 
HPLC (method 5) purity 95% (ELSD), RT 3.81 mm. 
mlz (ES+) 949.3 [M+2H]2 (30%),633.2 [M+3H]3  (90%),475.2 [M+4H]4  (100%). 
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Compound 4.16 was prepared on Rink 151 amide resin (PEGA) 25 mg, 0.4 mmol/g, 10 
prnoI). Synthesis followed the peptide synthesis protocols described in section V.2.3 
(couplings under microwave conditions, Fmoc deprotection, Dde deprotection, TFA 
cleavage and ether precipitation). Fmoc-Lys(Dde)-Heptapeptoid resin was Frnoc 
deprotected and and 5(6) carboxyfluorescein was coupled to the a lysine amine. 
FAM-Lys(Dde)-Heptapeptoid resin was treated with a solution of trityl chloride (0.1 
M) and DIPEA (0.1 M) in DMF for 16 h (protection of the phenolic groups of 
carboxyfluorescei n).'85 FAM(Tr)-Lys(Dde)-Heptapeptoi d resin was Dde deprotected 
and the remaining building blocks (4.13, Fmoc-Ahx-OH and 4.11) were coupled to 
the c lysine amine. TFA cleavage (solution 1), and ether precipitation gave 4.16 (13 
mg, 5 j.imol). 
HPLC(method 5) purity 95% (ELSD), RT 4.62 mm. 
rn/z (MALDI-TOF) for C, 17H,92N24028 calcd. 2382.92, found 2383.91 [M+H]. 
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3.2.9. Cellular uptake of Ni ligandfunctionalised peptoids. 
Compounds 4.15 and 4.16 were dissolved in PBS buffer at a 100 jiM concentration. 
Peptoid solution (17.5 jiL) was added to 13I6FIO cells in a 24 well plate (350 L 
DEMEM complete medium with 10% FCS) to give a final concentration of 5 1iM. 
Cellular uptake of fluorescently labelled heptapeptoid 4.15 and 4.16 was measured by 
FACS analysis (see V.3.1.3) following 4 h incubation. 
Mean 
fluorescence 
% of cell with fluorescence 
Intensity> 1000 
Untreated cells 429 6 
4.15 5 	g 22,201 83 
4.165jsM 13,011 79 
Table 5.3 Uptake of 4.15 and 4.16 with B 16F 1 0 cells after 4h incubation 
3.2.10. Ni2 mediated delivery of His6-GFP. 
Heptapeptoids 4.11 and 4.14 were dissolved in PBS buffer (pH 7.4) at a concentration 
of 1mM. To this solution was added I equivalent of NiCl2 (1mM solution in PBS), 
and the solution (0.5 mM) gently stirred for I h. To this solution was then added I 
equivalent of His5-GFP (0.5 mM in PBS). The solution (0.25 mM) was incubated for 
I h with occasional gentle mixing. After the incubation the solution was diluted to 
100 jsM with PBS. The 100 jiM solution (3.5, 7, 17.5, 35 jiL) containing the GFP-
(His6)Ni2theptapeptoid (4.11 and 4.14) complex was added to B16FIO cells in a 24 
well plate (350 jiL of DEMEM complete medium, with FCS (10%) and without 
FCS). GFP cellular uptake was measured by FACS analysis (see V.3.1.3) following 
24 h of incubation. 
Mean fluorescence % of cell with fluorescence 
Intensity > 400 
Untreated cells 82 2.2 
GFPl0iM 105 3.6 
4.11 10 jtM 95 2.9 
4.1410tM 159 8.6 
Table 5.4 Fluorescence ofBl6FlO cells incubated with His(,-GFP and GFP-His6-Ni-(4.11 or 4.14) 
for 24 h with 10% FCS. 
3.2.11. Con focal microscopy analysis. 
For the confocal assay 4 x 105  cells were seeded onto a glass coverslip within a 6-well 
plate (1.6 mL) and incubated over night. The day after the medium was replaced and 
160 p.L of the GFP(His6)Ni2t(4.14) solution (100 tiM) were added to the cell which 
were incubated for 24 h. Before analysis cells were washed twice with warm PBS. 
Confocal experiments were carried out on living cells using a Delta Vision RT 
Microscope with excitation at 488 urn. 
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